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CHAPTER I 
INTRODUCTION 

PSORIASIS 
EPIDEMIOLOGY, AETIOLOGY AND GENETICS 
Psoriasis is a chronic skin disease prevaling in 2% of the Dutch population. It 
appears to be most common in northern Europe and North America. In certain 
ethnic groups no psoriasis is seen, such as the American Indians, and Eskimos. 
Psoriasis is equally common in males and females1. The age of onset of psoriasis is 
variable, the first manifestations may occur at any age and its duration may vary 
from a few weeks to a whole lifetime. Triggering factors can induce psoriatic 
phenomena in predisposed persons. These include exogenous and endogenous 
systemic factors, such as psychological stress, somatic disease, drugs, and climate. 
In addition, local factors such as trauma to the skin can precipitate a psoriatic lesion 
(Koebner phenomenon)2"1. 
The genetic component in the aetiology of psoriasis is indisputable. A family history 
for psoriasis is indicated by about one third of the patients. However, the sig-
nificance of hereditary factors seems variable in various patients. It is now clear 
from population surveys, family studies, twin studies and pedigree analysis that 
psoriasis is a polygenic and multifactorial disease5. This implies that the cause of the 
disease is due to the effect of several genes, each of small psoriatic effect, with a 
controlling function for some of these genes. Psoriatic patients possess a critical 
number of causative factors, unaffected individuals carry varying amounts of these 
factors, but not in sufficient quantity to cause disease. 
The discovery of the HLA antigen system has provided additional support for the 
genetic base of psoriasis. Firstly, associations of psoriasis vulgaris with HLA-B13 
and HLA-B17 were demonstrated6"'. Afterwards, similar associations with HLA-
B379 and with HLA-Bwl610 were added. The association with HLA-Bwl6 is not 
clear in all populations. An individual with HLA-B13, HLA-B17 or HLA-B37 has 
about a 5-6 times higher relative risk of developing psoriasis than a person without 
these antigens2. Later studies suggested that these associations were secondary to a 
primary association of psoriasis vulgaris with HLA-Cw69 and with HLA-DR7". 
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It appears that HLA-types dictate in part the course of the disease12. The influence of 
environmental factors and the polygenic inheritance make it difficult to estimate the 
chance that psoriasis will become manifest in any particular person. 
CLINICAL ASPECTS 
Psoriasis has a chronic relapsing course. The cutaneous lesions of psoriasis are 
highly characteristic for the disease (Fig 1). They show prominent features: a sharp 
demarcation, the presence of silvery, non-coherent scales, elevation and a homoge-
nous erythema. This indicates that both the dermal compartment (erythema), and the 
epidermal compartment (elevation, increased scaling) are involved. After scratching 
the lesions, the scales become white, like scratching a candle (signe de la tache de 
bougie). When scales are removed, small bleedings are seen on the surface (Auspitz 
sign). Often a white ring is seen around a lesion, first described by Woronoff. 
A considerable variation in morphology of the lesion exists. The clinical picture can 
be dominated by small lesions (guttäte psoriasis), by large plaques (chronique plaque 
psoriasis), or they may have a considerable pustular component (pustular psoriasis). 
Lesions may be generalized (generalized pustular psoriasis, erythrodermic psoriasis) 
or localized. The most common form of psoriasis is chronic plaque psoriasis or 
psoriasis vulgaris (Fig 2). Lesions are then distributed symmetrically on predeliction 
areas: elbows, knees, scalp, sacral region, and umbilicus. Topographical variations 
of psoriasis vulgaris are flexural psoriasis or psoriasis inversa (involvement of groins 
and axillae), psoriasis capitis (scalp), palmoplantar psoriasis (palms and soles) and 
psoriasis unguium (nails)3,4·13'14. 
Psoriasis is not exclusively a skin disease. Extracutaneous manifestations are 
common. Nail changes (Fig 3) are frequent in psoriasis1·15. The main alterations are 
pits within the nail plate, brownish macules (oil spots) beneath the nail plate, 
subungual hyperkeratosis, and distal onycholysis. Psoriatic arthropathy is a compli-
cation of psoriasis which occurs in 5-10% of the patients (Fig 4). It is also seen in 
patients without cutaneous lesions. Most often arthritis of the peripheral interphalan-
geal joints of the fingers, and a negative serological test for rheumatoid factor are 
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Figure 1. Sharply demarcated erythematosquamous psoriatic lesion. 
Figure 2. Chronic plaque psoriasis. 
seen. In patients with psoriatic arthropathy, an increased frequency of HLA-B2716 
and HLA-Bw382 is found. 
The typical course of psoriasis is a chronic one, with remissions and exacerbations. 
The prognosis of psoriasis is good. Threatening complications are psoriatic arthro-
pathy and erythroderma. Triggering factors for exacerbation of psoriasis include 
systemic factors such as infections, endocrine factors, hypocalcaemia, various drugs 
(lithium, indomethacin, antimalarials, beta-adrenergic antagonists), and psychogenic 
stress. In addition, local trauma can induce psoriatic lesions (Koebner phenomenon). 
Psoriasis does not show a static clinical picture, lesions grow and regress. New 
lesions start as small pinpoint papules. In the early phase, the papules unite, become 
confluent, and form plaques. These plaques may enlarge by centrifugal expansion. 
Involution of the psoriatic lesions can proceed gradually and evenly, however 
sometimes involution starts in the center of the lesion. The end result is often a 
psoriatic leukoderma, which becomes repigmented later13. 
The differentiation of psoriasis from other skin diseases is not difficult in patients 
with a classical clinical picture. However sometimes it is not easy to delineate 
psoriasis from several other skin disorders with abnormal epidermal growth and 
inflammation. Seborrhoeic dermatitis can be quite similar to psoriasis. Some 
infections can mimic psoriatic lesions such as syphilis, dermatophytic infections and 
candidiasis. Mycosis fungoides in the premycotic phase can look like psoriasis. In 
widespread psoriasis especially the differentiation from pityriasis rubra pilaris can be 
difficult". 
HISTOLOGY 
The histologic picture of psoriasis vulgaris varies with the stage of the lesion and is 
diagnostic in early scaling papules and near the margin of advancing plaques17·18. 
Controversy exists whether the initiating events in early psoriasis are located 
primarily in the epidermal or in the dermal compartment19. 
In the initial psoriatic lesion, a preponderance of dermal changes is seen (capillary 
dilatation, dermal oedema, mononuclear infiltrate around the capillaries)20. Also the 
phenomenon of the "squirting papillae" seems to occur early in the development of 
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Figure 3. Nail changes in psoriasis: onycholysis, pits. 
Figure 4. Arthritis psoriatica with nail changes. 
the psoriatic lesion21. This means that neutrophil polymorphonuclear leukocytes 
(PMN) are moving from the tip of capillary loops in the dermal papillae, into the 
epidermis. Early in the evolution of a lesion, thickening of the stratum corneum and 
parakeratosis are seen. Whether parakeratosis appears before or after invasion of 
inflammatory cells in the epidermis remains controversial. PMN can often be seen 
trapped in the parakeratotic stratum comeum. They form micro-abscesses (Munro-
abscesses) in the stratum corneum. Sometimes PMN can be seen in the stratum 
spinosum, where they aggregate as spongiform pustules (of Kogoj). 
In the fully developed lesion of psoriasis, the histologic picture is again charac-
terized by epidermal and dermal changes (Fig 5). Epidermal characteristics are elon-
gation of the rete ridges, thinning of the suprapapillary epidermis, absence of the 
granular layer, hyperparakeratosis, and the presence of Munro microabscesses con-
taining PMN (Fig 6). Sometimes spongiform pustules of Kogoj are seen in the 
epidermis. These are highly diagnostic for psoriasis'7. Munro abscesses are easily 
found in early psoriatic lesions, but more difficult in old lesions22. In the psoriatic 
lesion, mitoses are not limited to the basal cell layer (as in normal skin), but are also 
found in two to three rows of cells above the basal layer. Due to this, in com-
bination with the elongation of the rete ridges, the number of mitoses per unit skin 
surface area is increased more than twenty times compared to normal skin23 (Fig 7). 
Dermal changes include elongation and oedema of the papillae, with dilated and 
tortuous capillaries24. An inflammatory infiltrate is present in the upper dermis and 
the papillae (Fig 8). It consists mainly of T-lymphocytes25, but PMN are also 
present, especially during periods of exacerbation. It is postulated that also mast 
cells are increased26. Lymphocytes and macrophages are present in the epidermis as 
well27. 
In pustular psoriasis, not only microabscesses are formed within the epidermis, but 
also macro-abscesses. The fully developed pustule is large, unilocular and intraepi-
dermal in location. In the dermis a variable dense lymphohistiocytic infiltrate is 
seen, with some neutrophils around dilated vessels in the oedematous papillae28. 
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Figure 5. Psoriasis: dermal and epidermal aberrations (χ 350). 
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Figure 6. РоІутофЬописІеаг leukocytes in lesionai psoriatic skin (x 200). 
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PATHOGENESIS 
In psoriasis, an excess of cellular proliferation and inflammation exists, that 
nevertheless remains controlled. There is no animal model to investigate psoriasis. 
Therefore it is difficult to study the events with in vivo relevance in the pathogenesis 
of psoriasis. An attempt to investigate the earliest changes in the development of 
psoriasis has been made by studying initial psoriatic lesions such as pinpoint 
papules20,21·29, the margin zone of spreading psoriatic plaques18·30-32, or relapsing 
psoriatic lesions after corticosteroid treatment33. In addition, psoriatic lesions have 
deliberately been induced by tape-stripping of the epidermis, thereby removing the 
stratum corneum34,35. As mentioned before, it still remains controversial whether the 
epidermal or the dermal compartment show the earliest changes. 
After corticosteroid treatment under occlusion, the first changes in relapsing lesions 
were swelling and intercellular widening of endothelial cells, followed by the ap-
pearance of mast cells, showing degranulation. Afterwards, macrophages migrated 
into the lower epidermis. Only then lymphocytes and neutrophils were seen33. 
Various other investigations have postulated that dermal vascular changes were the 
first abnormalities detected in initial psoriatic lesions2021, and in the clinically 
uninvolved skin adjacent to spreading psoriatic plaques30,31. In other studies, the 
invasion of the dermis and epidermis by PMN proved to be the first event in the 
inition of a lesion29. 
On the other hand, various abnormalities of the keratinocytes have been described in 
diseased and uninvolved skin in psoriasis36: changes in size of keratinocytes37, in 
ultrastructure38, in plasma membrane binding sites39, and various biochemical abnor-
malities such as increased levels of phospholipase A2 activity, calmodulin levels, and 
activity of ornithine decarboxylase (ODC)36,40,41. 
In vivo42 and in vitro experiments43 showed that skin, removed from its psoriatic 
host, loses its psoriatic features. This implies that both epidermis and dermis are 
needed to produce and maintain a psoriatic lesion44. Although intrinsic abnormalities 
of the keratinocytes are present, also cellular or humoral factors are required to 
induce a clinical psoriatic lesion. 
Alterations in various cell types of skin have been reported in psoriasis. 
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Figure 7. Cycling cells in psoriasis stained with the antibody Ki-67 (x 250). 
Figure 8. Inflammatory infiltrate in a psoriatic lesion (x 155). 
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Keratinocytes: 
A characteristic feature of involved psoriatic skin is hyperproliferation, first 
described by Scott and Van Ekel23. Hyperproliferation can be concluded from the 
higher number of mitotic figures and the greater number of cells labelled with 
tritiated thymidine45. This increase in the proliferative cell population was suggested 
to be due to a shortening of the cell cycle time44. However, strong evidence is 
available that in normal human skin only a part of the germinative cells are really 
cycling, the others are in a resting phase (GQ). The fraction of the cells that is 
actively cycling is called the growth fraction. Recruitment of G0 cells provides an 
explanation for the increased growth fraction in psoriasis47. Not only keratinocyte 
proliferation is changed, keratinocyte differentiation is altered as well. This is 
reflected in the altered expression of intermediate filaments, components of the 
cytoskeleton. For example, increased amounts of keratin 16, and reduced expression 
of keratin 10 have been reported in psoriatic epideгmis4M,. As mentioned before, 
many structural and functional abnormalities have been identified in psoriatic kera­
tinocytes36. 
Granulocytes: 
Much attention has been focussed on the polymorphonuclear leukocyte (PMN)50. 
These cells accumulate in the dermis and epidermis of early and active psoriatic 
lesions. Many abnormalities in blood granulocytes from psoriatic patients have been 
reported, such as enhanced Chemotaxis51 and phagocytosis52, increased cytotoxic 
activity53 and adherence54. PMN are attracted by mediators of inflammation, 
especially leukotriene B4. Several antipsoriatic therapies such as corticosteroids
55
, 
ultraviolet light (UVB and PUVA)56, dithranol57 and retinoids58 have proven to 
inhibit the intra-epidermal accumulation of PMN in normal skin after epicutaneous 
application of leukotriene B,,. The exact role of PMN in psoriasis is not clear. The 
migration of PMN into the epidermis is probably a necessary link in the pathoge­
nesis of psoriasis. From a therapeutical point of view, the migration of PMN into 
the skin seems important50. 
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Monocytes: 
Monocytes from psoriatic patients show increased locomotion" and increased 
phagocytosis60, as well as enhanced cytotoxic activity53. 
Langerhans cells: 
Histochemical and immunological methods have demonstrated clustering of Langer-
hans cells in psoriatic epidermis61"63. It is controversial whether their numbers are 
decreased or increased61·64·65. 
Lymphocytes: 
The dermal mononuclear infiltrate in psoriatic lesions is composed mainly of T-
lymphocytes25. Several abnormalities of circulating T-lymphocytes have been report-
ed66"69. A disequilibrium is found between suppressor-T-cells and helper-T-
cells62,66·67. The ratio between T-helper and T-suppressor-cells is increased compared 
to normal skin62·68. T-lymphocytes are present in the epidermis as well. They belong 
to a "memory" subpopulation of T-cells (CD4-I-, CDw29+)70. The success of 
treatment with cyclosporin indicates that the T-lymphocyte plays an important role in 
psoriasis71. 
Dermis: 
The dermal microcirculation is altered in psoriasis and has been incriminated as the 
primary defect72·73. Fibroblasts cultured from psoriatic dermis show abnormal 
functions such as increased proliferation and synthesis of collagen74. They have been 
reported to be less sensitive to vitamin Dj75, but this is controversial. Whether the 
sensitivity to vitamin D, is altered in psoriatic keratinocytes is disputed76·77. There is 
also evidence that the composition of extracellular matrix proteins is changed74,78""1. 
Data to support a role for each of these components in the initiation, maintenance or 
resolution of psoriasis are still accumulating. Research has shifted from inves-
tigations of peripheral blood cells to studies of the inflammatory and immunological 
cells in the skin81. The mechanism which brings the inflammatory cells into the 
lesions of psoriasis is unknown. Proposed mechanisms include chemotactic factors 
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from the arachidonic acid cascade, immunological mechanisms, and metabolic 
abnormalities. 
The arachidonic acid cascade: 
Arachidonic acid is an unsaturated fatty acid and is present in phospholipids in the 
plasmamembrane of keratinocytes. It is the precursor of prostaglandins, throm-
boxanes, hydroxyeicosatetranoic acids (12-HETE, 15-HETE), and leukotnenes (Fig 
9), substances which are formed after epidermal trauma and which are mediators of 
inflammation and proliferation82'84. In psoriatic epidermis, the amounts of arachido-
nic acid, 15-HETE, and leukotriene B4 are increased84-87. Leukotriene B4 is a potent 
chemo-attractant for PMN and is formed via the enzyme 5-lipoxygenase. Inhibitors 
of this enzyme proved to be benefitial in the treatment of psoriasis8889. 
ARACHIDONIC ACID 
cyclo-oxygenase 12-llpoxygenase 5-lipoxygenase 
prostaglandins 12-HETE 
thromboxane 
Figure 9. Arachidonic acid cascade. 
LTA4 
LTB4 LTC4 
J 
LTD4 i 
LTE4 
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Immunological factors: 
After the discovery of depositions of IgG and complement in the stratum comeum of 
psoriatic epidermis, the hypothesis has been formulated that immunological factors 
play an important role in its pathogenesis90·91. In this hypothesis, it is assumed that in 
normal skin a stratum comeum antigen is present, but masked. In psoriasis, this 
antigen is unmasked, possibly presented by Langerhans cells, leading to an im-
munological answer, e.g. an influx of T-helper cells92·93. These T-lymphocytes are 
able to trigger the development of a psoriatic lesion (Fig 10). During therapeutical 
Figure 10. T-lymphocytes in an untreated psoriatic lesion (x 200). 
regression of a lesion, the ratio of T-helper/T-suppressor cells changes in favour of 
the T-suppressor cells71. T-lymphocytes are able to secrete various interleukins, such 
as interleukin-2 (IL-2), which is a signal for activation and proliferation of other T-
lymphocytes94. Not only T-lymphocytes, but also other epidermal cells produce 
cytokines95. The epidermis of psoriasis contains abnormal amounts of interleukin-1 
(IL-1)96, interleukin-6 (IL-6)97·98, interleukin-8 (IL-8)99, tumor necrosis factor a 
(TNF-a)100, and transforming growth factor ß (TGF-ß)101. In addition, the expression 
of the intercellular adhesion molecule 1 (ICAM-1), which permits leukocytes to 
adhere to endothelium, to leave the bloodstream, and infiltrate the skin, proved to be 
increased in the microvasculature and epidermis of psoriatic skin102. Current interest 
of psoriasis research focusses on cytokines and adhesion molecules as an integrated 
regulatory circuit103. 
Metabolie abnormalities: 
The levels of cyclic AMP and cyclic GMP are changed. cAMP is decreased and 
cGMP is increased in psoriatic epidermis104,105, and various investigations support the 
possibility of a defective cAMP system106·107. Lithium is known to inhibit the 
formation of cAMP, and exacerbates psoriasis108. Certain polyamine levels are raised 
in psoriasis109. Putrescine and spermidine levels are increased, as well as their rate-
limiting synthetic enzyme, ornithine-decarboxylase109. Various data suggest a 
disturbed protease-anti-protease equilibrium in psoriasis110"112. 
THERAPY 
Psoriasis is a chronic relapsing benign skin disease and administration of a drug may 
continue for a long time. Therefore therapeutics are needed with a small risk of side 
effects. Stable psoriasis should first be treated with extensive topical therapy. 
Phototherapy or photochemotherapy is indicated in cases of more widespread 
psoriasis. If the psoriasis is extensive, more intensive topical therapy should be 
considered in a day-care unit or hospital. In cases of severe psoriasis, systemic 
treatment with for example retinoids or methotrexate is indicated. 
Coal tar 
Coal tar has been used in topical therapy for more than a century. It is assumed to 
have an antimitotic effect115. Tar can be incorporated in various vehicles such as 
creams, ointments, lotions, gels and shampoos. It is a safe and effective treat-
ment"4·"5. Disadvantages are the colour and odour of coal tar, the induction of 
folliculitis and enhanced sunburn. 
Dithranol (anthralin) 
A century ago the value of chrysarobin, a tree bark extract, in psoriasis was 
discovered accidentally. Dithranol is a synthetic analogue of chrysarobin and is 
working maximally when formulated in a stiffened base'. The exact working 
mechanism is unknown. Its effect is however tightly linked with its side effects: 
staining of the skin and textiles by oxidation products, and irritation of the skin. 
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Dithranol inhibits key enzymes of cell metabolism, interacts with mitochondriae, and 
has an antiproliferative effect in psoriasis116. Formulations with increasing strength 
should be used to avoid excessive irritation of the skin. Several regimes have been 
used. For out-patient treatment, short-contact therapy using dithranol in an ointment 
base is useful. This therapy is based on the hypothesis that dithranol is absorbed 
quicker by lesionai psoriatic skin than by unaffected skin116. Dithranol therapy 
requires intensified control and instruction. It has no systemic effects and is a very 
effective treatment. 
Corticosteroids 
Corticosteroids possess anti-proliferative, anti-inflammatory and immunosuppressive 
properties117·118. They are very effective in the treatment of psoriasis and widely 
used. After binding to a cytoplasmatic receptor, the corticosteroid is transported to 
the nucleus, and lipocortins are induced, a group of biomolecules with phospholipase 
A2 inhibiting activity1". Disadvantages of corticosteroid therapy (especially when 
applicating the stronger formulations used in the treatment of psoriasis) are the 
induction of dermal atrophy, perioral dermatitis, suppression of the pituitary-adrenal 
axis, and the rapid relapse of treated lesions"7. 
Photo(chemo)therapy 
UVB as well as UVA in combination with psoralens are effective in the treatment of 
psoriasis. UV-light induces free radicals and subsequently inflammation. The number 
of Langerhans cells decreases during treatment and the shape of these cells changes. 
The duration of the remission after photo(chemo)therapy is relatively long compared 
to corticosteroid treatment. Prolonged and intensive use of UV-light increases the 
risk of skin malignancies, especially of squamous cell carcinomas3·120. 
Methotrexate 
Methotrexate (MTX) inhibits DNA-synthesis by competing as a substrate for 
dihydrofolate reductase and acts on the rapidly dividing epidermal cells of the 
psoriatic lesion. MTX is also capable of inhibiting PMN-chemotaxis and preventing 
their metabolic burst121·122. Long-term MTX therapy is very effective in the treatment 
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of psoriasis, however the risk of liver damage and cirrhosis limits the indication for 
MTX therapy4. 
Retinoids 
Retinoids are derivatives of vitamin A, and are bound by a cytoplasmatic receptor. 
Subsequently they are transported to the nucleus, bind to a nuclear receptor123 and 
act via modulation of transscription and translation of DNA. The process of ke-
ratinization is altered by retinoids. The best results are achieved in pustular psoriasis 
or in guttäte psoriasis of recent onset. These drugs are teratogenic, which has an 
important impact for women of childbearing age. Side effects are dose-related and 
include cheilitis, hair loss, generalized pruritus, dryness of the skin, hypertriglyce-
ridemia, and hyperostosis. Relapses occur usually after treatment is discontinued4,124. 
Cyclosporin 
Cyclosporin is an immunosuppressive drug that reversibly suppresses the immuno-
modulating functions of cells of the immune system. It is effective in the treatment 
of psoriasis, although side effects may limit its use, e.g. hypertension and impair-
ment of renal function. It is especially useful in patients with extensive psoriasis. 
Lesions re-occur after discontinuation of therapy125,126. 
Vitamin D3 
Vitamin Dj and analogues decrease proliferation and increase differentiation of 
keratinocytes in culture127. In addition, it posesses immunomodulating properties in 
vivo128. This hormone also posesses a cytoplasmatic receptor, is afterwards bound to 
a nuclear receptor, and acts via interference with transcription and translation12'. It is 
effective in the treatment of psoriasis, but can show serious side effects. The results 
of treatment with analogues having less systemic actions such as MC903 are promi-
sing130,1'1. 
Although all these treatment modalities are very useful in the treatment of psoriasis, 
it is important to search for new or modified classical treatments which are more 
effective and/or show less side effects. 
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AIM OF THE THESIS 
Despite all the investigations on the pathogenesis of psoriasis, the specific role of 
various cell types in epidermal and dermal compartment is not known. In this thesis, 
epidermal growth in combination with inflammation in epidermal and dermal 
compartment were studied using immunohistochemical techniques. In order to 
achieve further information on the pathogenetic processes involved in psoriasis the 
following aims were formulated: 
1. To investigate the phases of the psoriatic process during the evolution of a 
lesion, using immunohistochemical techniques for assessment of epidermal 
growth and inflammation. 
2. Elucidation of the order of events concerning epidermal growth and inflam­
mation during normalization of a psoriatic lesion. 
3. Evaluation of the clinical efficacy of new and modified classical therapies for 
psoriasis. 
4. To establish to what extent the markers for epidermal growth and inflammation 
are of diagnostic relevance with respect to psoriasis. 
METHODOLOGY AND TECHNIQUES 
Approach: 
1. In order to study the phases in the induction of psoriasis, two in vivo models 
were used. Firstly, the transition zone between lesionai and clinically unin-
volved skin from a spreading psoriatic plaque was investigated (chapter 2.1). 
Secondly, application of leukotriene Ъ4 on normal skin was carried out. This 
results in features as seen in the psoriatic lesion132134. The different phases of 
inflammation and epidermal growth can be studied carefully using this model. 
The changes induced by application of leukotriene B4 and the relevance of this 
model as an in vivo model for psoriasis is discussed in chapter 2.2. 
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Before and during treatment courses with various anti-psoriatic therapies, 
biopsies were taken at different time intervals and processed for im-
munohistochemistry. This approach permits the monitoring of changes in 
inflammation and epidermal growth during regression of psoriatic lesions 
(Chapter 3). In addition, the effect of one of these therapies (dithranol) on 
normal skin has been investigated using the same immunohistochemical 
markers. The relevance of each marker for monitoring therapies and the 
correlation between histological features and clinical scores were studied. The 
value of a new marker for monitoring anti-psoriatic therapies, keratin 17, is 
evaluated in chapter 3.7. 
To investigate the clinical effect of various new or modified classical anti-
psoriatic therapies, patients from the out-patient department were treated and 
monitored using the Psoriasis Area and Severity Index (PASI-score). This 
score is calculated from the percentage of the body surface involved: 
A: 0 = no involvement, 1 = < 10% involvement, 2 = 10-29%, 3 = 30-
49%, 4 = 50-69%, 5 = 70-89%, 6 = 90-100%, 
and from the amount of erythema (E), desquamation (D), and infiltration (I): 0 
= no involvement, 1 = slight involvement, 2 = moderate involvement, 3 = 
severe involvement, 4 = severest possible involvement. 
PASI = upper extremities: 0.2 χ A(E+D+I) + 
trunk: 0.3 χ A(E+D+I) + 
lower extremities: 0.4 χ A(E+D-I-I). 
The capacity to reduce PASI-scores of new and modified classical therapies is 
evaluated in chapter 3. 
Epidermal growth and inflammation were assessed in three other erythe-
matosquamous skin disorders. To establish to what extent the changes as seen 
in psoriasis are specific, the following three skin diseases were investigated: 
1. Inflammatory Linear Verrucous Epidermal Nevus (ILVEN) versus linear 
psoriasis (Chapter 4.1). ILVEN is a congenital nevus and has been 
suggested to be a separate disease entity. The delineation from linear 
psoriasis has been discussed in the literature. So far the question as to 
the nosological independency of ILVEN remains unsettled135. 
2. Pityriasis Rubra Pilaris (PRP). The relationship between psoriasis and 
PRP has been discussed by many authors. Firstly, it can be rather 
difficult to differentiate both conditions on clinical grounds, secondly, the 
transition of the one in the other has been suggested136. 
3. Discoid Lupus Erythematosus (OLE). Initial lesions of DLE show 
sharply demarcated erythema, hyperkeratosis, and elevation. If not 
adequately treated, a marked atrophy results. In the etiology of DLE 
auto-immunity plays an important role137. 
These three skin diseases show clinically overlap, especially in the initial 
phase. DLE however, ends in a contrasting state. 
Immunohistochemistry: 
Monoclonal antibodies: 
To assess epidermal proliferation the monoclonal antibody Ki-67 was chosen. This 
antibody is directed against a nuclear antigen present in cycling cells. This antigen is 
presented in the late Gl-phase, S-phase, G2-phase and M-phase of the cell cycle. It 
is an appropriate marker for changes in proliferation13'. 
To assess epidermal differentiation antibodies against cytokeratins were used. These 
are proteins which are components of the cytoskeleton13'. The pattern of keratins 
expressed by keratinocytes changes as they mature140,141. In this thesis we have 
selected antibodies against keratin 10 (RKSE60), a keratin that is present in supra-
basal differentiated keratinocytes49, and against keratin 13 and 16 (Ks8.12). Keratin 
13 is absent in normal adult human skin141, whereas keratin 16 is expressed by 
hyperproliferative keratinocytes in vitro as well as in vivo48·142. Keratin 16 was 
reported to correlate well with clinical scores for psoriasis143. Two other markers for 
epidermal differentiation are involucrin and filaggrin. Involucrin is a cytoplasmatic 
protein precursor of the comified envelope144, filaggrin is involved in the formation 
of keratohyalin granules145. In normal skin, involucrin is found in the granular layer 
and in the upper stratum spinosum. Filaggrin is present in the stratum comeum and 
in the granular layer. These two proteins were stained using a polyclonal antibody 
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against involucnn and a monoclonal antibody against filaggnn. In one study, a 
monoclonal antibody against keratin 17 was used (E3)146. Keratin 17 is not present in 
normal human epidermis, but is restricted to the outer root sheath of the hair follicle 
and to myoepithelial cells of the sebaceous gland147. In Chapter 3.7 it's distribution 
in psoriatic lesions is investigated. An indirect peroxidase technique was used for 
staining with this antibody. 
Inflammation: A panel of antibodies was chosen to visualize cells involved in 
inflammation. T-lymphocytes were stained with a pan-T cell marker, directed against 
CD2 (Dako Ti l)"" . B-lymphocytes were stained using an antibody against CD22 
(Dako Pan-B)94. A CD14-antibody was chosen to stain monocytes and macrophages 
(WT14)"". For assessment of PMN, a polyclonal antibody against elastase was 
used150. Elastase is not totally specific for PMN. Monocytes are reported to contain 
5% of the elastase activity of monocytes'". Finally, Langerhans cells were stained 
using the antibody OKT6, directed against CD la152. 
Dermal extracellular matrix proteins: Three important components of the extracel­
lular matrix are heparansulphate, fibronectin, and the recently described protein 
tenascin78"80. Staining was performed using the antibodies JM-72, anti-fibronectin, 
and T2H5 respectively. 
Staining techniques: 
The antibodies used in this thesis are indicated in Table I. 
Biopsies were embedded in Tissue Тек OCT compound (Miles Scientific, Naper-
ville, USA), snap frozen in liquid nitrogen and stored at -80 "С until use. 
Skin sections of 7 μπι were cut. The slides were fixed for 10 minutes in acetone/-
ether 60/40 vol% for Ki-67, or in acetone for staining with the other antibodies. 
Staining with Ks8.12, RKSE60, Ki-67, anti-elastase, T2H5, JM-72, anti-fibronectin, 
anti-involucrin, anti-filaggrin and E3 were performed using a peroxidase-technique. 
In brief, slides were incubated with the antibodies for 30 minutes (Ki-67, Ks8.12, 
RKSE60, anti-elastase, anti-involucrin, anti-filaggrin, E3) or for 60 minutes (T2H5, 
JM-72, anti-fibronectin) at room temperature in the dark. After 3 washes with phos­
phate buffered saline (PBS) slides were incubated with rabbit-anti-mouse antibody 
(RAMPO, Dakopatts, Copenhagen, Denmark), or with swine-anti-rabbit-immuno-
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Table 1. 
ANTIBODY (MANUFACTURER) 
Κι-67 (Dakopatts, Copenhagen, Denmark) 
Ks8.12 (Sigma, St Louis, USA) 
RKSE60 (F Ramaekers, Maastricht, NL) 
Anti-elastase (Serotec, Oxford, England) 
Tl 1 (Dakopatts, Copenhagen, Denmark) 
Pan-B (Dakopatts, Copenhagen, Denmark) 
WT14 (W Tax, Nijmegen, NL) 
0KT6 (Ortho Diagn Systems, Rantan, USA) 
T2H5 (A Verstraeten, Amsterdam, NL) 
JM-72 (J vd Bom, Nijmegen, NL) 
Anti-fibronectin (Sigma, St Louis, USA) 
Anti-mvolucnn (Biomed Techn Ine, Stoughton, 
USA) 
Anti-filaggnn (Biomed Techn Inc. Stoughton, 
USA) 
E3 (S Troyanovski, Moscow, USSR) 
SPECIFICITY 
nuclear antigen in late Gl, S, G2 and M phase 
keratin 13 and 16 
keratin 10 
elastase in polymorphonuclear leukocytes 
T-Iymphocytes (CD2) 
B-lymphocytes (CD22) 
monocytes/macrophages (CD 14) 
Langerhans cells (CD la) 
tenascin 
heparansulphate 
fibronectm 
mvolucrm 
filaggnn 
keratin 17 
DILUTION 
1:40- 1:100 
1:25- 1:40 
1:10 
1:100 
1.100 
1100 
1:100 
1:100 
1:2000 
1:500 
1:500 
1:10 
1:500 
1:10 
TECHNIQUE 
mdirect peroxidase 
mdirect peroxidase 
mdirect peroxidase 
direct peroxidase 
PAP" 
PAP 
PAP 
PAP 
mdirect peroxidase 
mdirect peroxidase 
mdirect peroxidase 
mdirect peroxidase 
mdirect peroxidase 
mdirect peroxidase 
* PAP = peroxidase-anti-peroxidase 
globulin (Dakopatts, Copenhagen, Denmark, for staining with involucrin), con-
jugated with peroxidase 1:50 in phosphate buffer containing 5% human AB-serum 
for 30 minutes. This incubation step was skipped in the elastase-staining as the anü-
elastase antibody is directly conjugated with peroxidase. After 3 more washes with 
PBS and pre-incubation with sodium acetate buffer, pH 4.9, slides were stained in 
sodium acetate buffer containing 200 mg/1 3 amino-9-ethyl-carbazole solution and 
0.01 % H202 prepared freshly (AEC-solution) for 10-15 minutes at room temperature 
in the dark. 
Staining with TU, Pan-B, WT14 and OKT6 were carried out using a peroxidase-
anti-peroxidase technique (PAP-technique). Slides were incubated with the mono-
clonal antibodies (dilution 1:100) for 60 minutes. After 3 washes in PBS, incubation 
followed with rabbit-anti-mouse immunoglobulins (RAM-Ig, Dakopatts, Copen-
hagen, Denmark) 1:25 in PBS for 20 minutes. After 3 more washing steps in-
cubation with peroxidase-anti-peroxidase complexes (PAP, Dakopatts, Copenhagen, 
Denmark) 1:100 in PBS for 20 minutes was performed. Incubation with RAM-Ig 
and PAP was repeated and slides were stained with AEC-solution after 2 washes 
with PBS and pre-incubation with sodium acetate buffer pH 4.9. 
All slides were finally washed with demineralized water and counterstained with 
Mayer's haematoxylin (Sigma, St.Louis, USA). Slides were mounted in glycerine 
gelatin and studied by light microscopy. 
Histological examinations 
The number of Ki-67 stained nuclei was counted per mm length of section. 
Staining with Ks8.12, RKSE60, anti-involucrin, anti-filaggrin and E3 was assessed 
in the basal and suprabasal epidermal compartment using a semi-quantitative scale 
(Chapter 2, 3 and 4). 
Inflammatory cells (PMN, T- and B-lymphocytes, CD14-positive cells and Langer-
hans cells) were assessed in dermis and epidermis using a semi-quantitative scale 
(Chapter 2, 3 and 4). 
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Distribution of extracellular matrix proteins was described compared to classical 
histological features (Chapter 2.1). 
Stalistical analysis 
For statistical analysis were used: the Mann-Whitney test , the Wilcoxon ranking test 
for paired data, and the Kruskal-Wallis test for group means. 
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CHAPTER 2 
SEQUENTIAL STUDIES ON IN VIVO MODELS FOR 
PSORIASIS 
This chapter is based on the following publications: 
1. De Jong EMGJ, Schalkwijk J, van de Kerkhof PCM. Epidermal proliferation 
and differentiation, composition of the inflammatory infiltrate and the extracel­
lular matrix in the margin of the spreading psoriatic lesion. European Journal 
of Dermatology 1991; 1: 221-227. 
2. De Jong EMGJ, van Ε φ PEI, van Vlijmen IMJJ, van de Kerkhof PCM. The 
interrelation between inflammation and epidermal proliferation in normal skin 
following epicutaneous application of leukotriene B4; An immunohistochemical 
study. Clin Exp Dermatol 1992; 17: 413-420. 

2.1 EPIDERMAL PROLIFERATION AND DIFFERENTIATION, COM-
POSITION OF THE INFLAMMATORY INFILTRATE AND THE 
EXTRACELLULAR MATRIX IN THE MARGIN OF THE SPREADING 
PSORIATIC LESION. 
EMGJ de Jong 
J Schalkwijk 
PCM van de Kerkhof 
Department of Dermatology 
University Hospital Nijmegen 
The Netherlands 
SUMMARY 
Changes seen in uninvolved skin adjacent to spreading psoriatic lesions represent 
early events in the evolution of a lesion. 
In the margin of spreading psoriatic plaques, epidermal proliferation as well as 
keratinization (keratin 16, keratin 10), the inflammatory infiltrate, and extracellular 
matrix proteins (tenascin, heparansulphate, fibronectin) were analyzed using 
immunohistochemistry. 
Dermal changes (expression of tenascin) and the inflammatory infiltrate (T-lym-
phocytes, Langerhans cells) appeared peripherally to the epidermal changes (a-
canthosis, keratin 16 expression, hyperproliferation). 
The present study indicates that the stroma is an important target for studies on 
initial events in psoriasis. 
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INTRODUCTION 
Early changes taking place in the evolution of a psoriatic lesion, are difficult to 
catch. Therefore, various investigative approaches have been evaluated to study the 
incipient events of psoriasis. Tape-stripping1·2, injection3 or application of leuko-
triene-B/·5, and taking biopsies from early lesions6"9 have been used in the past. In 
addition, studying changes in the uninvolved skin adjacent to a spreading psoriatic 
lesion, can reveal new information10"12. 
Whether the epidermal or the dermal compartment show the earliest changes, 
remains controversial. In previous studies it has been shown that dermal infiltrate 
cells12 and dermal vascular changes (increased blood flow11, increased alkaline 
phosphatase10) can be found distant from the clinically involved skin. On the other 
hand, epidermal alterations can also be found outside the boundaries of the macros-
copic psoriatic lesion12. 
In this study, three different units have been investigated: the epidermal com-
partment, the inflammatory infiltrate, and dermal extracellular matrix proteins 
(ECM). 
In the epidermis, parameters for proliferation and keratinization were studied. 
Epidermal proliferation was characterized using the monoclonal antibody Ki-67, 
which stains a nuclear antigen present in cycling cells. Keratinization was inves-
tigated by studying the expression of keratin 16 and keratin 10 with the antibodies 
Ks8.12 and RKSE60 respectively. 
The various components of the inflammatory infiltrate were studied using antibodies 
against T-lymphocytes (Til, CD2), against polymorphonuclear leukocytes (anti-
elastase), against monocytes/macrophages (WT14, CD14), and against Langerhans 
cells (OKT6, CD la). 
The expression and localization of extracellular matrix proteins were also inves-
tigated. Tenascin, which is a recently described ECM, is present in the subepidermal 
dermis of normal skin and is discontinuously distributed13'17. In psoriasis and in other 
hypcrproli ferali ve skin disorders, an increased expression of tenascin is present". In 
addition, the distribution of heparansulphate and fibronectin were investigated in the 
margin of active psoriatic lesions. 
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MATERIALS AND METHODS 
Patients and biopsies 
Six patients (three male, three female; mean age 48 (27-76) years) suffering from 
chronic plaque psoriasis participated in the study. They had used no topical trea­
tment for at least two weeks, and no systemic treatment for at least one year. In all 
patients the disease was in an unstable phase. From each patient one lesion was 
selected that, according to the patients history, had been extending during the last 
week. A punch biopsy (Ψ 6mm) was taken after local anaesthesia, across the margin 
of the spreading lesion. The biopsy was embedded in Tissue Тек OCT Compound 
(Miles Scientific, Naperville, USA), snap frozen in liquid nitrogen and stored at -
80oC until use. From each biopsy consecutive sections of 7 μπι were cut and fixed 
in acetone/ether 60/40 % for staining with the antibody Ki-67, or in acetone (0 eC) 
for 10 minutes for staining with the other antibodies. 
Antibodies 
Epidermal proliferation For assessment of epidermal proliferation the antibody Ki-67 
was used (Dakopatts, Copenhagen, Denmark) which stains a nuclear antigen present 
in cycling cells. 
Epidermal keratinization For assessment of epidermal keratinization, the antibody 
Ks8.12 (Sigma, St Louis, USA) was used, directed against keratin 13/16. Keratin 
16 is expressed by hyperproliferative keratinocytes". Keratin 13 is not present in 
adult human skin20. In addition, the antibody RKSE60 (gift of F. Ramaekers) was 
used, directed to keratin 10, which is expressed by differentiated keratinocytes. 
Inflammation For assessment of inflammation in epidermis and dermis, antibodies 
against T-lymphocytes (Til, anti-CD2, Dakopatts, Copenhagen, Denmark), against 
polymorphonuclear leukocytes (anti-elastase, Serotec, Oxford, UK), against Langer­
hans cells (OKT6, anti-CDla, Ortho Diagnostic Systems, Raritan, USA) and against 
monocytes/macrophages (WT14, anti-CD14, Dept of Medicine, Division Nephrolo­
gy, University Hospital Nijmegen, The Netherlands21) were used. 
Extracellular matrix proteins A monoclonal antibody against tenascin (T2H5) was 
obtained from AA Verstraeten, The Netherlands Cancer Institute, Amsterdam, The 
Netherlands18, and used in combination with a monoclonal antibody (JM-72) to 
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heparansulfate core protein (J vd Bom, Department of Nephrology, University 
Hospital Nijmegen), and a monclonal antibody to human plasma fibronectin (Sigma, 
St Louis, USA (clone F7387, ascites fluid)). 
Staining procedures 
For staining with the antibodies Ki-67 (1:100 in phosphate buffer), Ks8.12 (1:40), 
RKSE60 (1:10), anti-tenascin (1:2000), anti-heparansulfate (1:500) and anti-
fibronectin (1:500), an indirect peroxidase technique was used. For staining PMN 
(anti-elastase, 1:100), a direct peroxidase technique was carried out. Slides were 
incubated with the primary antibodies for 30 minutes (for staining with Ki-67, 
Ks8.12, RKSE60 or anti-elastase); or for 60 minutes (antibodies to tenascin, 
heparansulphate, fibronectin) at room temperature in the dark. After washing in 
phosphate buffer the slides were incubated with a solution of rabbit-anti-mouse-
immunoglobulin conjugated with peroxidase 1:50 in phosphate buffer containing 5% 
human AB-serum for 30 minutes, except for the anti-elastase antibody. After 3 
washing steps in phosphate buffer and preincubation in sodium acetate buffer pH 
4.9, slides were stained in a solution of 3-amino-9-ethyl-carbazole (AEC) in sodium 
acetate buffer containing 0.01% H202 for 10 minutes. All slides were counterstained 
with Mayer's haematoxylin (Sigma, St Louis, USA) and mounted in glycerin gelatin. 
Staining with T i l , OKT6 and WT14 was carried out using a peroxidase-anti-
peroxidase technique. Slides were incubated for 60 minutes with the monoclonal 
antibodies in a dilution of 1:100. Three washing steps in phosphate buffer were 
followed by incubation with rabbit-anti-mouse-immunoglobulin (Dakopatts, Copen-
hagen, Denmark) 1:25 in phosphate buffer for 20 minutes. This was followed by a 
washing step and incubation with peroxidase-anti-peroxidase complexes (Dakopatts, 
Copenhagen, Denmark) 1:100 in phosphate buffer for 20 minutes. The last two 
incubation steps were repeated. The slides were stained in the same AEC-solution in 
sodium acetate buffer and H202 and counterstained with Mayer's haematoxylin. 
Finally they were mounted in glycerin gelatin. 
40 
Histological examination 
The immunohistochemical stainings were compared with the localization of parakera­
tosis, the геарреагепсе of the granular layer, with the amount and localization of the 
inflammatory infíltrate, and with the development of initial acanthosis and full 
acanthosis. 
RESULTS 
Figure 1 shows the margin of a psoriatic lesion. The point where the parakeratotic 
homy layer changed into an orthokeratotic stratum comeum was an abrupt transition 
point in all biopsies. In addition, the granular layer reappeared immediately adjacent 
to the parakeratosis transition point. Full acanthosis developed more centrally than a 
parakeratotic stratum comeum. 
In the suprabasal compartment of the epidermis, staining with the antibody Ks8.12 
(keratin 13/16) was seen in the periphery of the lesion, well before the transition 
point of parakeratosis and full acanthosis in all six biopsies. In the psoriatic lesion, 
staining with RKSE60 (keratin 10) was diminished and discontinuous. The transition 
to the staining pattern of normal skin was seen abruptly at the site where the 
granular layer reappeared in all biopsies. 
Initial acanthosis was the first histological change in the epidermis. In the basal cell 
compartment of the epidermis, the number of Ki-67 stained nuclei was high in the 
psoriatic lesion, and low in the uninvolved skin. In 4 out of 6 patients, Ks8.12 
staining in the suprabasal compartment extended into the uninvolved skin beyond the 
point where a high number of Ki-67 stained nuclei was found. In 2 out of 6, the 
reverse was seen, high numbers of Ki-67 stained cells were found peripherally from 
suprabasal Ks8.12 staining. 
The dermal inflammatory infiltrate was maximally present at the parakeratosis tran-
sition point in five out of six biopsies, but the infiltrate extended beyond the lesion 
into the clinically uninvolved skin in all patients (Fig 2). The infiltrate was com-
posed mainly of T-lymphocytes. Above the dermal infiltrates, considerable epider-
motropism was seen, mainly in the involved areas. In the uninvolved areas, rarely 
epidermotropism was found. Langerhans cells constituted only a small part of the 
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Figure 1. Margin of the spreading psoriatic lesion. Shaded bars represent the localization of the 
various parameters. Black bars (Ki-67 antigen, keratin 16) represent variable expression. 
infiltrate in the center of the psoriatic lesion. In the infiltrates at the margin and in 
uninvolved skin, their contribution was more substantial (Fig 3). Epidermal Langer-
hans cell numbers were low in the lesion compared to uninvolved epidermis. The 
transition from low to high numbers was located outside the border of the lesion as 
defined by full acanthosis and parakeratosis in one patient, and at the parakeratosis 
transition point in 2 patients. In 3 patients, a gradual transition was seen. CD14-cells 
were extensive in the dermis of the psoriatic lesion. Also the lesionai epidermis con-
tained large numbers of CD14-cells. Towards uninvolved skin, a gradual decrease 
was seen in the dermis. In the epidermis of uninvolved skin, only sporadically 
CD14-cells were seen. PMN were seen sparsely in the stratum comeum in the 
psoriatic lesion. The inflammatory infiltrate contained only sporadically PMN. 
The extracellular matrix protein heparansulphate was restricted to basal membranes 
both in the lesionai and in the non-lesional skin; no differences in expression were 
seen. Fibronectin was present diffusely throughout the dermis; however no differen-
ces between lesionai and non-lesional skin were found. Tenascin was found in a 
continuous pattern not only in the papillary dermis and reticular dermis of the 
psoriatic lesion, but also far beyond the parakeratosis transition point in the unin-
volved skin. In three out of six biopsies, dermal presence of tenascin decreased 
gradually, and became discontinuous in two out of these three, at the most distant 
edge of the sections (Fig 4). In the other three patients, tenascin expression in the 
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dermis remained high in the distant uninvolved dermis. This is in contrast to the 
pattern of expression of tenascin in normal skin18, where a discontinuous expression 
is seen just under the basal membrane. 
• " ' • . 
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Figure 2. T i l staining (T-lymphocytes) in the margin of the psoriatic lesion (x 200) 
DISCUSSION 
Changes seen in uninvolved skin adjacent to the spreading psoriatic lesion represent 
early events in the evolution of such a lesion. In this investigation, epidermal 
proliferation, keratinization in combination with the inflammatory infiltrate in the 
margin of psoriatic lesions was studied. In addition, the extracellular matrix proteins 
tenascin, heparansulphate and fibronectin were investigated. 
In the epidermal compartment, keratin 16 expression was seen peripherally from the 
parakeratosis transition point and full acanthosis, however not extending as far as the 
increased infiltrate in the dermis or as the increased tenascin expression. In the 
epidermis, discontinuous keratin 10 expression was seen confined to the full 
acanthotic epidermis. This is in agreement with previous studies12. Nuclear Ki-67 
staining, indicating epidermal proliferation, showed a more variable pattern than in 
an earlier study12. In all patients, initial acanthosis was seen before the number of 
Ki-67 stained nuclei was high, and in 4 out of 6 patients, Ks8.12 staining was seen 
more peripherally than high numbers of Ki-67 stained nuclei. Possibly a lag time 
between entering S-phase and the expression of the antigen recognized by the 
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antibody Ki-67, as postulated22, can explain this discrepancy. Alternatively, a delay 
in differentiation of keratinocytes might explain the early onset of initial acanthosis, 
especially since keratin 16 is seen early in the evolution of a lesion. 
The composition of the dermal inflammatory infiltrate in the uninvolved skin 
consisted of T-lymphocytes, a considerable part was formed by Langerhans cells, 
and CD 14 cells. In the lesion, the composition of the infiltrate was different from 
that in the uninvolved skin. It consisted of only few Langerhans cells, many T-
lymphocytes and numerous CD 14 cells. CD 14 cells were also diffusely distributed in 
the papillary and reticular dermis and along skin adnexes. The maximal presence of 
the infiltrate, in the margin of the lesion, contained considerably more Langerhans 
cells than the infiltrate in the central part of the lesion. In this respect it is of interest 
that in a previous study, CD la positive Langerhans cells were found in high 
amounts in the infiltrate of initial psoriatic lesions (50-60%), and consisted only 
10% of the infiltrate cells in chronic psoriasis23. Langerhans cell numbers in the 
epidermis were low in the lesion. This is in agreement with earlier studies23. An 
active migration of Langerhans cells in psoriasis has been postulated. CD14 positive 
cells (monocytes, macrophages) show a dense pattern in the dermis and epidermis of 
the central part of the lesion. In the uninvolved epidermis, they are not present. A 
previous study proposed a role of macrophages in the inition of a lesion24, as they 
appeared before T-lymphocytes and PMN were seen. In the present study, mono-
cytes/macrophages were seen maximally in the fully developed lesion, and no 
epidermal CD 14 cells were seen outside the involved section. The low number of 
PMN in the infiltrates of psoriatic lesions and uninvolved skin is striking. Most 
PMN seen were trapped in the stratum comeum of the psoriatic lesion. This is in 
disagreement with earlier studies, where PMN were the first cells invading the 
epidermis in the initiation of a lesion9·25. 
The extracellular matrix proteins in the dermis were differentially distributed. 
Heparansulphate was evenly distributed over the total length of the biopsy along the 
basement membrane, showing the pattern of normal skin26. Fibronectin showed no 
difference in distribution comparing involved and uninvolved dermis. Its expression 
in the uninvolved skin was high compared to that of normal skin27. Tenascin 
expression however, was strong in papillary and reticular dermis of the lesion, and 
gradually diminished towards the periphery in three out of the six biopsies. Tenascin 
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Figure 3. ОКТ6 staining (Langerhans cells) in the margin of the psoriatic lesion (x 200) 
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Figure 4. T2H5 staining (tenascin) in the psoriatic lesion and in clinically iminvolved skin (x 200). 
Reference points are marked with an arrow. A: Clinically uninvolved skin at the left 
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has shown to be increased in hyperproliferative skin diseases18 and is probably 
involved in wound healing1*. In general, tenascin seems to correlate with remodel­
ling of the epidermis. The observation that tenascin is high in the uninvolved skin 
adjacent to the psoriatic lesion suggests that it is involved in the early phase of the 
evolution of a lesion. Whether the first signal for induction of tenascin is derived 
from the inflammatory cells or from the epidermis is unknown. 
This study demonstrated in the periphery of the lesions, an increase in the extracel­
lular matrix protein tenascin and an increase in the dermal inflammatory infiltrate. In 
previous studies also dermal changes have been detected in the clinically uninvolved 
skin surrounding a psoriatic lesion, such as an increase in vascular endothelium 
measured by alkaline phosphatase10, and an increased dermal blood flow using Laser 
Doppler Flowmetry11. The maximum of the inflammatory infiltrate was present at 
the margin of the lesion, just beneath the parakeratosis transition point. The early 
expression of tenascin and the peripheral presence of the inflammatory infiltrate 
containing many Langerhans cells in the dermis, in combination with the apparent 
undisturbed epidermis, provide further evidence that the dermal compartment is 
early involved in the pathogenesis of psoriasis. 
REFERENCES 
1. Jablonska S, Chowaniec O, Beutner EH, Maciejowska E, Jarzabek-Chorzelska M, Rseza G. 
Stopping of the stratum comeum in patients with psoriasis. Production of prepmpoint papules 
and psoriatic lesions. Arch Dermatol 1982; 118: 652-657. 
2. Heng MCY, Kloss SG, Kuehn CS, Chase DG. The sequence of events ш psoriatic plaque 
formation after tape-stnpping. Br J Dermatol 1985; 112: 517-532. 
3. Camp RDR, Coulto AA, Greaves MW, Kay AB, Walport J. Responses of human skin to 
intradermal injection of leukotnenes C«, D4 and B4. J Invest Dermatol 1982; 78: 329 (abstr).Br 
J Pharmacol 1983; 80: 497-502. 
4. Wong E, Camp RD, Greaves MW. The responses of normal and psoriatic skin to single and 
multiple topical applications of leukotnene B4. J Invest Dermatol 1985; 84: 421-423. 
5. Bauer FW, van de Kerkhof PCM, Maassen-de Grood. Epidermal hyperprohferation following 
the induction of microabscesses by leukotnene B,. Br J Dermatol 1986; 114: 409-412. 
6. Pinkus H, Mehregan H. The primary histologic lesion of seborrheic dermatitis and psoriasis. J 
Invest Dermatol 1966; 46: 109-116. 
7. Braun-Falco O, Christophers E. Structural aspects of initial psoriatic lesions. Arch Derm 
Forsch 1974;251:95-110. 
47 
8 Soltam К, Van Scott EJ Patterns and sequence of tissue changes ш incipient and evolving 
lesions of psoriasis Arch derm 1972; 106: 484-490 
9. Chowamec O. Jablonska S, Beutner EH, Proniewska M, Jarzabek-Chorzelska M, Rseza G. 
Earliest clinical and histological changes in psoriasis. Dermatologica 1981; 163: 42-51. 
10. Van de Kerkhof PCM, van Rennes H, de Grood R, Bauer FW, Mier PD. Metabolie changes 
at the margin of the spreading psoriatic lesion. Br J Dermatol 1983; 108. 647-652. 
11. MacDonald Hull S, Goodfield M, Wood EJ, Cunliffe WJ. Active and inactive edges of 
psoriatic plaques: Identification by tracing and investigation by laser-doppler flowmetry and 
immunocytochermcal techniques. J Invest Dermatol 1989; 92: 782-785. 
12. De Mare S, de Jong E, van Εφ PEJ, van de Kerkhof PCM. Markers for proliferation and 
keratimzation in the margin of the active psoriatic lesion. Br J Dermatol 1990; 122: 469-475. 
13. Mackie EJ, Chiquet-Ehnsmann, Pearson CA et al. Tenascin is a stromal marker for epithelial 
malignancy in the mammary gland. Proc Natl Acad Sci USA 1987; 84: 4621-4625. 
14 Thesleff I, Mackie E, Vainio S, Chiquet-Ehnsmann R. Changes in the distribution of tenascin 
during tooth development Development 1987; 101: 289-296. 
15. Mackie EJ, Thesleff I, Chiquet-Ehnsmann R. Tenascin is associated with chondrogenic and 
osteogenic differentiation in vivo and promotes chondrogenesis in vitro. J Cell Biol 1987; 105: 
2569-2579 
16. Mackie EJ, Halfter W, Liveram D. Induction of tenascin in healing wounds. J Cell Biol 1988; 
107 2557-2767 
17. Lightner VA, Gumkowski FD, Bigner DD, Enckson HP. Tenascin/hexabrachion ш human 
skin' biochemical identification and localization by light and electron microscopy. J Cell Biol 
1989; 108· 2483-2493. 
18. Schalkwijk J, van Vlijmen IMMJ, Oosterling В, Perret С, Koopman R, Van den Bom J, 
Mackie EJ. Tenascin expression in hyperproliferative skin diseases. Br J Dermatol 1991; 124. 
13-20. 
19. Weiss RA, Eichner R, Sun TT. Monoclonal antibody analysis of keratin expression in 
epidermal diseases: a 48- and 56-kDalton keratin as molecular markers for hyperproliferative 
keratinocytes J Cell Biol 1984; 98. 1397-1406. 
20. Van Muijen GNP, Wamaar SO, Ponec M. Differentiation related changes of cytokeiatin 
expression in cultured keratinocytes and in fetal, new bom and adult epidermis. Exp Cell Res 
1987; 171. 331-345. 
21. Bogman MJJT, van de Winkel JGJ, Hoitsma AT, Ruiter DJ, Dooper IMM, Tax WJM, 
Assmann KJM, Koene RAP. Diagnosis of renal allograft rejection by macrophage immuno-
staining with a CD14 monoclonal antibody, WT14. The Lancet 1989; u: 235-238. 
22. Gerdes J, Lemke H, Baisch H, Wacker HH,Schwab U, Stein H. Cell cycle analysis of a cell 
proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67 J 
Immunol 1984, 133· 1710-1715. 
48 
23. Bieber Τ, Braun-Faico О. Distribution of CDla-positive cells in psoriatic skin during the 
evolution of the lesions. Acta Derm Venereo! (Stockh) 1989; 69: 175-178. 
24. Schubert C, Christophers E. Mast cells and macrophages in early relapsing psonasis. Arch 
Dermatol Res 1985; 277: 352-358. 
25. Pinkus H, Mehregan AH. The primary histologic lesion of seborrheic dermatitis and psoriasis. 
J Invest Dermatol 1966; 46: 109-116. 
26. Tammi RH, Hyyryläinen АМН, Maibach HI, Tammi MI. Ultrastructural localization of 
keratinocyte surface associated heparan sulphate proteoglycans in human epidermis. His­
tochemistry 1987; 243-250. 
27. Fryrand O. Studies on fibronectin in the skin. Indirect immunofluorescence studies in psonasis 
vulgaris. Arch Dermatol Res 1979; 266: 33-41. 
49 
2.2 THE INTERRELATION BETWEEN INFLAMMATION AND EPIDER-
MAL PROLIFERATION IN NORMAL SKIN FOLLOWING EPICUTA-
NEOUS APPLICATION OF LEUKOTRIENE B4; AN IMMUNOHIS-
TOCHEMICAL STUDY. 
EMGJ de Jong 
PEJ van Erp 
IMJJ van Vlijmen 
PCM van de Kerkhof 
Department of Dermatology 
University Hospital Nijmegen 
The Netherlands 
SUMMARY 
Topical application of leukotriene B4 (LTB4) on normal skin has been used as an in 
vivo model to investigate cutaneous inflammation and epidermal proliferation, which 
are important phenomena in the pathogenesis of psoriasis. The aim of the present 
investigation is to further elucidate the interrelation between inflammation and 
epidermal proliferation, using specific monoclonal antibodies as markers for 
different cell types involved and to investigate to what extent this model reflects 
changes as observed in the psoriatic lesion. 
Aliquots of LTB4 were applied on the upper arms of 8 healthy volunteers. After 
LTB^-application, biopsies were taken at consecutive time intervals. On frozen 
sections, epidermal proliferation was assessed by Ks8.12- (keratin 16) and Ki-67-
binding (cycling cells), inflammation was characterized using anti-elastase (PMN), 
Til (T-lymphocytes), pan-B (B-lymphocytes), WT 14 (CD14-positive cells) and 
OKT 6 (Langerhans cells). 
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New observations were that the density of CD14-positive cells was increased already 
after 8 hours and decreased slightly at 72 hours. A striking rearrangement of 
Langerhans cells was seen in close vicinity to intraepidermal accumulation of PMN. 
Remarkably an increased density of these cells in the dermis at 72 hours was seen 
and a decrease in the epidermis. In line with previous studies, the accumulation of 
PMN reached a maximum 24 hours after LTB^challenge. The identity of the 
mononuclear infiltrate cells which have been reported 48 to 72 hours after LTB4 
proved to be T-lymphocytes. No B-lymphocytes were observed. Кі-67-positive 
nuclei were maximally increased 72 hours after LTIVapplication, which implies that 
recruitment of cycling cells is of relevance for the LTB4-induced proliferation in 
vivo. The hyperproliferation-related keratin 16 was expressed variably in the 
suprabasal compartment. The present study demonstrates that CD 14 cells and 
Langerhans cells participate in acute LTB4 induced inflammation. 
The relevance of leukotriene B4 induced changes in normal skin for studies on the 
pathogenesis of psoriasis is discussed. In particular events in the initial psoriatic 
lesion are approached by this model. 
INTRODUCTION 
Leukotrienes are mediators that are generated in the inflammatory response in 
various tissues, including skinM. They are produced from arachidonic acid present in 
the membrane of cells including keratinocytes57 via a lipoxygenase pathway. Of par­
ticular significance in this respect is the 5-lipoxygenase product leukotriene B4 
(LTB4), which has been shown to have a potent chemoattractant activity for both 
polymorphonuclear leukocytes (PMN) and monocytes8. In addition, LTB4 stimulates 
epidermal growth in vitro'. 
Topical application of LTB4 on normal skin produces an acute inflammation, 
dominated by PMN10, followed by a perivascular mononuclear cell infiltrate after 48 
hours" and epidermal proliferation12, reaching a maximum after 72-96 hours. A 
dose-response relationship has been shown between these phenomena and the 
concentration of LTB4 applied to the skin. Therefore this approach has been used as 
an in vivo model to investigate the influence of therapies such as corticosteroids, 
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dithranol, photochemotherapy, methotrexate end retinoids on transcutaneous migra­
tion of PMN13. 
Inreased amounts of LTB4 have been found in lesionai skin of atopic dermatitis, 
allergic contact dermatitis, urticaria and psoriasis314"16. In psoriasis, a skin disorder 
characterized by epidermal proliferation and inflammation, increased production of 
12-HETE, 15-HETE, platelet activating factor, interleuldn-8, and LTB4 has been 
demonstrated in lesionai skin2"4,1617. In view of the relatively high biologic activity of 
LTB4 compared to other leukotrienes, this compound seems of particular relevance 
for inflammation control. 
The aim of the present investigation is to further elucidate the interrelation between 
inflammation and epidermal proliferation after epicutaneous application of LTB4, 
using monoclonal antibodies as markers for different cell types involved. In par­
ticular, the following questions were adressed: 
(i) what is the identity of infiltrate cells of the LTI^-induced inflammation and what 
is their relation with epidermal proliferation and keratinization. 
ii) to what extent are these changes compatible with the abnormalities observed in 
the psoriatic lesion. 
MATERIALS AND METHODS 
Subjects 
A group of 8 healthy subjects participated in the study. They had no history or signs 
of skin disease. The group consisted of 2 females and 6 males. Their age was 
between 21 and 28 years. Prior to the experiment, approval of the Ethical Commit­
tee was obtained. 
LTB4-application and biopsy procedures 
Aliquots of 100 ng of LTB4 (Paesel GmbH, Frankfurt, FRG) diluted in 10 μΐ of 
ethanol were applied on the outer surface of the upperarms of the volunteers via a 
glass cylinder (5.5 mm diameter) and the ethanol was evaporated under a stream of 
nitrogen". The test sites were covered with impermeable dressings (Silver patch, 
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van der Bend BV, Brielle, The Netherlands) held at place with leukosilk tape 
(Beiersdorf, Hamburg, FRG). 
Before LTB4-application and at time intervals of 8, 24, 48 and 72 hours biopsies 
were taken using a razor blade in conjunction with a metal guard. Chloraethyl spray 
was used as a local anaesthetic (Aethylchlorid, Adroka, Switzerland). 
The biopsies were snap frozen in liquid nitrogen, embedded in Tissue Тек OCT 
compound (Miles Scientific, Naperville, USA) and stored at -80 "С. 
Staining procedures 
To assess epidermal proliferation staining with the following monoclonal antibodies 
was performed 
i) Ks8.12 (Sigma, St Louis, USA) to assess keratin 16, which is expressed in 
hyperproliferative epidermis19,20 
ii) Ki-67 (Dakopatts, Copenhagen, Danmark) to detect a nuclear antigen present 
in actively cycling cells. 
Inflammation was characterized with the antibodies 
iii) Anti-elastase (Serotec, Oxford, England) a marker for polymorphonuclear 
leukocytes21 
iv) Tl 1 (Dakopatts, Copenhagen, Denmark) to assess T-lymphocytes (CD2) 
v) Pan-B (Dakopatts, Copenhagen, Denmark) to assess B-lymphocytes (CD22) 
vi) WT14 (Dept. Medicine, Div.Nephrol. University Hospital Nijmegen)22 to 
demonstrate CD14-positive cells which represent activated monocytes and 
macrophages 
vii) OKT6 (Ortho Diagnostic Systems, Raritan, USA) to assess Langerhans cells 
(CDla) 
Skin sections of 7 μπι were cut. The slides were fixed for 10 minutes in acetone/a­
ether 60/40 vol% for Ki-67, or in acetone for staining with the other antibodies. 
Staining with Ks8.12, Ki-67, and anti-elastase were performed using a peroxidase-
technique. In brief, slides were incubated with the monoclonal antibodies for 30 
minutes, and after 3 washes with phosphate buffered saline (PBS) incubated with 
rabbit-anti-mouse antibody (Dakopatts, Copenhagen, Denmark) conjugated with 
peroxidase for 30 minutes except for the anti-elastase antibody, which is directly 
conjugated with peroxidase. After 3 more washes with PBS and pre-incubation with 
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sodium acetate buffer, pH 4.9, slides were finally stained in sodium acetate buffer 
containing 200 mg/1 3-amino-9-ethyl-carbazole solution and 0.01% HjOj prepared 
freshly (AEC-solution) for 15 minutes at room temperature in the dark. 
Staining with Ti l , Pan-B, WT14 and OKT6 were done using a peroxidase-anti-
peroxidase technique (PAP-technique). For this technique slides were incubated with 
the monoclonal antibodies for 60 minutes. After 2 washes with PBS an incubation 
step followed with rabbit-anti-mouse immunoglobulins (RAM-Ig, Dakopatts, 
Copenhagen, Dan mark) and after 2 more washes an incubation with peroxidase-anti-
peroxidase complexes (PAP, Dakopatts, Copenhagen, Danmark) was performed. 
The incubation with RAM-Ig and PAP were repeated and the slides stained with 
AEC-solution after 2 washes with PBS and pre-incubation with sodium acetate buffer 
pH 4.9. 
All slides were finally washed with demineralized water and counterstained with 
Mayer's haematoxylin (Sigma, St.Louis, USA). Slides were mounted in glycerine 
gelatin and studied by light microscopy. 
Histological examinations 
The density of PMN, T- and B-lymphocytes, CD14-positive cells and Langerhans 
cells were assessed blind by two investigators in dermis and epidermis using a 5-
point scale: 0 = no positive cells observed, 1 = only sporadic staining of cells, 2 = 
minimal presence, 3 = moderate presence, 4 = pronounced presence. The dermal 
infiltrate was subdivided in perivascular and diffuse localization. 
The number of actively cycling cells was assessed by counting Кі-67-positive nuclei 
per mm length of section. 
Ks8.12-binding of the suprabasal and basal compartments was assessed using a 5-
point scale: 0 = no staining, 1 = sporadic staining, 2 = minimal staining, 3 = 
moderate staining, 4 = pronounced staining. 
Statistical analysis 
The Mann-Whitney test was used for statistical analysis. 
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RESULTS 
Clinical response 
Apart from a small blister in one of the volunteers at 72 hours after LTB4-ap-
plication, no signs of inflammation were seen. 
Inflammation 
Density and localization of inflammatory cells following LTB^application, are 
summarized in Figure la-Id. 
PMN (Fig. la) A reproducable accumulation of PMN in dermis and epidermis was 
found, with a maximum at 24 hours after application of LTB4. In the epidermis the 
accumulation was already present and distributed over basal and suprabasal com-
partment at 8 hours. At 24 hours, maximum accumulation, the microabscesses were 
predominantly localized in the subcorneal zone (Fig.3). After 48 hours and 72 hours 
the microabscesses became progressively flattened and faded away in all patients. 
The dermal PMN-accumulation was in phase with the epidermal infiltration, 
however, at 8 hours relatively more cells were seen in the dermal compartment. At 
72 hours, the PMN-extravasation had considerably diminished but was still present. 
CPU-positive cells (Fig. lb) In the epidermis, CD14-positive cells were only 
sporadically present at all time intervals. In contrast, dermal CD14-positive cells 
already were increased diffusely (p = 0.05) at 8 hours after LTB^application (Fig. 
4a-b). Their numbers remained increased until 48 hours, and diminished at 72 hours. 
Ixtngerhans cells (Fig. 1c) In the epidermis the CDla-positive Langerhans cells 
were present at all time intervals. The density of these cells in the epidermal 
compartment showed a statistically significant decrease at 72 hours (p < 0.01). The 
Langerhans cells showed in all subjects consistently the following migration pattern 
(Fig 5a,b,c,): Before and 8 hours after LTB^application the Langerhans cells were 
seen midepidermally. After 24 hours they lined up at the margins of the micro-
abscesses, high in the epidermis. At 48 hours they were distributed diffusely in the 
epidermis, and after 72 hours mainly in the midepidermal compartment and basal 
layer. No clustering of Langerhans cells was observed at any time interval. In the 
dermis at 8 hours Langerhans cells were seen in increased amounts compared to 
unchallenged skin (p < 0.03). Remarkably, at 72 hours a substantial increase was 
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observed in the perivascular zone and diffusely in the dermis (p < 0.02, ρ < 0.01, 
respectively). 
T-lymphocytes (Fig. Id) In the epidermis only sporadic T-lymphocytes were seen 
at 8 hours after LTB4-application. Their number increased gradually and at 48 hours 
a maximum was seen. At 72 hours T-lymphocytes were still present. Dermal 
perivascular and diffuse T-lymphocytes, however, showed an increase in number 
(Fig. 6 a-b) and a maximum was reached at the end of the observation period (p < 
0.05, ρ < 0.02, resp.). 
B-lvmphocytes No B-lymphocytes were seen in the epidermis and dermis of normal 
skin after LTB4-appl¡cation. 
Proliferation 
Numbers of Кі-67-positive nuclei and Ks8.12-binding are summarized in figure 2. 
Ks8.12 (Fig. 2a) The pattern of Ks8.12-binding after LTB^application was variable. 
A slight increase was seen of basal and suprabasal staining, however, the increase 
was not statistically significant. The interindividual variability was considerable. 
Ki-67 (Fig. 2b and Fig. 7a + b) The number of Кі-67-positive nuclei in the 
epidermal basal layer did not increase significantly during the first 24 hours, 
increased slightly after 48 hours (p < 0.05), and markedly after 72 hours (p < 
0.02). 
Figure 3: Staining with anti-elastase, showing maximal accumulation of PMN 24 hours after 
LTB4-application (x 800). 
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KS8.12 
suprabasal staining in epidermis 
hours after LTB4-application 
^ keratin tt | 
KS8.12 
basal staining in epidermis 
,A 
1Θ 24 32 40 4β 66 64 72 80 
hours after LTB4-application 
Ki-67 
epidermis 
Ο θ 16 24 32 40 48 56 84 72 80 
hours after LTB4-applicaHon 
ι
 0
 cycling nuclei 
Figure 2: Markers for epidermal proliferation at time intervals following LTB4-appIication 
(mean ± SEM); (a) Ks8.12-binding, (b) Кі-67-expression. 
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DISCUSSION 
The dynamics of inflammation and epidermal growth following epicutaneous 
application of LTB4 have been studied extensively with respect to PMN-accumula-
tion and DNA-synthesis using standard histological, enzymological and flow-
cytometrical methods10,2'·23. The infiltrate has been studied on H and E sections". In 
the present investigation different components of inflammation and epidermal growth 
are studied together, using the immunohistochemical approach which permits the 
assessment of the topography of the changes. 
The PMN-accumulation following LTB4-application has been studied using standard 
histological methods (H and E sections)10·'8 and by enzymological assessment of the 
enzyme elastase21·23. Elastase is a marker for PMN. Monocytes contain some 
leukocyte elastase but in substantially lower amounts (5%) compared to PMN24·25. 
The present study confirms the dynamics of PMN-accumulation observed in these 
studies with a maximum after 16-24 hours. 
Remarkably, in contrast to previous studies11, monocytes/macrophages (CD14-
positive cells) appeared simultaneously with PMN, within the first 8 hours. In this 
respect it is of importance that both PMN and monocytes demonstrate a chemotactic 
response to LTB4 in vitro8. 
To the best of our knowledge, a chemotactic response of Langerhans cells to LTB4 
has never been reported. Unexpectedly, an increased density of CD la positive 
Langerhans cells was observed in the dermis 8 hours after UnVapplication. An 
alternative explanation might be the expression of CD la, by dermal macrophages in 
some phases of the inflammatory process26. However, at 8 hours, CDla-positive 
cells were restricted to the subepidermal zone, whereas CD14-positive cells were 
distributed more uniformly over the dermis. 
The Langerhans cell has a well-established position as an antigen-presenting cell and 
as an initiator of the immune response and is involved in aspecific inflammation27·28. 
At 24-48 hours after LTB^-challenge, Langerhans cells marginated the PMN-ac-
cumulation. The functional aspect of this rearrangement of Langerhans cells could 
well be a response to altered structures in the epidermis, that are subsequently 
presented as antigen to the T-lymphocytes. Alternatively, Langerhans cells might 
phagocytose products released from the PMN or damaged structures of the epider-
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Figure 4: Staining with WT14, showing CD14-positive cells before (a) and 8 hours 
(b) after application of LTB4 (x 400). 
mis. Indeed, it has been shown that Langerhans cells phagocytose exogenous 
proteins29, including peroxidase. The increase of Langerhans cells in the dermis and 
a decrease in the epidermal compartment at 72 hours after LTB4-application could be 
an indication that Langerhans cells migrate from the epidermis into the dermis. 
Alternatively, the possibility can not be ruled out that the dermal increase of 
Langerhans cells is due to new influx, possibly as a reaction to epidermal loss of 
Langerhans cells. The observations in the present study confirm the function of 
Langerhans cells in non-specific inflammation involving the epidermis. Their 
possible migration pattern from the epidermal microabscesses to the dermis might be 
an indication that the Langerhans cells are part of an immunological reaction in this 
model. 
A direct interference of LTB4 with T-lymphocyte migration and proliferation never 
has been demonstrated. In the present study, an increased number of T-lymphocytes 
is observed as late as 48-72 hrs after LTB4-challenge (Fig Id). It is attractive to 
speculate that increased density of T-lymphocytes is the result of activation of 
Langerhans cells. In vitro, Langerhans cell activation results in T-cell proliferation30. 
Release of interleukine-1 has been reported to occur following Langerhans cell 
activation31. This cytokine induces the production of interleuldn-2 by T-lymphocytes; 
interleukin-2 promotes T-cell proliferation32. In addition, interleukin-1 is a chemotac-
tic substance for T-lymphocytes33. Therefore, Langerhans cell activation is likely to 
result in T-cell accumulation in vivo. 
In line with a previous study on DNA-synthesis12 the present investigation showed an 
increased number of cycling cells. Epidermal hyperproliferation might be the result 
of LTB4 itself. Alternatively, the invasion of the epidermis by PMN might desin-
tégrate the epidermis and hence induce a recovery-response comparible to the 
situation following standardized injury such as sellotape stripping. The increased 
number of Кі-67-positive nuclei implies an increased recruitment of cycling cells 
from the resting Go-population. Hyperproliferative keratinocytes in culture and in 
vivo express keratin 16"·20. Ks8.12 is a monoclonal antibody which detects keratin 
16 and 1334, however, keratin 13 is not expressed in adult human skin35. In 
contrast, in 3 out of 8 subjects no suprabasal staining was found at 72 hours after 
LTB4-application, although the marker Ki-67 showed a pronounced nuclear binding. 
Therefore, we conclude that the suprabasal expression of keratin 16 is not always 
associated with epidermal hyperproliferation in vivo. 
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Figure 5; Langerhans cells before application of LTB4 (a); after 24 hours in the vicinity of micro-abscesses 
(b); and after 72 hours decreased density in epidermis, increased density in dermal compartment (c) (x 400). 
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Inflammation with intraepidermal invasion of PMN and T-lymphocytes and par-
ticipation of monocytes are well established features of the psoriatic lesion. The 
observation that the PMN are seen relatively frequent in the acute phase and 
relatively seldom in the chronic phase of the psoriatic lesion36·37 is well reflected in 
the dynamics of this model. In the psoriatic lesion38 and in normal skin after LTB4-
application no B-lymphocytes were observed. In the early phase of the psoriatic 
lesion a pronounced accumulation of Langerhans cells in the dermal compartment 
and a decrease in the epidermis were observed by several investigators39,40. A similar 
redistribution was observed following LTB4-application on normal skin. In the 
chronic psoriatic lesion Langerhans cell density was only slightly increased in the 
dermis compared to normal skin, and the epidermal Langerhans cell counts were 
markedly decreased40. An increase in the number of cycling cells is observed in the 
psoriatic plaque41 and following LTB^application. On the other hand differences 
exist between the psoriatic lesion and the normal skin following LTB4-challenge. 
Firstly, the general architecture of the skin is strikingly different. Papillomatosis 
with tortuous capillaries are consistent findings in the psoriatic lesion but are not 
present in LTB4 treated skin. The appearance of LTB4-induced micropustules is well 
demarcated in contrast to the spongiform pustules of Kogoj in psoriasis. The 
suprabasal expression of keratin 16 is a consistent phenomenon in the psoriatic 
lesion. However, in the suprabasal compartment of LTB4-treated skin, keratin 16, 
visualized by 'Ks8.12-binding, is not present in 3 out of 8 subjects after 72 hours. 
Epicutaneous application of LTB4 induces several changes as observed in the initial 
psoriatic lesion. Therefore, it can be used as a model for the acute stages. The in 
vivo response comprizes the invasion of CD14 positive cells and a rearrangement of 
Langerhans cells. In addition, the model is of importance as an inflammation model 
to assess the potency of anti-inflammatory drugs, including antipsoriatic therapies. 
64 
ι л
ш
 · 
ШгЩа 
Щ. ^ **гу& 
" ^ ^ . . 
* 
• _ 
' ^ ¿ · 
• ν . . . • • . > .-
** 
:
 ( · ч — . _ · - , • · : · 
^ · - • / • ' : . , · - . : " -
^ 'jÊ^^b^ 
ЩтЩ
 1 /Л. -% 
Щ 
-'•· :-Л ν 
. . % - • . . » , , % . , 
• · - — л . ^ 
' · _ • > » Í 
А 
^yflË^^gfe 
и^^^г^? 
./.v:PÖI, 
'И*^ 
\ % : ^ · 
.^л>\^ ^^: 
и * " ^ * 
; 
• , • ' 
- ν 
и - • . ^ . . 
-ч 
Figure 6; Tl 1 staining, showing T-lymphocytes at 0 hours (a) and at 72 hours after LTB4-appIication 
(b) (x 200). 
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CHAPTER 3 
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3.1 SIMULTANEOUS ASSESSMENT OF INFLAMMATION AND EPIDER-
MAL PROLIFERATION IN PSORIATIC PLAQUES DURING LONG-
TERM TREATMENT WITH THE VITAMIN D3 ANALOGUE MC903: 
MODULATIONS AND INTERRELATIONS. 
EMGJ de Jong 
PCM van de Kerkhof 
Department of Dermatology 
University Hospital Nijmegen 
The Netherlands 
SUMMARY 
The influence of topical application of MC903, an analogue of la,25-dihydroxyvi-
tamin Dj, on psoriatic plaques, was investigated during a long-term treatment study. 
Parameters for epidermal growth and for inflammation were assessed on frozen 
sections using immunohistochemical methods. The aim was to elucidate the modula-
tions of these parameters in time, and interrelations between the different cell types 
involved during MC903 treatment. 
Biopsies were taken before treatment and after 1, 2, 4 and 12 weeks of treatment. 
Monoclonal antibodies against the hyperproliferation-associated keratin 16, against 
cycling cells, and against T-lymphocytes, B-lymphocytes, Langerhans cells and 
CD14-positive cells were used in combination with a polyclonal antibody against 
polymorphonuclear leukocyte (PMN) - elastase. 
The earliest change was a statistically significant decrease of PMN after one week of 
treatment followed by a decline of cycling cells after two weeks. These changes 
preceded the decrease of T-lymphocytes which occurred after 4 weeks. Keratin 16-
content tended to diminish after 4 weeks of treatment. The number of CD14-positive 
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cells decreased slightly during the observation period, whereas the number of 
Langerhans cells tended to increase. No B-lymphocytes were found. 
These results suggest that MC903 influences not primarily T-lymphocytes; PMN and 
epidermal growth seem to be more directly affected. 
INTRODUCTION 
The observation in a patient with psoriasis and senile osteoporosis, treated with 
la,25-dihydroxycholecalciferol, who showed clearing of her psoriasis, by Morimoto 
et al. in 1985', has led to a new group of therapeutics for psoriasis. Several trials 
have been carried out with different derivatives of vitamin D32·3,4. In order to 
minimize side effects on blood-calcium and -phosphate, an analogue of la,25-
dihydroxyvitamin Dj was developed which is 100 times less active on calcium and 
phosphate metabolism compared to loi,25-dihydroxyvitamin D35. In clinical trials 
this analogue, MC903, has shown to improve psoriasis*·7,8 (figure 1). 
In psoriasis both inflammation and epidermal proliferation are the well known 
HO ^ N OH 
calcitriol 
Figure 1. Chenucal structure of the vitamin D, analogue МС90Э and la,25-dihydroxycholecalciferol 
(calcitnol). 
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pathological features. Epidermal proliferation of the lesion can be defined as an 
increased recruitment of cycling cells', and the expression of hyperproliferative 
keratins (keratin 16)10. Cutaneous inflammation in psoriasis is a complex interplay of 
polymorphonuclear leukocytes (PMN), T-lymphocytes, Langerhans cells and 
monocytes. The order in which inflammation and proliferation appear during the 
pathogenesis and disappear during treatment is not yet elucidated. 
Although the clinical efficacy of MC903 is well established, its anti-psoriatic 
working mechanism is not yet totally unravelled. In vitro studies showed the anti­
proliferative and differentiation-inducing effect of la,25-dihydroxyvitamin D, on a 
HL60-cell line" and on cultured keratinocytes1213. In addition, various investigations 
also showed an immunomodulating effect, such as interference with cytokine 
production and T-cell proliferation, of lcr,25-dihydroxyvitamin оз 1 4 ·"· 1 ' · 1 7 , 1 ' as well 
as МССОЗ"·
20
. However, the in vivo relevance of these in vitro observations remains 
to be explored. 
The aim of the present investigation is to visualize changes in inflammation and 
epidermal proliferation using immunohistochemical methods during long-term 
treatment of psoriasis with the vitamin Ό3 analogue MC903. From consecutive 
biopsies frozen sections were stained with monoclonal antibodies against T- and B-
lymphocytes, CD14-positive cells and Langerhans cells, and with a polyclonal 
antibody against PMN-elastase, in combination with monoclonal antibodies against 
keratin 13 and 16, and against cycling cells. The order of events in epidermal and 
dermal compartment, and the interactions between different cell types involved, were 
studied. 
MATERIALS AND METHODS 
Patients 
Eight patients suffering from psoriasis were treated with MC903 ointment (50 Mg/g) 
twice daily (Leo Pharmaceutical Products, Copenhagen, Denmark). These patients 
had shown to respond well to MC903-treatment in a previous double-blind in-patient 
comparison study using MC903 and betamethasone21. The patients were included in 
a multi-centre trial covering 12 months of treatment. Their age was between 27 and 
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85 years, and they had received no local anti-psoriatic treatment within 4 weeks or 
systemic treatment within 2 months before the start of the study. The patients had 
normal blood calcium, phosphate, albumin, bilirubin, alkaline phosphatase, aspartate 
amino transferase, creatinine and urate. White and red blood cell counts, haemoglo­
bin, platelets and differential counts were within normal ranges. These parameters 
were measured every 4 weeks. Clinical improvement was described using the PASI-
score. 
Biopsies 
Punch biopsies (3 mm diameter) were taken from psoriatic lesions of 6 patients 
before treatment and after 1 week, 2 weeks, 4 weeks and 12 weeks of treatment with 
MC903. Biopsies were embedded in Tissue Тек OCT compound (Miles Scientific, 
Naperville, USA), snap frozen in liquid nitrogen and stored at -80oC. Sections of 7 
μπι were cut and fixed for 10 minutes in acetone-ether 60/40 vol% for staining with 
the antibody Ki-67 and with acetone for the remaining antibodies. 
Monoclonal antibodies 
To assess epidermal proliferation monoclonal antibodies were used against a nuclear 
antigen present in cycling cells (Ki-67, Dakopatts, Copenhagen, Denmark)22, and 
against keratin 13 and 16 (Ks8.12, Sigma, St Louis, USA). Keratin 16 is present in 
hyperproliferative epidermis23, meanwhile keratin 13 has not been found in adult 
human skin24. To characterise the inflammatory infiltrate staining was performed 
with antibodies against leukocyte-elastase which visualises PMN (Serotec, Oxford, 
England); against T-lymphocytes (CD2) (Til, Dakopatts, Copenhagen, Denmark); 
against B-lymphocytes (CD22) (pan-B, Dakopatts, Copenhagen, Denmark); against 
CD14-positive cells which represent monocytes and macrophages (WT14, Dept. 
Medicine, Div. Nephrol. University Hospital Nijmegen)25; and against Langerhans 
cells (OKT6, Ortho Diagnostic Systems, Raritan, USA)26. 
Staining procedures 
An indirect peroxidase technique was used for staining with Ks8.12 and Ki-67. In 
brief, slides were incubated for 30 minutes with the monoclonal antibodies and after 
a washing step with phosphate buffered saline (PBS) incubated with rabbit-anti-
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mouse-immunoglobulin conjugated with peroxidase (RAMPO) for 30 minutes. A 
solution of 3-amino-9-ethylcarbazole (AEC) in sodium acetate buffer pH 4.9 
containing 0.01% H202 was added for 15 minutes after preincubation with sodium 
acetate buffer pH 4.9. Staining with anti-elastase was done using a direct im-
munoperoxidase technique. After an incubation step of 30 minutes and 3 washes in 
PBS, AEC-solution was added after preincubation with sodium acetate buffer pH 
4.9. Staining with T i l , pan-B, WT14 and OKT6 was performed using a peroxidase-
anti-peroxidase technique (PAP-technique). Slides were incubated for 60 minutes 
with the monoclonal antibodies. After a wash-step with PBS an incubation cyclus 
followed of 20 minutes with rabbit-anti-mouse-immunoglobulin (RAM-Ig, Dakopatts, 
Copenhagen, Denmark), 2 washes with PBS, and 20 minutes with peroxidase-anti-
peroxidase-complexes (PAP, Dakopatts, Copenhagen, Denmark). This cyclus was 
repeated one more time, slides were preincubated with sodium acetate buffer pH 4.9 
and finally stained in AEC-solution. All slides were counterstained with Mayer's 
haematoxylin (Sigma, St Louis, USA) and mounted in glycerin gelatin. 
Histological examinations 
Epidermal proliferation was measured by counting the number of Ki-67 positive 
nuclei per mm length of section, and by assessing Ks8.12-staining in suprabasal and 
basal layers of the epidermis using a 5-point scale: 0 = no staining, 1 = sporadic 
staining, 2 = minimal staining, 3 = moderate staining, 4 = pronounced staining. 
Dermal inflammation (PMN, T-lymphocytes, B-lymphocytes, Langerhans cells, 
CD14-positive cells) was semiquantitatively enumerated by expressing the number of 
positively stained cells as a percentage of the total number of infiltrate cells similar 
to Synkowski and Provost27: 0 = no positive cells, 1 = sporadic, 2 = 1-25%, 3 = 
26-50%, 4 = 51-75%, 5 = 76-99%, 6 = 100%. Inflammatory cells in the epider-
mis were assessed using the 5-point scale as used for Ks8.12-staining. 
Statistical analysis 
For statistical evaluation the Mann-Whitney test was used. 
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RESULTS 
Clinical response 
In all patients MC903 resulted in an improvement of the psoriatic lesions. Total 
clearance was not achieved in any of them after 12 weeks of treatment. The amelior­
ation was most pronounced in the first 4 weeks of treatment (p < 0.05). Con­
tinuation beyond this period resulted in a modest improvement only. No side effects 
were observed during treatment. No flare ups were seen in this period. Clinical 
results from this multi-center study covering 12 months will be available in the near 
future. 
Epidermal growth 
The effect of MC903 on parameters of epidermal growth are summarized in figures 
2, 4 and 5. The number of actively cycling epidermal cells (Кі-67-positive nuclei) 
showed a statistically significant decrease after 2 weeks of treatment (p < 0.03). 
After this initial improvement the number of Кі-67-positive nuclei only decreased 
slightly. Values as found in uninvolved psoriatic skin by other investigators28 were 
not reached in the 12 weeks observation period. Keratin 16, seen as Ks8.12-staining 
was high in the suprabasal layers of the epidermis. The intensity of this staining 
remained pronounced and diminished only in the period between 4 and 12 weeks of 
treatment. However, this decrease was not statistically significant. Basal staining was 
almost unchanged throughout the whole observation time, and varied only from no 
staining to sporadic staining in all biopsies. The distribution and intensity of keratin 
16 did not switch to the pattern characteristic for clinically uninvolved psoriatic skin 
which consists of sporadic staining of the basal layer and no staining of the supra-
basal compartment10. 
Inflammation 
Density of inflammatory cells are shown in figures 3a,b,c,d and 6. In untreated 
psoriatic plaques, PMN as shown by the antibody anti-elastase, were present as 
micro-abscesses in the stratum comeum, and dispersed in the epidermis. Already 
after 1 week of treatment with MC903, only sporadic and small micro-abscesses 
were seen. After 4 weeks the number of PMN had decreased strikingly and no 
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Figure 2. Markers for epidermal growth before and during treatment of psoriatic plaques with 
MC903, expressed as means ± sem. a) Ki-67 (cycling epidermal cells), b) Ks8.12 (epidermal cells 
expressing keratin 16), [13= suprabasal staining, В = basal staining. 
microabscesses were found anymore (p < 0.01). Dermal PMN also diminished in 
this treatment period. Remarkably, after 12 weeks an increase of epidermal as well 
as in dermal PMN was measured (Fig 3a). T-lymphocytes (Tll-positive cells) were 
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Figure 3. Markers for inflammation before and during treatment of psoriatic plaques with MC903, 
expressed as means ± sem. H = epidermal cells, £ 3 = dermal cells, a) anti-elastase (PMN), 
b) Ti l (T-lymphocytes), c) WT14 (CD14-positive cells), d) OKT6 (Langerhans cells). 
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Figure 4. Ki-67 staining (155x), a) before treatment, b) after 12 weeks of treatment with MC903. 
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numerous in the dermis and epidermis of untreated psoriatic lesions. Of the dermal 
infiltrate, 76-90% of the cells were T-lymphocytes. Also a considerable epider-
motropism was seen. In the period of treatment with MC903, T-lymphocytes 
diminished gradually in both dermal and epidermal compartment, resulting in a 
borderline significant decrease after 4 weeks (p = 0.05). B-lymphocytes (pan-B-
positive cells) were not found in psoriatic skin. CD14-positive cells, assessed by the 
monoclonal antibody WT14, were seen diffusely in as well dermis as epidermis. 
Their numbers decreased slightly however not statistically significant. Their 
distribution pattern did not show a consistent change. Epidermal Langerhans cells, 
visualised by OKT6, tended to increase within the first week (p > 0.05) of treat-
ment and remained at the same level during the observation period of 12 weeks. 
The pattern of distribution of these cells correlated with the general histological 
appearance: prctreatment biopsies, showing marked acanthosis, papillomatosis and 
parakeratosis, demonstrated focal aggregates of Langerhans cells intermingled with 
Langerhans cell-free zones whereas biopsies of treated skin with a more modest 
degree of involvement, showed a more diffusely .distributed network of Langerhans 
cells. Dermal Langerhans cells decreased slightly during treatment with MC903. 
Relation between clinical and histological scores 
If the clinical response and scores for different histological parameters are com-
pared, it can be seen that the decrease of the number of epidermal PMN and the 
number of Ki-67 positive nuclei, preceded the decrease in PASI-score. T-lym-
phocytes diminished simultaneously with the clinical scores. Also Ks8.12 binding 
tended to diminish at the same time as the PASI-score. 
The patient group was divided into a group showing marked improvement (PASI 
after 12 weeks < 3, n=4) and a group showing slight to moderate improvement 
(PASI after 12 weeks > 3, n=2). If these two groups are compared, it can be seen 
that the decrease in Ki-67 positive nuclei is twice as high in the group showing 
marked improvement compared to the decrease in the group showing slight to 
moderate improvement (decrease in stained nuclei/mm length of section 157 and 70 
respectively). The reduction of epidermal PMN in the group showing marked 
improvement was also twice as high as the reduction in the other group (reduction of 
2.25 and 1 respectively). The number of T-lymphocytes reduced substantially in the 
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Figure 5. Ks8.12 staining (155x), a) before treatment, b) after 12 weeks of treatment with MC903. 
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Figure 6. Tl 1 staining (lOOx), a) before treatment, b) after 4 weeks of treatment with MC903. 
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first group, whereas the decrease in the second group was marginal (reduction of 1.4 
and 0.1 respectively). Ks8.12 binding diminished in both groups to the same extent 
(2.4 and 2.8 respectively). 
DISCUSSION 
The dynamics of the changes observed in psoriatic lesions during treatment with 
MC903, are described in figure 2 and 3. In the order of events the earliest change is 
a pronounced decrease of PMN, which is already statistically significant after one 
week of treatment (p < 0.05). Simultaneously a tendency can be seen of the number 
of Langerhans cells to increase, however this change is not statistically significant. 
After two weeks a significant decrease in Кі-67-positive nuclei occurs (p < 0.05) of 
almost 40%. Following this event, PASI-scores diminished after 4 weeks of 
treatment and a reduction of T-lymphocytes was observed, reaching borderline 
significancy (p = 0.05). Ks8.12-staining diminishes only in the period between 4 
and 12 weeks of treatment. Although all parameters tended to improve during 
further treatment, the number of PMN showed a slight increase in this period (p > 
0.05). The group of patients reaching the lowest PASI-scores after 12 weeks of 
treatment showed the most pronounced reduction of the number of Ki-67 positive 
nuclei, epidermal PMN and T-lymphocytes. 
The skin plays an important role in vitamin D metabolism. It is not only the site 
where vitamin D is produced29, but keratinocytes also have receptors for la,25-
dihydroxyvitamin D3 and function as a target organ30. Growing evidence indicates 
that la,25-dihydroxyvitamin D3 can suppress proliferation and induce differentiation 
of different cell types including keratinocytes"·'2'". It is not clear through which 
working mechanism la,25-dihydroxyvitamin D3 influences proliferation and 
differentiation of skin. la,25-dihydroxyvitamin Dj possesses a cytosolic receptor31 
that is transported to the nucleus after binding, and is thought to work through 
DNA-transcription32. In addition, several authors reported a rapid effect of la,25-
dihydroxyvitamin D3 on intracellular calcium transport33 and on cGMP in human 
skin fibroblasts34. These observations suggest that more immediate mechanisms, not 
mediated via the genom, might be of relevance for the mode of action of la,25-
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dihydroxyvitamin Dj. MC903 is very similar to the natural metabolite la,25-
dihydroxyvitamin Dj. They possess the same receptor and they induce cell differen­
tiation and inhibit cell proliferation at the same concentrations in vitro. In addition, 
MC903 is at least 100 times less potent in its effect on calcium metabolism in vivo5. 
In the present investigation a rapid decrease of the number of proliferating cells, 
measured as Кі-67-positive nuclei, was found after two weeks, resulting in a total 
decrease of 48% after 12 weeks. This result shows that the in vitro effect on 
proliferation of MC903 is also found in the in vivo situation. These findings are in 
accordance with values found by de Mare et al who observed a decrease in DNA-
content after 6 weeks of treatment with MC903 using flowcytometrical methods. 
This effect was comparable with the effect of betamethason21. Ks8.12-binding, in 
psoriasis revealing keratin 16 expression, only showed a tendency to diminish after 
4-12 weeks of treatment. In a previous investigation, using flowcytometrical 
quantification, Ks8.12-binding proved to be reduced significantly after 6 weeks of 
treatment with MC9032'. The discrepancy between the immunohistochemical and 
flowcytometrical assessment can be explained by the precise quantification which is 
provided by the flowcytometrical approach. Although the number of cycling cells is 
reduced in an early stage of MC903-treatment, the reduction of the intraepidermal 
accumulation of PMN proved to anticipate the antiproliferative effect in vivo. 
Receptors for la,25-dihydroxyvitamin D3 are present in cell types involved in 
immunological reactions, such as activated T-lymphocytes, B-lymphocytes, mono­
cytes and thymocytes15. Cytokine production such as IL-1, IL-2, IL-6 and EGF-ß, is 
modulated by la,25-dihydroxyvitamin Dj and / or MC9031416"M. It has been 
suggested that IL-1 might induce epidermal proliferation35. The present study 
demonstrates the effect of MC903 on the immune system in vivo. At first, the 
accumulation of PMN diminishes and after the most significant reduction of 
epidermal proliferation (two weeks) T-lymphocytes appear less frequently (4 weeks). 
CD14-positive cells tend to diminish slightly and gradually during the 12-week treat-
ment with MC903, however without reaching a statistically significant reduction. 
The reappearance of PMN and the slight reduction of the remaining parameters 
during 4-12 weeks of treatment is intriguing. Further studies are needed to elucidate 
this phenomenon. The molecular basis of the interference of MC903 with inflam-
mation in vivo remains speculative. However, based on in vitro observations, it is 
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feasible that MC903 might work via modulation of IL-1 and IL-2 production or by 
interference with the response of keratinocytes to interleukin-l. 
Well-known antipsoriatic therapies such as UV-irradiation and corticosteroids36·, 
decrease epidermal Langerhans cells during treatment. In this light it is intriguing 
that Langerhans cells did not diminish but increased during therapy with MC903. In 
several biopsies, in which the histological appearance normalised to a large extent, 
the distribution of Langerhans cells returned to the normal pattern of a diffuse 
midepidermal network. Therefore, a reduction of the number of Langerhans cells 
does not seem a conditio sine qua non necessary for the improvement of psoriatic 
plaques. 
The present study suggests that the effect of the vitamin D3 analogue MC903 is not 
primarily via interference with the number of T-lymphocytes. However, MC903 
might alter the response of keratinocytes to interleukin-l, resulting in a down 
regulation of epidermal proliferation. The PMN and epidermal growth seem to be 
targets with substantial relevance for MC903 in psoriasis. 
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SUMMARY 
Topical retinoids have been suggested to be of potential value in the treatment of 
psoriasis. The aim of the present study was to find out whether topical application of 
13-cis retinoic acid (13-cis-RA) has an antipsoriatic effect. Nine patients participated 
in the investigation. In each patient, two comparable psoriatic lesions (5 χ 5 cm or 
more) were selected for treatment with either 13-cis-RA in a 0.1 % cream base or 
with the vehicle only (placebo), using a double-blind approach. The investigation 
was a left-right within-subject comparison. Before and after four weeks the lesions 
90 
were recorded for clinical scores. Punch biopsies were taken in 8 patients before and 
after treatment and examined using immunohistochemical methods to assess epider-
mal proliferation and keratinization, and to assess inflammation. 13-cis-RA treatment 
resulted in a mild decrease of scaling and induration. Erythema however increased. 
No statistically significant difference in biological effects was reached between 13-
cis-RA and placebo treated lesions and no changes in expression of the immuno-
histochemical markers were seen. 
INTRODUCTION 
Systemic application of retinoids is a well-established treatment for severe acne, 
disorders of keratinization and psoriasis'"1. Side effects however restrict the use of 
this treatment to the most severe expressions of these disorders. Therefore, the 
search for topical administration of retinoids seemed worthwhile. 
Several clinical studies in plaque-type psoriasis have shown that treatment with 
topically applied all-trans retinoic acid (All-trans RA) results in a modest therapeutic 
effect which can be observed after 2 weeks of treatment5"12. Nevertheless, the 
clinical usefulness of topically applied all-trans RA in psoriasis is limited by the 
appearance of skin irritation ("retinoid dermatitis") in most patients. 
Topical 13-cis-retinoic acid (13-cis-RA) proved to be moderately effective in the 
treatment of acne13. Recently, Steijlen et al. reported a beneficial effect of 13-cis-RA 
0.1% cream in Darier's disease14. Topical application of a cream containing 13-cis-
retinoic acid 0.1% has been shown in a previous study to inhibit inflammation 
induced by leukotriene B4 (LTB4). Following treatment of normal skin with this 
cream, the intraepidermal accumulation of polymorphonuclear leukocytes (PMN) 
after epicutaneous application of LTB4 proved to be remarkably inhibited15. In additi-
on, topically applied 13-cis-RA as a 0.1% cream has been shown to be well 
tolerated in human volunteers16. Since LTB4 induced migration of PMN has been 
suggested to be of importance as an antipsoriatic target17, and the characteristics 
concerning the local tolerability of 13-cis-RA signify a potential advantage over all-
trans RA, a study was conducted aimed at evaluating the efficacy and safety of 
topical 13-cis RA in plaque-type psoriasis and estimating to which extent this 
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treatment modulates immunohistochemical parameters for epidermal growth and 
inflammation. 
MATERIALS AND METHODS 
Patients 
Nine patients, aged 33 to 67 years with chronic plaque psoriasis, participated in the 
study. The group consisted of 5 males and 4 females. In 5 patients, the involvement 
of the skin was below 10% of the body surface, and in 4 patients the involvement 
ranged between 10 and 30% . Before starting the trial, no systemic treatment had 
been administered for at least 4 weeks, and the patients had refrained from topical 
treatment for at least 2 weeks. Prior to the experiment, approval of the medical 
ethical committee was obtained. 
Application of creams 
In each patient, two comparable psoriatic plaques (5 χ 5 cm or more) were selected 
for the investigation. Plaques were selected on areas which are usually not exposed 
to sunlight. As the study was double-blind, the identity of the cream was not known 
to the patient and investigators throughout the observation period. During 4 weeks; a 
0.1% 13-cis-RA cream (F. Hoffmann-La Roche AG, Basel, Switzerland) or the 
vehicle only (placebo) were applied twice daily thinly and evenly on the selected 
areas without occlusion. 
Clinical monitoring 
Before treatment and at the end of the investigation, a photographic documentation 
was performed. During the treatment, the severity of the lesions was recorded using 
a 5-point scale for erythema, scaling and induration, as follows: 0 = no invol­
vement, 1 = slight involvement, 2 = moderate involvement, 3 = severe invol­
vement, 4 = severest possible involvement. 
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Cellbiological assessment 
Before and at the end of the treatment punch biopsies (3 mm diameter) were taken 
from the psoriatic lesions treated with 13-cis-RA cream and placebo. The biopsies 
were embedded in tissue Тек OCT Compound (Miles Scientific, Naperville, USA), 
snap frozen in liquid nitrogen and stored at -80eC. Sections of 7 /*m were cut and 
fixed for 10 minutes in acetone/ether 60/40% for staining with the antibody Ki-67 
and with acetone for staining with the remaining antibodies. 
For immunohistochemical studies a panel of monoclonal antibodies was used. 
Inflammation was characterized with the antibodies: 
(i) Anti-elastase (Serotec, Oxford, England), a marker for polymorphonuclear 
leukocytes (PMN) 
(ii) Ti l (Dakopatts, Copenhagen, Denmark) against T-lymphocytes (CD2) 
(iii) WT14 (Dept. Medicine, Div. Nephrol., University Hospital Nijmegen) 
against CD 14 positive cells which represent monocytes and macrophages" 
(iv) OKT6 (Ortho Diagnostic Systems, Rari tan, USA) to assess Langerhans cells 
(CD la) 
Epidermal proliferation was characterized with the antibody Ki-67 (Dakopatts, 
Copenhagen, Denmark) which binds with a nuclear antigen present in cycling cells. 
Keratinization was characterized with the antibodies: 
(i) Ks8.12 (Sigma, St. Louis, USA) to assess keratin 16, which is expressed in 
hyperproliferative epidermis. 
(ii) RKSE60 (Gift from Dr. Fr. Ramaekers, Dept. of Pathology, Nijmegen) 
against keratin 10, a keratin present in differentiated epidermis. 
For staining with RKSE60, Ks8.12 and Ki-67, an indirect peroxidase technique was 
used. In brief, the slides were incubated with the monoclonal antibodies for 30 
minutes, washed three times with phosphate buffered saline (PBS) and incubated 
with rabbit-anti-mouse antibody (RAMPO, Dakopatts, Copenhagen, Denmark) 
conjugated with peroxidase for 30 minutes. After another washing step with PBS and 
preincubation with sodium acetate buffer pH 4.9, slides were stained in sodium 
acetate buffer, which contained 200 mg/1 3-amino-9-ethyl-carbazole-solution and 
0.01% H202 (AEC-solution) for 15 minutes. A direct immunoperoxidase technique 
was used for staining with anti-elastase. The slides were incubated for 30 minutes 
with the antibody; and after washing with PBS and a preincubation with sodium 
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acetate buffer, pH 4.9, AEC-solution was added. Staining with Ti l , WT14 and 
OKT6 was performed using a peroxidase-anti-peroxidase technique (PAP-technique). 
After an incubation of 60 minutes with the antibody and a washstep with PBS, the 
slides were incubated for 20 minutes with rabbit-anti-mouse-immunoglobulin (RAM-
Ig, Dakopatts, Copenhagen, Denmark), washed two times with PBS, incubated for 
20 minutes with peroxidase-anti-peroxidase-complexes (PAP, Dakopatts, Copen­
hagen, Denmark) and again washed with PBS. After repeating the incubation with 
RAM-Ig and PAP, the slides were preincubated with sodium acetate buffer, pH 4.9, 
and finally stained in AEC-solution. At last, all slides were counterstained with 
Mayer's haematoxylin (Sigma, St. Louis, USA) and mounted in glycerin gelatin. 
Histological examination 
The number of Ki-67 positive nuclei was counted per mm length of section. To 
assess Ks8.12 and RKSE60-staining in suprabasal and basal layers of the epidermis, 
we used a 5-point scale: 0 = no staining, 1 = sporadic staining, 2 = minimal 
staining, 3 = moderate staining, 4=pronounced staining. The same scale was used 
for assessment of anti-elastase. Ti l , WT14 and ОКТб-staining in the epidermis. In 
the dermis we assessed staining with anti-elastase, T i l , WT14 and OKT6 by 
semiquantitative enumeration of positively stained cells as a percentage of the total 
number of infiltrate cells": 0 = no positive cells; 1 = sporadic; 2= 1-25%; 3= 26-
50%; 4= 51-75%; 5= 76-99%; 6= 100%. 
Statistical analysis 
Statistical analysis was carried out using the Wilcoxon Ranking Test for paired data. 
RESULTS 
Before treatment the clinical severity scores for erythema, scaling and induration 
were similar in the lesions to be treated with 13-cis-RA and the placebo cream. 
Topical treatment with 13-cis-RA and its placebo cream was well tolerated. In one 
patient a tenderness was experienced on both sides. The overall improvement was 
inconspicious. 
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Figure 1 summerizes clinical scores. Scaling and induration decreased statistically 
significant following treatment with 13-cis-RA (P<0,05). In contrast, scaling and 
induration in patients treated with placebo cream decreased without reaching statisti-
cal significancy. Erythema, however showed a tendency to increase (P>0,05) after 
treatment both with 13-cis-RA and placebo cream. The differences were not 
statistically significant. No erythema was seen on the perilesional skin. 
The histological examination of the pretreatment and posttreatment biopsies showed 
a characteritic psoriatic appearance. Papillomatosis, acanthosis and parakeratosis of 
the epidermis were distinct features in both pretreatment and posttreatment biopsies. 
Ki-67 staining showed average numbers of 200 actively cycling cells per mm length 
of epidermis. In additon, an intense suprabasal Ks 8.12 staining (keratin 16) demon-
strated the hyperproliferative state of the epidermis. Staining with RKSE60 (keratin 
10) also showed suprabasal staining and distinct locations without keratin 10. These 
loci were observed in epidermis overlying dermal papillae. This distribution was also 
found in a previous study20. The untreated and treated psoriatic lesions showed a 
dermal infiltrate consisting mainly of T-lymphocytes. Polymorphonuclear leukocytes 
in epidermis and dermis were also found. Langerhans cells were seen focally in the 
epidermis and in the dermal infiltrate. CD14-positive cells were seen predominantly 
in the dermis. These cells were not restricted to the perivascular infiltrate, but were 
diffusely distributed in the dermis. 
No statistically significant changes in the parameters for epidermal proliferation (Ki-
67), keratinization (Ks8.12, RKSE60) or for infiammation (anti-elastase, T i l , 
WT14, OKT6) could be found in 13-cis-RA versus placebo treated lesions and in 
pretreatment versus posttreatment (13-cis-RA and vehicle only) lesions. 
DISCUSSION 
The present study demonstrates a mild decrease of scaling and induration following 
topical application of 13-cis-RA. On the other hand, erythema tended to increase 
following this treatment. Immunohistochemical markers were not changed after 
treatment with 13-cis-RA. 
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The slight improvement of scaling and induration is compatible with the previous 
observation of a beneficial effect of 13-cis-RA in Dariers disease14. Topical 13-cis-
RA also causes slight improvement in acne13. In addition, topical application of this 
retinoid on normal skin reduced the LTB4-induced PMN accumulation15. However, 
in the present study the density and composition of the infiltrate did not change 
during therapy with the same preparation. 
Concentrations of 13-cis-RA between 0.05 % and 0.1 % in a cream base proved to 
have a therapeutic benefit in acne, and in Darier's disease 13-cis-RA in the same 
concentration and same vehicle as used in the present study proved to be effective14. 
In addition, a clear effect on LTB4-induced accumulation of PMN was shown with 
the same preparation13. In contrast, 0.1 % 13-cis-RA in a cream base showed no 
convincing amelioration of clinical and histological parameters in psoriatic lesions 
(present study). An increase of the concentration of 13-cis-RA or an ointment base 
might add to the therapeutic effect. In conclusion, the clinical value of topical 13-
cis-RA (0.1 % cream base) in the treatment of psoriasis is limited. This parallels the 
observations in acne where systemic therapy is far more efficacious than topical 
treatment. 
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3.3 SHORT-CONTACT DITHRANOL TREATMENT OF PSORIASIS, 
USING A NOVEL EMULSIFYING OINTMENT (HERMAL-AW"): 
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SUMMARY 
In this communication the clinical and immunohistochemical effects of short contact 
applications of dithranol (0.5-5%) in the novel emulsifying ointment Hermal-AW are 
reported. Twenty patients were treated and biopsies were taken before treatment 
(n=16), after two (n=5) and eight weeks (n=16) for immunohistochemical as-
sessment of proliferation, keratinization and inflammation. Among the patients 75% 
showed a satisfactory clinical response. Of the parameters investigated, Ks8.12 
binding (keratin 13 and 16) showed the most pronounced correlation with the clinical 
scores. Although T-lymphocytes and CD14-cells persisted up to 8 weeks, epidermal 
polymorphonuclear leukocytes diminished in an earlier phase. The epidermal 
changes preceded the dermal changes. 
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INTRODUCTION 
Dithranol is a well-established treatment for chronic plaque psoriasis1,2. In-patient 
treatment with dithranol monotherapy or combined regimes of dithranol with 
ultraviolet radiation and tar ("Ingram scheme") have a remarkably high clearing 
efficiency and are safe*. However, irritation of the skin and staining limit the 
classical application largely to in-patient departments or day care centres. 
During the last 15 years, short contact therapy with dithranol has become an 
important alternative for the classical longterm applications4"13. The limited ap-
plication periods (10-30 minutes) using relatively high doses of dithranol have 
revolutionized out-patient dithranol therapy. Staining of clothes, textiles and 
bathroom equipment however, has seriously decreased the first enthusiasm of short 
contact therapy. 
The development of new formulations which permit an efficient removal of dithranol 
from the skin has opened new perspectives for short contact dithranol treatment. In 
the present study the clinical efficiency and staining properties of dithranol (0.5-5%) 
in the emulsifying ointment Hermal-AW (Hernial, Hamburg, FRG) is evaluated 
using clinical severity scores. 
The effect of dithranol on classical histological parameters has been studied in the 
past. Proliferation has been investigated measuring epidermal thickness using H & E 
staining, the number of mitoses or 3[H]-thymidine incorporation14"16. The inflam-
matory infiltrate has been studied mainly on H & E sections17. 
In the present study, the effect of dithranol-treatment in a new ointment base on 
specific markers for proliferation, keratinization and inflammation was studied using 
immunohistochemistry. Especially the correlations between clinical scores and the 
different markers was of our interest. 
MATERIALS AND METHODS 
Patients 
A group of 20 patients, 11 females and 9 males, aged between 19-73 years, 
participated in the investigation. The percentage of their body surface involved with 
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psoriasis varied between few palm-sized plaques to 49%. The Psoriasis Area and 
Severity Index (PASI) before treatment varied between 5 and 27, averaging 13.2. 
All patients had been untreated for at least two weeks. Patients had refrained from 
systemic treatments (retinoids, methotrexate) for at least six months. Patients with 
exsudative eczematized or pustular manifestations were excluded from the study. 
Permission from the Ethics Committee and written informed consent from all 
patients were obtained. 
Treatment protocol 
Dithranol Hernial AW applications were carried out on an out-patient basis using a 
short contact scheme. The ointments were applied daily by the patients at home. The 
duration of the application was 20 minutes per day. Dithranol 0,5%, 1%, 2%, 3%, 
4% and 5% were manufactured by the pharmacist in Hernial-AW (Herma!, Ham­
burg, FRG). The concentrations were increased after 3 days of application if no 
burning or stinging sensation was reported. If the concentration of 5% was reached 
and no further improvement was observed the application periods were extended two 
hours. The ointments were removed with water and a detergent. Changes in the 
duration of the application period were done at three day intervals. No increase of 
the concentration or lengthening of the application period was done in case the 
patient experienced a burning sensation and/or in case of the appearance of a 
pronounced erythema around the plaques. 
During the phase that the concentrations of dithranol were increased, the patient 
visits were three times a week. If an optimal concentration was reached the patient 
visited the department once a week. The duration of treatment was eight weeks. 
During the treatment the clinical response was monitored at every visit. Clinical 
monitoring was done using the PASI". To express the relative improvement of the 
individual patient, the following equation was used: 
PASI before - PASI after χ 100% = relative improvement. 
PASI before 
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The appearance of irritation and staining was monitored on a 3-point scale (-
/ + / + + ) . Following discontinuation of treatment the patient was seen at regular 
intervals. A relapse was defined as the reappearance of new lesions. 
Biopsy procedures and immunohistochemical staining 
In all 20 patients, biopsies were taken from the lesions before and after treatment. 
An additional biopsy was taken from a subgroup of 5 patients after two weeks of 
treatment. The biopsies were snap frozen in liquid nitrogen and stored at -80oC until 
use. Slides of 7 μπι were cut and fixed in acetone or in acetone/ether 60/40% for 10 
minutes. Staining to assess epidermal proliferation, keratinization and epidermal and 
dermal inflammation, was done using the following antibodies: 
Proliferation 
Ki-67 (Dakopatts, Copenhagen, Denmark): binds to a nuclear antigen present in 
cycling cells 
Keratinization 
Ks8.12 (Sigma, St Louis, USA): binds to keratin 13 and 16. Keratin 16 is expressed 
by hyperproliferative keratinocytes". Keratin 13 is not present in adult human skin20. 
RKSE60 ( a gift of F. Ramaekers): binds to keratin 10. Keratin 10 is expressed by 
differentiated keratinocytes. 
Inflammation 
Anti-elastase (Serotec, Oxford, England): staining leukocyte elastase, present in 
polymorphonuclear leukocytes (PMN) 
Til (Dakopatts, Copenhagen, Denmark): stains CD2, present on T-lymphocytes 
OKT6 (Ortho Diagnostic Systems, Raritan, USA): stains CDla, present on Langer­
hans cells 
WT14 (Dept. Medicine, Div. Nephrol. University Hospital Nijmegen): directed 
against CD 14, present on monocytes and macrophages21. 
A direct peroxidase technique was used to visualize PMN. An indirect peroxidase 
technique was used for staining with the antibodies Ki-67, Ks8.12 and RKSE60. 
Slides were incubated for 30 minutes with the antibodies in a dilution of 1:100, 
1:40, 1:25 and 1:10 respectively. After washing in phosphate buffer the slides were 
incubated with a solution of rabbit-anti-mouse-immunoglobulin conjugated with 
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peroxidase 1:50 in phosphate buffer containing 5% human AB-serum for 30 
minutes, except for the anti-elastase antibody. After 3 washing steps in phosphate 
buffer and preincubation in sodium acetate buffer pH 4.9, slides were stained in a 
solution of 3-amino-9-ethyl-carbazole (AEC) in sodium acetate buffer containing 
0.01% H202 for 10 minutes. All slides were counterstained with Mayer's haemato-
xylin (Sigma, St Louis, USA) and mounted in glycerin gelatin. 
Staining with T i l , OKT6 and WT14 was carried out using a peroxidase-anti-
peroxidase technique. Slides were incubated for 60 minutes with the monoclonal 
antibodies in a dilution of 1:100. After washing in phosphate buffer the slides were 
incubated with rabbit-anti-mouse-immunoglobulin (RAM-Ig, Dakopatts, Copenhagen, 
Denmark) 1:25 in phosphate buffer for 20 minutes. This was followed by a washing 
step and incubation with peroxidase-anti-peroxidase complexes (PAP-complexes, 
Dakopatts, Copenhagen, Denmark) 1:100 in phosphate buffer for 20 minutes. Once 
more the slides were incubated with RAM-Ig, followed by PAP-complexes. The 
slides were stained in AEC-solution in sodium acetate buffer and H2O2 and counter-
stained with Mayer's haematoxylin. Finally they were mounted in glycerin gelatin. 
Histological changes in the epidermal and dermal compartment were assessed using 
a semi-quantitative scale: 
Epidermis: 0= no staining, 1= sporadic staining, 2= minimal staining, 3 = 
moderate staining, 4= moderate-pronounced staining, 5= pronounced staining, 6= 
whole epidermis stained. 
Dermis: 0= no stained cells, 1= sporadic, 2= 1-25% of the infíltrate cells stained, 
3= 26-50%, 4= 51-75%, 5= 76-99%, 7= 100%. 
Кі-67-positive nuclei were counted per mm length of epidermis. 
Statistical analysis 
The Wilcoxon ranking test for matched pairs was used for the statistical analysis. 
RESULTS 
Clinical response 
The clinical response to the treatment is summarized in figure 1 and table I. In two 
patients treatment was discontinued due to non-compliance of the patients. In two 
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other patients dithranol had induced a worsening of the lesions due to an intercurrent 
instability of psoriasis. 
In 16 patients the treatment had resulted in some improvement (figure 1). PASI 
scores reduced from 13.3 +/- 1.5 (SEM) before treatment, to 3.1 +/- 0.8 after 8 
weeks of treatment. An average reduction of PASI-scores of 10.1 was obtained. A 
satisfactory response was observed in twelve patients (Table I). The degree of 
improvement was not correlated with the extent of the lesions. 
The remission period in patients showing a satisfactory response, varied from two 
weeks to four months, averaging 6.3 weeks. 
The final concentrations reached in the patients were 3% (one patient), 4% (three 
patients) and 5% (twelve patients). In three patients the treatment was complicated 
by an irritation of the surrounding skin. A pronounced and dysfigurating staining 
was observed in three patients. In 11 patients a moderate staining was observed 
which was well-accepted by the patients. In two patients no staining was seen at all. 
The removal of the ointments with water and a detergent was relatively easy and 
complete. Minimal staining of clothing or furniture was recorded by any of the 
patients. 
Histological findings 
The immunohistochemical observations before treatment (n=16), after 2 weeks of 
treatment (n=5) and 8 weeks after treatment (n = 16) are summarized in Figure 2. 
After two weeks of treatment with dithranol, already a statistically significant 
decrease in Ki-67 positive nuclei could be seen ( ρ < 0.05, figure 3), in corn-
Table I. Clinical results expressed as the number of patients showing different degrees of relative 
improvement. 
Present study 
<50% 
4 
50-90% 
10 
>90% 
2 
Drop out 
4 
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Figure 1: Clinical scores before and after treatment with dithranol in emulsifying ointment (means 
+ /- SEM). 
bination with a decrease in Ks8.12 binding ( ρ < 0.05, figure 4). In addition, 
epidermal PMN diminished (p < 0.05). However the other parameters showed no 
significant changes in the early phase of dithranol treatment. 
After 8 weeks of treatment with dithranol, a pronounced effect on proliferation could 
be seen. Ki-67 positive nuclei decreased in a statistically significant manner ( ρ < 
0.04). Keratinization assessed by the antibodies Ks8.12 (keratin 16) and RKSE60 
(keratin 10) also showed a statistically significant change at the end of the treatment 
period ( ρ < 0.04 and ρ < 0.03 respectively). Different cell types involved in 
inflammation in epidermal and dermal compartment were evaluated. The number of 
PMN decreased as well in epidermis as in dermis ( ρ < 0.02, ρ < 0.03 respec­
tively). T-lymphocytes showed the same pattern, a diminution in both compartments 
( ρ < 0.02 in epidermis, ρ < 0.03 in dermis, figure 5). CD14 cells showed no 
significant change in number, distribution or shape in the dermal compartment, but 
decreased statistically significant in the epidermis after 8 weeks. The number of 
Langerhans cells showed no significant change. However another remarkable 
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Figure 2: Scores for proliferation, keratinization and inflammation during dithranol treatment (means 
+/- SEM). A : Number of nuclei per mm length of epidermis stained with Ki-67; B: Ks8.12-bmdmg 
( ) and RKSEöO-binding ( ), representing keratin 16 and keratin 10 respectively; C: 
Expression of anti-elastase ( ), Ti l ( ) and WT14 ( ), representing PMN, T-lym-
phocytes and CD14-positive cells in the epidermis; D: Expression of anti-elastase ( ), T i l 
( ) and WT14 ( ), representing PMN, T-lymphocytes and CD14-positive cells in the dermis. 
phenomenon was observed. After dithranol therapy, the staining pattern using OKT6 
showed intercellular distribution of the antibody (figure 6). 
Linear regression analysis was carried out to assess correlation between clinical 
severity scores and the immunohistochemical parameters showing a statistically 
significant change during treatment. Ks8.12 proved to be correlated with clinical 
improvement in all patients, The remaining parameters (Ki-67 staining, keratin 10 
staining, PMN and T-lymphocytes) were less indicative for clinical resolution. 
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Figure 3: Staining with the antibody Ki-67, marker for proliferation; (a) psoriasis before treatment, 
(b) same patient after two weeks of treatment with dithranol. Bar = 4 μπ\. 
Figure 4: Staining with the antibody Ks8.12, showing keratin 16; (a) psoriasis before treatment, (b) 
same patient after two weeks of treatment with dithranol. Bar = 5 ¿im. 
4
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Figure 5: Staining with the antibody T U , staining T-lymphocytes; (a) psoriasis before treatment, (b) 
same patient after eight weeks of treatment with dithranol. Bar = 5 μιη. 
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DISCUSSION 
Short contact therapy with dithranol in paste, paraffin and cream bases have been 
reported to be successful in the treatment of chronic plaque psoriasis4"13,22. If short 
contact therapy is carried out at an in-patient department, its effectivity has been 
reported to be equal or even better compared to classical dithranol therapy5·7·10. If 
carried out at the out-patient department with supervision and concentration ad-
justments three times a week, a satisfactory response (complete or almost complete 
clearing) was seen in 15 out of 20 patients, using Psoralon (Hermal) preparations12. 
However, less frequent out-patients supervisions yielded a far lower therapeutic 
effectivity reaching 10% clearing9·23. 
In the present study dithranol was manufactured in Hermal-AW by the local 
pharmacist. This monotherapy proved to have a satisfactory response in 12 out of 20 
patients. An average reduction of PASI scores of 10.1 was obtained. The clinical 
efficacy of the present treatment is comparable with the results obtained using 
Psoralon (12). The remission period of 6.3 weeks following dithranol Hermal-AW is 
in line with the average remission period of 6 weeks following the classical Ingram 
Scheme, using the same criterion for an initial relapse24. 
Following short contact treatment removal of dithranol from the skin is essential in 
order to prevent staining of textiles, clothing etc. Using stiffened paraffin base, the 
paste and also the various cream bases, postapplication staining is an important 
drawback. Using Psoralon MT and dithranol Hermal-AW, postapplication staining of 
textiles proved to be minimal. In this respect the possibility of manufacturing 
dithranol in Hermal-AW by the local pharmacist opens new possibilities for in-
dividualising modem dithranol treatment at an out-patient basis. 
Proliferation assessed by Ki-67 binding, diminished statistically significant after two 
weeks of treatment. This confirms earlier studies in which a 50% decrease in 3[H] 
thymidine incorporation was seen after 2 weeks (16). Also in- the present study the 
number of Ki-67 positive nuclei decreased with about 50% after two weeks of 
treatment. In previous studies the number of mitoses reduced already after 4 days15. 
Some investigators found a decrease in DNA-content after dithranol therapy25·2* 
whereas others found no change1227,28. A possible explanation for this phenomenon is 
an arrest of cells in the S phase12. 
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Keratinization during dithranol therapy showed a clear change. In a previous study 
using flowcytometry, a decrease in Ks8.12 binding was demonstrated after 6 weeks 
of treatment12. In the present study, Ks8.12 binding diminished already statistically 
significant after two weeks of treatment. Ks8.12 binding was very low after two 
weeks of treatment selectively in patients who showed a considerable further 
improvement between 2 and 8 weeks. This observation suggests that reduction of 
Ks8.12 binding might predict further clinical improvement. RKSE60 binding (keratin 
10) increased during therapy. RKSE60 binding correlated well with restoration of 
the general histology. A remarkable feature was that in lesions showing complete 
clinical clearance after dithranol therapy, still some histological abnormalities were 
seen: acanthosis, papillomatosis and a noticeable hyperorthokeratosis. 
Inflammation persisted relatively long during dithranol treatment. However epider­
mal PMN diminished already in the early phase. After 8 weeks also dermal PMN 
and T-lymphocytes in both skin compartments reduced. CD14-positive cells dimi­
nished in the epidermal compartment. The epidermal changes therefore, precede the 
dermal changes during dithranol treatment. In a previous study Braun Falco et al 
reported on "the persisting cellular inflammatory reaction" during dithranol treat­
ment17. In the present study a dissociation between the reduction of PMN versus T-
lymphocytes and CD14-cells could be shown. In vitro studies suggested an effect of 
dithranol on PMN29·30 and lymphocytes30. The present in vivo study suggests that the 
interference with PMN migration is relevant in the early phase of dithranol treat­
ment. In the present study the number of Langerhans cells did not change. Remarka-
Figure 6: Staining with the antibody OKT6, staining Langerhans cells; (a) psoriasis before treatment, 
(b) same patient after eight weeks of treatment with dithranol. Bar • 4 μνη. 
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bly, after dithranol therapy, staining of Langerhans cells in the epidermis using 
OKT6 showed an intercellular distribution. This has been described by other 
investigators in various skin diseases such as cutaneous В cell lymphoma, a variety 
of inflammatory skin disorders and in cutaneous T-cell lymphoma31,32. To the best of 
our knowledge, this phenomenon has not been described in untreated nor treated 
psoriatic lesions. The presence of intercellular OKT6 binding seemed to be as­
sociated with large numbers of Langerhans cells. However in our study the number 
of Langerhans cells did not increase statistically significant. Possibly damage or 
irritation of Langerhans cells by dithranol might cause leakage of the T6 antigen. 
Induction of CDla on keratinocytes might be an alternative explanation. 
It can be concluded that out-patient treatment with dithranol in the emulsifying 
ointment Hermal-AW is an efficient treatment modality. The order of changes of 
parameters for inflammation, proliferation and keratinization indicate that epidermal 
changes precede the dermal changes. In particular, a decrease of nuclear Ki-67 
staining, Ks8.12 binding and a decrease in PMN-accumulation constitute relatively 
early changes. 
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SUMMARY 
Although dithranol has been used for 75 years in the treatment of psoriasis, its 
working mechanism is still not resolved. In order to further define the mode of 
action of dithranol the interference with normal skin was studied. The effect of 
dithranol on epidermal proliferation, keratinization and inflammation was examined 
using immunohistochemistry. 
Punch biopsies from six volunteers who applied dithranol 0.5% in petrolatum, were 
taken before application, after 48 and 96 hours. Biopsies were processed for 
assessing epidermal proliferation by Кі-67-binding (cycling cells), for keratinization 
by Ks8.12-binding (keratin 13 and 16, keratin 16 is expressed by hyperproliferative 
keratinocytes) and RKSE60-binding (keratin 10). For assessing inflammation the 
antibodies anti-elastase (PMN), Til (T-lymphocytes, CD2), OKT6 (Langerhans 
cells, CDla) and WT14 (monocytes/macrophages, CD14) were used. 
Кі-67-staining started to increase between 48 and 96 hours whereas Ks8.12-binding 
had increased already between 0 and 48 hours. RKSE60 staining showed a decline 
between 48 and 96 hours. Inflammation in the dermis showed an increase after 48 
hours, and continued to increase. In the inflammatory infiltrate, the accumulation of 
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PMN was limited compared to the pronounced infiltration of T-lymphocytes. 
Langerhans cell shape and epidermal position altered in four volunteers. 
Application of dithranol on normal skin produces analogies and discrepancies 
compared to application of dithranol on psoriatic lesions. Direct interference with 
epidermal growth and differentiation seems less likely as the anti-psoriatic principle. 
INTRODUCTION 
Dithranol is a classical and time-honoured treatment for chronic plaque psoriasis. 
The anti-psoriatic principle, so far, is not exactly understood. 
Previous studies have shown interference of dithranol with DNA-synthesis, effects 
on mitochondrial function, and on cytosolic enzymes1"*. The ultimate result of 
dithranol therapy in psoriatic lesions is a down-regulation of epidermal proliferation 
and a decrease of inflammatory cells in the dermis5"9. In contrast, dithranol induces 
erythema in the surrounding skin of a psoriatic lesion10. 
In normal skin, however, the effects of dithranol are largely unknown. In order to 
achieve better insight in the mode of action, the events occurring in normal skin 
after application of dithranol were studied. Monoclonal antibodies were used on 
frozen sections to assess epidermal proliferation and keratinization (keratin 10 and 
16). Keratin 10 is expressed by differentiating keratinocytes and can be seen in the 
suprabasal layers of normal epidermis". Ks8.12 binds to keratin 13 and 16. Keratin 
13 is absent in adult human skin12. Keratin 16 is expressed by hyperproliferative 
keratinocytes in vitro as well as in vivo13. In addition the inflammatory infiltrate was 
studied (polymorphonuclear leukocytes (PMN), T-lymphocytes, Langerhans cells, 
monocytes and macrophages). 
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MATERIALS AND METHODS 
Volunteers 
Six healthy volunteers with no signs or history of skin disease participated in the 
study (3 females, 3 males, age varying between 22 and 32 years, mean age 26.7 
years). They applied dithranol 0.5% in petrolatum thinly and evenly on an area of 5 
χ 5 cm once a day for five consecutive days. Punch biopsies (4mm) were taken 
before application of dithranol, and at 48 and 96 hours application of dithranol. In 
addition, clinical signs were recorded such as discolouration, erythema, or itching. 
Staining procedures 
Biopsies were embedded in Tissue Тек OCT Compound (Miles Scientific, Naper-
ville, USA) and snap frozen in liquid nitrogen. Sections of 7 μπι were cut and fixed 
in acetone (0 0C) for 10 minutes, or in acetone/ether 60/40% (for Ki-67 staining). 
The antibodies used are indicated in Table I. A direct peroxidase (anti-elastase), 
indirect peroxidase (Ki-67, Ks8.12, RKSE60) or PAP technique was used (Til, 
OKT6, WT14). For staining with the antibodies anti-elastase, Ki-67, Ks8.12 and 
RKSE60, slides were incubated for 30 minutes with the primary antibodies. After 
washing in phosphate buffer the slides were incubated with a solution of rabbit-anti-
mouse-immunoglobulin conjugated with peroxidase 1:50 in phosphate buffer 
containing 5% human AB-serum for 30 minutes, except for the anti-elastase 
antibody. After 3 washing steps in phosphate buffer and preincubation in sodium 
acetate buffer pH 4.9, slides were stained in a solution of 3-amino-9-ethyl-carbazole 
(AEC) in sodium acetate buffer containing 0.01% H202 for 10 minutes. All slides 
were counterstained with Mayer's haematoxylin (Sigma, St Louis, USA) and 
mounted in glycerin gelatin. 
Staining with Ti l , OKT6 and WT14 was carried out using a peroxidase-anti-
peroxidase technique. Slides were incubated for 60 minutes with the monoclonal 
antibodies. After washing in phosphate buffer the slides were incubated with rabbit-
anti-mouse-immunoglobulin (RAM-Ig, Dakopatts, Copenhagen, Denmark) 1:25 in 
phosphate buffer for 20 minutes. This was followed by a washing step and in­
cubation with peroxidase-anti-peroxidase complexes (PAP-complexes, Dakopatts. 
Copenhagen, Denmark) 1:100 in phosphate buffer for 20 minutes. Once more the 
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slides were incubated with RAM-Ig, followed by PAP-complexes. The slides were 
stained in AEC-solution in sodium acetate buffer and H2O2 and counterstained with 
Mayer's haematoxylin. Finally they were mounted in glycerin gelatin. 
Histological scores 
Histological changes in the epidermal and dermal compartment were assessed using 
a semi-quantitative scale: 
Epidermis: 0= no staining, 1= sporadic staining, 2= minimal staining, 3 = 
moderate staining, 4= moderate-pronounced staining, 5= pronounced staining, 6= 
whole epidermis stained. 
Dermis: 0= no stained cells, 1= sporadic, 2= 1-25% of the infiltrate cells stained, 
3= 26-50%, 4= 51-75%, 5= 76-99%, 7= 100%. 
The number of Кі-67-stained nuclei was counted per mm length of section. 
Statistical analysis 
The Wilcoxon ranking test for matched pairs was used for the statistical analysis. 
Tabic I 
Antibody 
Ki-67 
Ks8 12 
KKSE60 
Til 
OKT6 
WT14 
Specificity 
nuclear antigen in late Gl-, S-, G2- and M-phase 
keratin 13 and 16 
keratin 10 
neutrophil elastase 
T-lymphocytes (CD2) 
Ungcrtians cells (CDla) 
monocytes/macrophages (CD14) 
Dilution 
1:40 
1:25 
1:10 
1:100 
1-100 
1:100 
1100 
Manufacturer 
Dakopalts, Copenhagen, Denmark 
Sigma, St Louis, USA 
F Ramaekers, Dept of Pathol, Nijmegen 
Dakopatts, Copenhagen, Denmark 
Dakopatts, Copenhagen, Denmark 
Dakopatts, Copenhagen, Denmark 
W Tax, Dept Nephrol, Nijmegen 
RESULTS 
Volunteers 
AH six volunteers showed after 48 hours a slight brown discolouration of the skin 
and some erythema. After 96 hours, the discolouration had increased and the 
erythema was less pronounced than at 48 hours. One volunteer showed vesicles at 
the application site, one other showed slight peeling of the stratum comeum. 
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Figure 1: Staining with the antibody Ki-67, marker for proliferation. A: normal skin before application 
of dithranol, B: normal skin after 96 hours application of dithranol. Bar = 20 μτα. 
Histological findings 
Epidermal proliferation Before application of dithranol, the number of Кі-67-positive 
nuclei numbered 16 +/- 2 (mean +/- SEM) per mm. After 48 hours, this number 
had not increased. After 96 hours, a statistically significant (p<0.03) increase in 
stained nuclei was seen up to 47 +/- 11 (mean +/- SEM) per mm. This is shown in 
figure 1. 
Epidermal keratinization Before application, staining with the antibody Ks8.12 
(keratin 13 and 16) showed only sporadical staining in the basal layer. No suprabasal 
staining was seen at all. AAer 48 hours, suprabasal staining had increased up to 1.2 
+/- 0.3 (mean +/- SEM), ρ<0.05. After 96 hours, Ks8.12 staining in the supra-
basal compartment had increased further (1.8 +/- 0.5, mean +/- SEM, p<0.05), 
whereas staining of the basal cell layer decreased (p<0.05) (figure 2). Staining with 
the antibody RKSE60 (keratin 10) showed no significant change between 0 and 48 
hours, but diminished between 48 and 96 hours application of dithranol (p<0.05). 
Inflammation in epidermis and dermis Intraepidermal accumulation of PMN (anti-
elastase-staining) did not occur during the observation period. In the dermis a 
significant increase of PMN was seen after 48 and 96 hours compared to the 
pretreatment biopsy (p< 0.04 and p< 0.03, respectively). In contrast to PMN, T-
lymphocytes (Til) showed a substantial increase in the epidermal as well as dermal 
compartment after 48 and 96 hours. In the epidermis, these cells increased from 0.5 
+/- 0.2, via 2.1 +/- 0.3 after 48 hours, to 2.7 +/- 0.6 (means +/- SEM, p < 0.05) 
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Figure 2: Staining with the antibody Ks8.12, showing keratin 16. A: normal skin before application of 
dithranol, B: normal skin after 96 hours application of dithranol. 
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Figure 3: Staining with the antibody OKT6, showing Langerhans cells. A: normal skin before apllication 
of dithranol, B: normal skin after 48h application of dithranol. OKT6 positive Langerhans cells can be 
seen in the basal layer of the epidermis. 
after 96 hours. In the dermal compartment, an increase from 1.4 +/- 0.3, via 2.8 
+/- 0.3, up to 4.8 +/- 0.2 after 96 hours was demonstrated (means +/- SEM, 
ρ <0.05 and ρ <0.03, respectively). Cells staining with the antibody WT14 (mono­
cytes, macrophages) also increased in epidermis as well as in dermis after 48 
(p<0.03) and 96 hours (p<0.03). Langerhans cells (OKT6) showed no statistically 
significant change in number in the epidermis. Their shape, however, altered 
compared to the shape of these cells in the untreated skin, e.g. their dendrites 
became smaller (figure 3). In four volunteers a rearrangement of Langerhans cells 
was seen. In two of these Langerhans cells were seen mainly in the basal layer of 
the epidermis after 48 hours (figure 3), in another volunteer this picture was found 
after 96 hours. In the fourth volunteer, Langerhans cells were seen in the vicinity of 
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small vesicles in the epidermis. In the dermal compartment, Langerhans cells 
showed a statistically significant increase after 96 hours (p<0.03). 
The inflammatory infiltrate showed an increase mainly in the dermis. T-lymphocytes 
contributed most to the increase of cells in the dermis. WT14-stained cells also 
showed a substantial increase. The contribution of PMN to the infiltrate remained 
limited. 
DISCUSSION 
The various events taking place after application of dithranol, can be summarized as 
follows: Кі-67-staining started to increase between 48 and 96 hours whereas Ks8.12-
binding had increased already between 0 and 48 hours. RKSE60 staining showed a 
decline between 48 and 96 hours. Inflammation in the dermis showed an increase 
after 48 hours, and continued to increase up to 96 hours. In the inflammatory 
infiltrate, the accumulation of PMN was limited compared to the pronounced 
infiltration of T-lymphocytes. 
In the treatment of psoriasis, the application of dithranol is an established therapy 
with few side effects. In previous studies, a decrease in 3[H]-thymidine incor­
poration, a decrease in DNA-content and cells in SG2M-phase, and a decrease in 
cells staining with the antibody Ki-67 has been observed during treatment of 
psoriatic lesions with dithranol5·'·15·1*. Also keratinocytes in culture, showed a 
decrease in growth after incubation with dithranol17. In the present study, normal 
skin in vivo showed a hyperproliferative response to dithranol applications, as 
demonstrated by an increase of Ki-67 stained nuclei. In addition, an increase of 
Ks8.12 staining in the suprabasal compartment was observed already after 48 hours. 
In this respect, it is of interest that Ks8.12 staining occurs already well before 
hyperproliferation is observed, indicated by Ki-67 staining. The explanation for the 
discrepancy as to the dynamics of dithranol-induced proliferation and the expression 
of keratin 16 -so far believed to be a proliferation associated event- is not clear. 
Some investigators have proposed an association of keratin 16 expression with a 
more general disturbance of the epidermal condition and may not necesseraly be 
hyperproliferation associated [IS]. Such a condition could be induced by dithranol. 
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Due to the so far unknown induction time for the epitope recognized by the Ki-67 
antibody, we cannot exclude the possibility that the transition from resting cell into 
cycling cell might occur earlier than at 96 hours. In hyperproliferative epidermis, 
such as psoriasis or normal skin after sellotape stripping18,19, the content of keratin 
10 is diminished. In the present investigation, also a decline in keratin 10 is shown 
that coincides with the increase in Ki-67 staining between 48 and 96 hours. 
Langerhans cells were seen mainly in the basal cell layers of the epidermis after 
application of dithranol in three volunteers. In particular, Langerhans cells are very 
sensitive to damage of the mitochondria by dithranol20. Possibly the Langerhans cells 
in the upper layers of the epidermis are destructed or have lost their CD la antigen. 
In the inflammatory infiltrate, the limited accumulation of PMN compared to T-lym-
phocytes is striking. Histologically, a toxic or irritative reaction shows in general a 
greater content of PMN21. In this respect, it is of interest that dithranol has shown to 
inhibit Chemotaxis of PMN in vitro22, and the leukotriene B4 induced accumulation 
of PMN in normal skin in vivo23. 
Comparing the responses of normal and lesionai psoriatic skin, we are faced with 
analogies as well as discrepancies. PMN decreased after two weeks of dithranol 
treatment of the psoriatic lesion and T-lymphocytes persisted beyond this period 
[15]. In normal skin treated with dithranol few PMN accumulated but T-lymphocytes 
proved to be pronounced. Whereas epidermal proliferation and keratin 16 expression 
decrease, and keratin 10 expression increases during treatment of the lesion15,16, the 
normal skin treated with dithranol shows the reverse. Therefore, a direct inter-
ference with epidermal growth and differentiation seems less likely as the anti-
psoriatic principle. 
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SUMMARY 
Antipsoriatic agents have been shown to decrease skin levels of arachidonic acid and 
its metabolites including 12-monohydroxy-eicosatetranoic acid (12-HETE), and 
leukotriene B4 (LTB4). In addition, specific systemic and topical lipoxygenase 
inhibitors have been reported to be effective in the treatment of psoriasis. 
The objective of this study was to investigate the effect of a potent oral leukotriene 
biosynthesis inhibitor (MK886) in patients with chronic plaque psoriasis. Clinical 
response together with the changes of LTB4 levels in lesionai skin biopsy specimens, 
and urinary leukotriene E* (LTE4) excretion was evaluated. In addition, markers of 
inflammation, proliferation and keratinization were studied immunohistochemically. 
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No change in clinical scores, or lesionai LTB4 levels were observed with a 10 1/3 
day course of MK886. A statistically significant reduction in urinary ЬТЦ, excretion 
was observed (mean LTE4 ng/hr were 5.14 and 1.51 pretreatment and day 11 with 
MK886 respectively; and 7.55 and 6.57 pretreatment and on day 11 with placebo 
treatment respectively). Epidermal accumulation of polymorphonuclear leukocytes 
(PMN) tended to diminish in the MK886 treatment group. These results indicate that 
despite a significant reduction (>70%) in systemic leukotnene levels, and epidermal 
PMN accumulation, no correlative changes in clinical scores or LTB4 levels in skin 
lesions were found with a short course of MK886. 
INTRODUCTION 
In the search for the pathogenesis of psoriasis, many cell types and substances have 
been investigated. One remarkable biochemical deviation in the psoriatic lesion is the 
increased amount of leukotrienes1·2. These leukotrienes have been studied in normal 
skin, and in involved and uninvolved psoriatic skin using different methods3. 
Leukotnene B4 (LTB4), seems to be of primary importance as it is increased in 
psoriatic skin compared to normal skin. LTB4 is a potent chemoattractant for 
polymorphonuclear leukocytes (PMN) in vitro and in vivo4. In addition, application 
of LTB4 on normal skin can produce microabscesses of PMN5·6, an inflammatory 
infiltrate7·8, and epidermal proliferation'. These features can also be found in the 
psoriatic lesion. Topical application of LTB4 to uninvolved and involved psoriatic 
skin induces a reaction different from normal skin. In psoriasis, a habituation to 
continuously high amounts of LTB4 seems to take place7. Various anti-psoriatic 
therapies can inhibit the LTB4-induced PMN-accumulation in normal skin
10
. There­
fore, their mechanism of action may in part be due to inhibition of LTB4 induced 
inflammation. 
In the past, different therapeutics have been investigated that interfered with LTB4-
metabolism. LTB4 is produced from arachidonic acid via the 5-lipoxygenase pathway 
(figure 1). Therapeutics that inhibit 5-lipoxygenase (5-LO) have been used in the 
past11·12, but had serious side effects. Recently, a successful trial with a topical 5-
lipoxygenase inhibitor has been published13. 
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The effect of a potent oral 5-lipoxygenase inhibitor MK886 ( 3-[l-(p-chlorobenzyl)-
3-t-butylthio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), Merck Frosst 
(Montreal, Canada), was studied in patients with chronic plaque psoriasis. MK886 is 
an indirect leukotriene biosynthesis inhibitor whose mechanism of action is through 
the binding of a membrane-bound 5-LO-activating protein (FLAP) thereby inhibiting 
the translocation and activation of 5-LO14·15. MK886 is a potent inhibitor of leuko­
triene biosynthesis in vitro in human PMN (IC50 = 2.5 nM) and in human whole 
blood (EC50 = 1.1 μΜ). At this concentration no effect is seen on cyclooxygenase 
or 12-lipoxygenase16. Studies in normal volunteers have demonstrated its ability to 
inhibit calcium ionophore stimulated LTB4 synthesis ex vivo in whole blood17. 
The objectives of this study were to investigate the effects of MK886 on: (1) the 
clinical appearance of psoriatic lesions; (2) LTBA levels in lesionai skin biopsy 
specimens; (3) inhibition of systemic leukotriene biosynthesis as reflected in the 
primary leukotriene metabolite in the urine (LTEJ18·1'; and on skin immunohis-
tochemical markers of inflammation, proliferation and keratinization. 
MATERIALS AND METHODS 
Study design 
This was a double-blind, placebo-controlled, parallel group, randomized study in 
which sixteen patients with chronic plaque psoriasis were treated with MK886 or 
placebo for ten and one third days. Eight patients received MK886 orally at a dose 
of 150 mg three times a day, and eight patients received matching placebo for a total 
of 31 doses per patient. Approval from the Medical Ethical Committee at the 
University Hospital Nijmegen was obtained. 
Clinical and laboratory safety measurements 
Prior to starting therapy, a clinical examination including EKG, and laboratory 
measurements were carried out. The laboratory measurements consisted of haemato-
logy (total and differential white blood cell counts, haemoglobin, haematocrit, 
platelet count) and blood chemistry ( AS AT, ALAT, bilirubin, gammaGT, alkaline 
phosphatase, urea, creatinine, total protein and fasting blood glucose). In addition, 
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urinalysis was done (pH, protein, glucose, sediment). During the treatment period, 
the same haematology and blood chemistry measurements were carried out at day 1, 
3, 5, 8 and 11. After the treatment period, clinical examination and laboratory 
measurements were repeated. 
Patients 
A group of 16 patients with chronic plaque psoriasis participated in this study. 
Informed consent was obtained from all patients. Their age varied from 25 years to 
66 years (mean 47.9 years). The group consisted of 11 males and 5 females who 
were postmenopausal or surgically sterilized. They had used no topical treatment for 
at least two weeks, or systemic treatment for at least two months. 
Clinical assessment and biopsy procedures 
Two symmetrical psoriatic lesions were selected for each patient. Before and after 
the treatment period a photograph was taken and a clinical assessment was made 
using a four point scale for scaling, erythema and plaque elevation (see Table I). 
The mean scores for these three parameters were used for analysis. Clinical 
assessment was performed again on days 5 and 11 of therapy. Just before the first 
dose of the test drug, two biopsies were taken from one of the selected psoriatic 
lesions. Two hours after the last dose (dose 31), two biopsies were taken from the 
second lesion. One pre- and posttreatment biopsy was used for measurement of 
LTB4. The remaining two biopsies were used for immunohistochemical processing. 
Biopsies for LTB,, measurements were taken using a keratotome after local anaes­
thesia with chlooraethyl spray, and after gently removing the scales with a scalpel, 
because scales contain large amounts of LTB4. Biopsies for immunohistochemistry 
were taken using a razor blade in conjunction with a metal guard after local 
anaesthesia with chlooraethyl spray. Biopsies were snap frozen in liquid nitrogen and 
stored at -80° С until use. 
Leukotriene Analysis 
Synthetic leukotrienes, leukotriene metabolites, hydroxy eicosatetranoic acid 
isomers, and rabbit antiserum against LTB4, LTC4 and LTE4 were obtained from Dr. 
Robert Young, Merck Frosst Canada. 
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LTB^ in skin biopsies: LTB4 in skin biopsies were extracted as described20, with 
minor modifications. Briefly, samples were ground under liquid nitrogen in a 
FREEZER/MILLR vial (SPEX Industries, Edison, USA) modified with a resealable 
aspiration hole to allow direct extraction with 2 χ 1 ml 75% methanol: 25% 0.1 M 
Tris-HCL, ImM EDTA, pH 3. Diluted extracts were partially purified on precon­
ditioned, disposable 500 mg C-8 columns (Amersham International, Amersham, 
UK). HPLC separation of leukotrienes and quantitative measurements of LTB4 by 
RIA were carried out as described previously17,21. 
Urinary ІЛТу Urine was collected over a four hour period before treatment with 
MK886 from zero to four hours after the last dose of MK886 on day 11. The total 
volume was measured and a 40 ml aliquot was stabilized and prepared for analysis 
as described previousIy20.Sample clean-up on C-8 columns and HPLC separation 
were carried out as described for skin LTB4. Quantitative measurements of LTE4 by 
RIA employed the procedure decsribed for LTB4 except for the substitution with 
antiserum against LTE4, ['HJ-LTEt and a lower charcoal concentration (0.1% w/v 
final concentration) used for removal of unbound counts22. 
Table I: Psoriasis lesion scores. 
1 
2 
3 
4 
Scaling 
none 
minimal 
moderate 
severe 
Erythema 
none 
very mild 
moderate 
strong 
Plaque elevation 
flat 
barely perceptible elevation 
elevation 
high elevation 
Immunohistochemical staining 
Biopsies were cut into sections of 7μτη and fixed in acetone for 10 minutes. Staining 
with the following antibodies was carried out: 
Ki-67 (Dakopatts, Copenhagen, Denmark): a proliferation marker, staining a nuclear 
antigen present in late Gl, S, and G2M-phase 
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Ks8.12 (Sigma, St Louis, USA): directed against keratin 13 and 16 
RKSE60 (gift of Dr F Ramaekers, Dept of Pathology, University Hospital Nij-
megen): directed against keratin 10 
Anti-elastase (Serotec, Oxford, England): staining elastase-positive cells (polymo-
rphonuclear leukocytes, PMN) 
Til (Dakopatts, Copenhagen, Denmark): a pan-T-lymphocyte marker 
WT14 (Dept Medicine, Div Nephrol, University Hospital Nijmegen): staining CD14 
positive cells (monocytes and macrophages)23 
OKT6 (Ortho Diagnostic Systems, Raritan, USA): staining Langerhans cells. 
In brief, staining with anti-elastase was carried out using a direct peroxidase-
technique, staining with Ki-67, Ks8.12 and RKSE60 was done using an indirect 
peroxidase technique, and staining with T i l , WT14 and OKT6 was done using a 
PAP-technique. The staining procedures are described previously24. Ki-67 positive 
nuclei were counted per mm length of section. Presence in the epidermis and dermis 
of the remaining stained structures were assessed using a 6-point scale: 
Epidermis: 0 = no presence, 1 = sporadically present, 2 = minimal presence, 3 = 
moderate presence, 4 = moderate-pronounced presence, 5 = pronounced presence, 
6 = whole epidermis stained. 
Dermis: 0 = no presence, 1 = sporadically present, 2 =1-25% of infiltrate cells 
stained, 3 = 26-50% of infiltrate cells stained, 4 = 51-75% of infiltrate cells 
stained, 5 = 76-99% of infiltrate cells stained, 6= 100% of infiltrate cells stained. 
Statistical analysis 
Statistical analysis was done using the Wilcoxon ranking test for paired data, and the 
Kruskal-Wallis test for group means. 
RESULTS 
Safety 
No serious clinical adverse experiences were reported, MK886 was overall well 
tolerated. A heavy feeling in the stomach was reported more frequently in the 
MK886 group (4 patients) than the placebo group (0 patients). One patient had to be 
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withdrawn from the trial because of an elevation of alkaline phosphatase (123 U/1 
before treatment, 153 U/1 after 5 days of treatment, normal values 0-120 U/1). After 
breaking the code, this patient turned out to be in the placebo group. In the other 
patients, all safety parameters remained within normal ranges. 
Clinical effect 
No significant change in any of the parameters of the lesion score were observed in 
the MK886 or placebo treated group after ten and one third days of treatment. Mean 
scores before treatment were 2.99 +/- 0.13 (sem) for the MK886-group, and 3.33 
+/- 0.15 for the placebo group. On day 11 these scores were 2.73 +/- 0.1 
(p=0.097) and 2.93 +/- 0.20 (p=0.470) respectively. 
Measurements of LTB4 In skin biopsies and urinary LTE4 
Baseline levels of LTB4 in skin biopsies, and urinary СЩ, excretion in the MK886-
treated group and the placebo treated group were comparable. 
Measurements of ЦЩ, in the psoriatic lesions were in line with the clinical effect of 
MK886. No significant reduction in the amount of LTB4 was seen after MK886-
treatment (p=0.5) (see Table II). 
In contrast, the amount of the metabolite LTE4 diminished in a statistically sig­
nificant manner in the MK886 treated group. These results are shown in Table III. 
Mean values for urinary LTE4 in ng per hour were 4.67 +/- 0.67 (sem) and 5.0 +/-
2.24 for the MK886 and the placebo group respectively at day 1; and 0.96 +/- 0.36 
(p=0.02) and 3.73 +/- 1.99 (p=0.72) respectively at day 11. The amount of ng 
LTE4 per mmol creatinine was 8.5 +/- 0.38 before treatment with MK886, and 8.51 
+/- 3.64 in the placebo group. After treatment, the mean concentrations were 1.72 
+/- 0.44 (p=0.02) and 7.345 +/- 1.9 (p=0.72) respectively. 
Histological examinations 
Results of staining with the different monoclonal antibodies can be seen in Table IV. 
No change in Ki-67-positive nuclei could be found. Keratin 10 and keratin 16 
expression did not differ before and after treatment. In addition, the amount of T-
lymphocytes, Langerhans cells and CD14-positive cells remained unchanged. The 
number of epidermal polymorphonuclear leukocytes (PMN) reduced in the MK886-
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Table II: LTB4 in psoriatic biopsies (pg LTB4/nig wet tissue), mean +/- sem 
MK886 
Placebo 
before treatment 
11.6 +/- 1.85 
24.8 +/- 10.60 
after treatment 
12.6 +/- 3.70 
13.6 +/- 3.03 
Ρ 
0.50 
0.14 
Table III: LTE4 excretion in urine (ng LTE4/hour), mean +/- sem 
MK886 
Placebo 
before treatment 
8.50 +/- 0.38 
8.51 +/- 3.64 
after treatment 
1.72 +/-0.44 
7.33 +/- 1.99 
Ρ 
0.02 
0.72 
treated biopsies reaching borderline significancy (p=0.05), whereas epidermal PMN 
in the placebo treated biopsies remained unchanged. 
DISCUSSION 
Eicosanoids are mediators of inflammation and are generated from arachidonic acid, 
which is present in the plasma membrane25. Three different enzymes produce 3 
groups of eicosanoids: via 12-lipoxygenase 12-HETE is produced, via cyclo-
oxygenase prostaglandins and thromboxane are produced, and via 5-lipoxygenase, 
leukotriene A4, B4, C4, D4 and E4 are generated (figure 1). Based on former inves­
tigations, leukotriene B4 seems to be of importance in the pathogenesis and main­
tenance of psoriasis1,3·26. LTB4 has been measured in biologically active amounts in 
chronic plaque skin lesions (33.1 +/- 9.7 ng/g wet tissue in scale and 5.3 +/- 2.0 
ng/g wet tissue in lesionai skin without scale)27. This LTB4 appears to be derived 
from both epidermis and PMN1·25·26. Arachidonic acid and its metabolites have been 
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Table IV: Immunohistochemical staining, results of proliferation (positive nuclei per mm length of section), keratinization and inflammation (score 0-6), 
mean +/- sem. 
PROLIFERATION 
KERATINIZATION 
INFLAMMATION 
Antibody 
Ki-67 (nuclear antigen) 
Ks8.12 (keratin 16) 
RKSE60 (keratin 10) 
EPIDERMAL 
Anti-€lastase (PMN) 
Til (T-lymphocytes) 
WT14 (CD14 + cells) 
OKT6 (Langerhans cells) 
DERMAL 
Anti-elastase (PMN) 
Til (T-lymphocytes) 
WT14 (CD14 + cells) 
OKT6 (Langerhans cells) 
Before treatment 
MK886 
56 +/- 7 
3.7 +/- 0.4 
4.0 +/- 0 
2.3 +/- 0.5 
2.3 +/-0.1 
1.4 +/- 0.2 
2.8 +/- 0.3 
1.1 +/-0.3 
3.0 +/- 0.2 
1.9 +/-0.1 
2.0 +/- 0 
Before treatment 
Placebo 
67 +/- 10 
4.7 +/- 0.3 
3.4 +/- 0 
2.5 +/- 0.5 
2.3 +/- 0.3 
1.7 +/- 0.2 
2.4 +/- 0.2 
1.3 +/- 0.3 
3.3 +/- 0.2 
2.0 +/- 0 
2.0 +/- 0 
After treatment 
MK.886 
62 +/- 7 
4.0 +/- 0.3 
4.0 +/- 0 
1.4 +/-0.3 
2.3 +/- 0.2 
1.6+/-0.2 
2.8 +/- 0.3 
1.0+/-0.2 
3.3 +/- 0.3 
2.0 +/- 0 
2.0 +/- 0 
After treatment 
Placebo 
59 +/- 11 
4.2 +/- 0.5 
3.6 +/- 0.6 
2.4 +/- 0.6 
2.6 +/- 0.2 
1.8+/-0.1 
2.2 +/- 0.3 
1.1 +/-0.2 
3.1 +/-0.2 
2.0 +/- 0 
1.9+/-0.1 
quantitated in skin chamber fluid from lesionai and non-lesional psoriatic skin28·29. In 
this model 12R-HETE and LTB4 are the most abundant products found. LTB4 is one 
of the most potent chemoattractants for PMN, 12R-HETE is less potent but is still a 
highly active neutrophil chemoattractant. Benoxaprofen which is a 5, 12, and 15-LO 
inhibitor, and a cyclooxygenase inhibitor (the mechanism is unclear) produced ameli-
oration of psoriasis, however side effects limited continued study of this com-
pound12. 
This study investigated the effect of a potent oral 5-lipoxygenase inhibitor on clinical 
scores and histological parameters of proliferation, keratinization and inflammation, 
LTB4 levels in psoriatic lesions and urinary LTE, excretion. Baseline levels of LTB4 
in skin biopsies and urinary LTE4-excretion were comparable in the MK886 and 
placebo-treated group. LTB4 in the psoriatic lesions before treatment with MK886 
were lower than values reported by Duell et al.20 who did not remove scales, a 
source of skin LTBf, but higher than the values reported by Fogh et al.27. In con-
clusion, no significant changes in clinical scores were seen. In accordance with these 
findings, no change in the amount of LTB4 in psoriatic lesions was measured. How-
ever a statistically significant decrease in urinary LTE4 was seen. All parameters for 
proliferation, keratinization and inflammation remained unchanged after therapy, and 
no statistically significant difference between MK886 and placebo treated patients 
could be seen. Only the number of epidermal PMN decreased and reached border-
line significance. 
Benoxaprofen appeared to be clinically effective11·12 and inhibits the migration and 
motility of PMN isolated from peripheral blood in vitro*0. Its effects on histological 
parameters was not investigated. As benoxaprofen is not a specific 5-LO inhibitor, 
other mechanisms might be involved in its antipsoriatic potential. It is of interest that 
in this study a decrease in epidermal PMN was found, whereas the amounts of LTB4 
in skin biopsies did not decrease. It is possible that MK886 reached concentrations 
in skin that were not sufficient to produce a statistically significant decrease of 
LTB4, while an effect on PMN migration could have occured via an alternative 
mechanism. In this respect it might be of relevance that MK886 reaches peak drug 
levels at l-2h post dose, and that the elimination half- time of MK886 is relatively 
short17. The concentration of MK886 in peripheral blood was sufficient to inhibit 
systemic leukotriene synthesis as reflected in the > 70% decrease in urinary LTE4 
132 
excretion. This decrease in the systemic level of leukotrienes may have had an effect 
on PMN in peripheral blood, thereby altering their migration into the skin. 
In the study of Black et al13 a topical 5-lipoxygenase inhibitor decreased the amount 
of LTB4 in skin chamber fluid in treated psoriatic lesions. A clear clinical effect was 
also shown. In their study, the decrease in the amount of LTB4 diminished before a 
clinical effect was seen. The clinical improvement was statistically significant after 
14 days, compared to the vehicle treated lesions. Although topical application of a 5-
lipoxygenase inhibitor can induce substantial clinical improvement13, the present 
study demonstrates that short term systemic administration of a selective 5-LO in-
hibitor, which produced a >70% inhibition of systemic leukotriene biosynthesis 
does not result in an anti-psoriatic effect. As MK886 is not a direct inhibitor of 5-
LO, but prevents its activation by binding to FLAP this might be an explanation for 
the differences in clinical effect between this study and the study of Black et al13. 
Another explanation might be the relatively short treatment period of 10 1/3 days. 
Otherwise, it is possible that the LTB4-like material found in the skin is not derived 
from the 5-LO-pathway, but may be derived either through lipid peroxidation or 
through a cytochrome P450-catalyzed pathway. Further investigation in this area is 
warranted. 
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SUMMARY 
Corticosteroids are important in the treatment of inflammatory dermatoses, such as 
psoriasis. They have anti-inflammatory, anti-proliferative and immunosuppressive 
actions. In order to elucidate which of these working principles are of relevance for 
corticosteroid treatment in psoriasis, six patients were treated for three weeks with 
Budesonide 0.025% ointment (PreferidR). 
Clinical effects were recorded using the PASI-score (Psoriasis Area and Severity 
Index). Biopsies from psoriatic lesions were taken before and during treatment and 
processed for immunohistochemistry. Antibodies were used to assess epidermal 
proliferation (Ki-67 binding) and keratinization (keratin 16 (Ks8.12) and keratin 10 
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(RKSE60)). In addition, inflammatory cells were stained; T-lymphocytes (Til), 
monocytes/macrophages (WT14), polymorphonuclear leukocytes (PMN, anti-
elastase) and Langerhans cells (OKT6). 
PASI-scores reduced significantly after one week and three weeks of treatment. 
Epidermal proliferation decreased after one week already, whereas the inflammatory 
infiltrate reduced in a later stage of treatment (after 3 weeks). 
Keratinocyte hyperproliferation is an important target of corticosteroid treatment in 
psoriasis. The relative long persistance of the infiltrate cells may explain the relapse 
seen after corticosteroid therapy. 
INTRODUCTION 
Corticosteroids have been of much benefit in the treatment of inflammatory der-
matoses. They posess anti-proliferative, anti-inflammatory and immunosuppressive 
properties1,2. Their working mechanism is mediated via a cytoplasmatic receptor and 
transportation to the nucleus, which results in transcription of DNA to mRNA and 
translation of mRNA to proteins. In addition a non-nuclear working mechanism has 
been postulated3"5. 
Topical application of corticosteroids in the treatment of chronic plaque psoriasis has 
proven to be an effective treatment6. While used for chronic dermatoses, local and 
systemic side effects (dermal atrophy, suppression of adrenal function) form an 
important disadvantage. Therefore, the search for potent formulations with few local 
and/or systemic side effects still goes on. 
One of these new generation corticosteroids is Budesonide (Preferid*) 0.025% 
ointment7"14, which has shown to be at least as effective as betamethasone-17-valerate 
0.01% ointment', and to have little effect on plasma Cortisol levels and urinary 
Cortisol excretion14. In the present investigation, the effect on clinical parameters of 
topical treatment with Budesonide 0.025% ointment has been investigated in six 
patients with chronic plaque psoriasis at the out-patient department. 
The effects of corticosteroid treatment on histological and biochemical parameters in 
epidermis and dermis have been investigated previously1·15"18. In psoriasis, epidermal 
hyperproliferation, disturbed keratinization and inflammation are inportant and well-
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known aberrations. More recently, it became clear that various cytokines play an 
important role in homeostasis and in pathology of skin. In psoriasis, interleukin-1 
(IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), tumour necrosis factor-α (TNFa), 
and transforming growth factor-ß (TGF-B) seem to play an important role in the 
pathogenesis and regression of a lesion1*"23. How these cytokines are involved in the 
antipsoriatic action of corticosteroids remains to be solved. 
In this study, the effect of treatment with Budesonide 0.025% ointment on his-
tological parameters for proliferation and keratinization were studied, using an-
tibodies against an epitope on the nucleus of proliferating keratinocytes (Ki-67), 
against keratin 13/16 (Ks8.12) and keratin 10 (RKSE60). The inflammatory cells 
were analyzed using monoclonal antibodies against T-lymphocytes (Til), monocy-
tes/macrophages (WT14), polymorphonuclear leukocytes (PMN) (anti-elastase) and 
Langerhans cells (OKT6). 
MATERIALS AND METHODS 
Patients 
Six patients with chronic plaque psoriasis participated in the study, one male and 
five females. Their age varied from 24 to 67 with an average of 47.5 years. They 
had used no systemic treatment for at least two months, and no topical treatment for 
at least two weeks. Patients applied Budesonide ointment 0.025% (Preferid*, Gist 
Brocades, Delft, The Netherlands) twice daily thinly and evenly to the psoriatic 
lesions during three weeks. Clinical scores were recorded before treatment, after one 
week and after three weeks of treatment for the lesions on the upper extremities, 
trunk and lower extremities. Erythema (E), infiltration (I) and scaling (S) of the 
lesions were assessed using a 5-point scale: 0= no cutaneous involvement, 1 = 
slight, 2= moderate, 3= severe, 4= severest possible involvement. The area (A) of 
the body surface that was involved was recorded using a 7-point scale: 0= no 
involvement, 1= <10%, 2= 10-29%, 3= 30-49%, 4= 50-69%, 6= 70-89%, 6= 
90-100% of the body surface involved. 
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The PASI-score was calculated as follows: 
upper extremities: 0.2 χ A(E+I+S) + 
trunk: 0.3 χ A(E+I+S) + 
lower extremities: 0.4 χ A(E+I+S) 
Punch biopsies (φ 4 mm) were taken from a lesion before treatment, after one week 
and after three weeks of treatment. 
Immunohistochemical stainings 
The biopsies were immediately embedded in Tissue Тек OCT Compound (Miles 
Scientific USA) and snap frozen in liquid nitrogen. Slides were cut of 7 μπι, fixed in 
acetone or in acetone/ether 60/40% (Ki-67 staining) for 10 minutes and stored at -80 
"C until use. Staining to assess epidermal proliferation, keratinization and epidermal 
and dermal inflammation, was carried out using the following antibodies: 
-Ki-67 (Dakopatts, Copenhagen, Denmark): binds to a nuclear antigen present in 
cycling cells 
-Ks8.12 (Sigma, St Louis, USA): binds to keratin 13 and 16. Keratin 16 is expres­
sed by hyperproliferative keratinocytes". Keratin 13 is not present in adult human 
skin20. 
-RKSE60 ( a gift of F. Ramaekers): binds to keratin 10. Keratin 10 is expressed by 
differentiated keratinocytes. 
-Anti-elastase (Serotec, Oxford, England): staining leukocyte elastase, present in 
polymorphonuclear leukocytes (PMN) 
-Tl 1 (Dakopatts, Copenhagen, Denmark): stains CD2, present on T-lymphocytes 
-OKT6 (Ortho Diagnostic Systems, Raritan, USA): stains CDla, present on 
Langerhans cells 
-WT14 (Dept. Medicine, Div. Nephrol. University Hospital Nijmegen): directed 
against CD 14, present on monocytes and macrophages21. 
A direct peroxidase technique was used to visualize PMN. An indirect peroxidase 
technique was used for staining with the antibodies Ki-67, Ks8.12 and RKSE60. 
Slides were incubated for 30 minutes with the antibodies in a dilution of 1:100, 
1:40, 1:25 and 1:10 respectively. After washing in phosphate buffer the slides were 
incubated with a solution of rabbit-anti-mouse-immunoglobulin conjugated with 
139 
peroxidase 1:50 in phosphate buffer containing 5% human AB-serum for 30 
minutes, except for the anti-elastase antibody. After 3 washing steps in phosphate 
buffer and preincubation in sodium acetate buffer pH 4.9, slides were stained in a 
solution of 3-amino-9-ethyl-carbazole (AEC) in sodium acetate buffer containing 
Í 
0.01% H202 for 10 minutes. All slides were counterstained with Mayer's haemato-
xylin (Sigma, St Louis, USA) and mounted in glycerin gelatin. 
Staining with T i l , OKT6 and WT14 was carried out using a peroxidase-anti-
peroxidase technique. Slides were incubated for 60 minutes with the monoclonal 
antibodies in a dilution of 1:100. After washing in phosphate buffer the slides were 
incubated with rabbit-anti-mouse-immunoglobulin (RAM-Ig, Dakopatts, Copenhagen, 
Denmark) 1:25 in phosphate buffer for 20 minutes. This was followed by a washing 
step and incubation with peroxidase-anti-peroxidase complexes (PAP-complexes, 
Dakopatts, Copenhagen, Denmark) 1:100 in phosphate buffer for 20 minutes. Once 
more the slides were incubated with RAM-Ig, followed by PAP-complexes. The 
slides were stained in AEC-solution in sodium acetate buffer and Η2θ2 and counter-
stained with Mayer's haematoxylin. Finally they were mounted in glycerin gelatin. 
Scores 
Histological changes in the epidermal and dermal compartment were assessed using 
a semi-quantitative scale: 
Epidermis: 0= no staining, 1= sporadic staining, 2= minimal staining, 3 = 
moderate staining, 4= moderate-pronounced staining, 5= pronounced staining, 6= 
whole epidermis stained. 
Dermis: 0= no stained cells, 1= sporadic, 2= 1-25% of the infiltrate cells stained, 
3= 26-50%, 4= 51-75%, 5= 76-99%, 6= 100%. 
Кі-67-positive nuclei were counted per mm length of epidermis. 
Statistical analysis 
The Wilcoxon ranking test for matched pairs was used for the statistical analysis. 
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RESULTS 
Clinical response 
The clinical response to Preferid treatment is summarized in figure 1. The treatment 
was well-tolerated. No local adverse effects were seen. After one week of treatment, 
the PASI-score had diminished in a statistically signifícant manner (p<0.03) from 
5.36 +/- 0.98 (mean +/- sem) to 3.63 +/- 0.67. After three weeks of treatment, 
the average PASI-score measured 2.12 +/- 0.58, ρ <0.03 compared to before 
treatment. 
Immunohistochemical observations 
Scores before treatment, after 1 week of treatment and 3 weeks after treatment in the 
epidermis were as follows. The number of Ki-67 stained nuclei diminished from 153 
+/- 24 to 44 +/- 10 after one week of treatment (p<0.03). After three weeks, their 
numbers had diminished further to 30 +/- 11 per mm length of epidermis (p<0.03, 
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Figure I. PASI-scores ( + /- SEM) before treatment, after one week and three weeks of treatment 
(n=6). * = first statistically significant reduction. 
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Table I. Markers for epidermal proliferation (means +/- SEM). 
Antibody 
Ki-67 
Ks8.12 
t = 0 
153 +/- 24 
4.5 +/- 0.6 
t = 1 week 
44 +/- 10 
2.5 +/- 0.8 
t = 3 weeks 
30 +/- 11 
2.8 +/- 1.8 
Table I). Staining with Ks8.12 (keratin 16) diminished significantly añer one week 
(p< 0.03) and continued to decline between one and three weeks of treatment 
(Table I). In contrast, keratin 10 showed no significant changes during treatment 
with Budesonide. Epidermal PMN, T-lymphocytes, and Langerhans cells did not 
show any statistically significant change. Otherwise, epidermal WT14-stained cells 
diminished in a statistically significant manner (p<0.03) after three weeks. 
In the dermal compartment, the presence of the infiltrate declined between 0 and 3 
weeks (p<0.05). The number of PMN diminished already after one week sig-
nificantly (p<0.05), in contrast to the percentage of T-lymphocytes, WT14 stained 
cells and Langerhans cells, which remained unchanged during the observation 
period. 
DISCUSSION 
Corticosteroids are very effective in the treatment of psoriasis, and possess anti-
proliferative, anti-inflammatory and immunosuppressive actions. In this study, the 
clinical effectiveness of Budesonide 0.025% ointment was confirmed9"13. After one 
week of treatment, already a statistically significant reduction in PASI-score was 
accomplished, which extended during two weeks of further treatment. 
It is not clear, which of the three working principles of corticosteroids are of 
relevance for the antipsoriatic potential. The order in which markers for prolifer-
ation, keratinization and inflammation change during treatment with corticosteroids, 
might provide further information on this issue. In the present investigation, biopsies 
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from psoriatic lesions were taken before treatment, after one week and after three 
weeks of treatment with Budesonide 0.025% ointment. 
The early decline of proliferating keratinocytes (Ki-78 positive nuclei) and of keratin 
16 expression after one week, indicates that keratinocyte proliferation is an impor-
tant target of corticosteroid treatment in psoriasis. Expression of keratin 10 did not 
change during this observation period. In addition, epidermal inflammatory cells (T-
lymphocytes, PMN) and Langerhans cell numbers remained unchanged. In contrast, 
the number of WTU staining cells (monocytes/macrophages) diminished in the 
epidermis after three weeks of treatment. Epidermal accumulation of PMN is 
suggested to be important in the anti-psoriatic working mechanism of cor-
ticosteroids24. The authors reached this conclusion based on an in vivo model for 
PMN migration. In the present investigation, although epidermal PMN remained 
constant during the first week of treatment, a dramatic decrease of markers for 
proliferation was observed. Therefore, it is likely that epidermal PMN migration is 
not an early target for corticosteroid treatment in psoriasis. 
The dermal inflammatory infiltrate diminished between one and three weeks of 
treatment. The relative persistance of dermal changes despite clinical success 
resulting from Budesonide treatment might provide an explanation for the relatively 
fast relapse following cessation of treatment with corticosteroids25'77. 
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SUMMARY 
Keratin 17 is not present in normal epidermis but occurs in the hair follicle, in 
myoepithelial cells, in psoriatic scalp, and in basal cell carcinomas. 
The aim of the present study was to investigate to what extent this keratin subtype 
was present in chronic plaque psoriasis, and to evaluate whether it's staining pattern 
changed during antipsoriatic treatment, using the antibody E3 on frozen sections. 
In 6 patients suffering from psoriasis, biopsies were taken before and after treatment 
with anthralin or with the vitamin Dj analogue MC903. Clinical evaluations were 
carried out using the PASI-score. 
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In all pretreatment biopsies pronounced staining was found high in the suprabasal 
compartment, while after treatment no staining was found in 4 out of 6 patients. One 
treated patient showed sporadically cells expressing keratin 17, and one patient a 
moderate staining of the suprabasal compartment after treatment. This latter patient 
showed the smallest reduction in PASI-score. 
This study suggests that keratin 17 is a useful marker to monitor success of anti-
psoriatic therapies. 
INTRODUCTION 
The investigation of changes that take place during development or therapeutical 
regression of psoriatic lesions can give us a more clear insight into processes which 
are of importance in the pathogenesis and treatment of this disease. 
In previous studies, different parameters have been used to investigate increased 
epidermal cell proliferation and disturbed differentiation in psoriasis. The his­
tological appearance13, percentage of cells in SG2M-phase
4
, incorporation of 3[H]-
thymidine5, or BrdUrd6, Кі-67-staining6·7, and up- or down-regulation of distinct 
keratins' have been used as parameters. 
The aim of the present study was to further investigate the effect of anti-psoriatic 
therapies on keratin expression in human epidermis. In psoriasis, keratins are 
expressed that can not -or only in small amounts- be found in normal human skin. 
Also down-regulation of keratins which are related to differentiation takes place'. 
Assessing the amount of keratins no. 2, 10, 16 and 18 in psoriatic skin proved to be 
a useful approach in monitoring therapies. Especially keratin 16 correlates well with 
progression or regression of the lesions8·10. 
Keratin no. 17 is a constituent which is not present in normal human epidermis. In 
skin it is restricted to the lower part of the outer root sheath of the hair follicle, and 
to myoepithelial cells of the sebaceous gland. It is also expressed by basal cell 
carcinomas and might be associated with hyperproliferation"12. Recently the 
expression of keratin 17 was shown in lesionai psoriatic epidermis of the scalp13. 
147 
In this study the presence and localization of keratin 17 in psoriatic lesions was 
further investigated and the effect of anti-psoriatic therapies on keratin 17 expression 
in such lesions was studied using monoclonal antibody E3 on frozen sections. 
MATERIALS AND METHODS 
Six patients suffering from psoriasis participated in this study. They had not received 
topical treatment for at least two weeks, and no systemic treatment for at least two 
months. Three patients were treated with anthralin in a cream-base and three patients 
were treated with the new vitamin D,-analogue MC903. Clinical response was 
measured using the PASI-score. Biopsies from psoriatic lesions were taken before 
therapy and after 8 weeks of anthralin-treatment or after 12 weeks of MC903-
treatment. The biopsies were snap-frozen in liquid nitrogen, and stored at -80°C. 
Frozen sections of 7 μιπ were cut and fixed in acetone (40C, 10 minutes). Staining 
with the mouse monoclonal antibody E3 to keratin 1711 was performed using a 
dilution of 1:10 in phosphate buffered saline (PBS). Incubation for 30 minutes at 
room temperature in the dark was followed by 3 washing steps with PBS. Thereafter 
the sections were incubated for 30 minutes with a peroxidase-conjugated rabbit-anti-
mouse antibody (Dakopatts, Copenhagen, Denmark) diluted 1:50 in PBS, containing 
5% human AB-serum. After 3 more washing steps in PBS and preincubation with 
sodium acetate buffer (pH 4.9) E3 binding was visualized in sodium acetate buffer 
containing 200 mg/1 3-amino-ethyl-carbazole (AEC) and 80 μΐ/l H202. Finally slides 
were counterstained with Mayers haematoxylin and mounted in Kaisers glycerin 
gelatin. 
RESULTS 
Results of the staining reactions with the antibody E3 in untreated psoriatic skin and 
in anthralin or MC903 treated psoriasis are shown in Table I. Staining with this 
keratin 17 antibody, showed a consistent pattern in all biopsies of untreated psoriatic 
skin. Keratin 17 was present in the upper layers of the suprabasal compartment, and 
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Table I. PASI-scores and keratin 17 expression before and after treatment. 
Patient 
1 
2 
3 
4 
5 
6 
Tratment 
anthralin 
anthralin 
anthralin 
МС90Э 
MC903 
MC!*» 
PAS! before 
20 
5 
27 
7.2 
54 
5 8 
PASI after 
6 
0.5 
8 
1.8 
3 
1.8 
Keratin 17 before 
pronounce! expression 
moderaie-proiKHDieed ex­
pression 
pronounced expression 
pronounced expression 
Keratin 17 after 
no expression 
no expression 
no expression 
sporadically present 
no expression 
was evenly distributed over the total length of the sections (figure 1A). Post-
treatment biopsies showed a clear reduction in keratin 17 (figure IB). In four out of 
six patients no keratin 17 expression could be found at all after treatment (three 
patients treated with anthralin, one patient treated with MC903). In one patient only 
sporadic keratin 17 positive cells were present after therapy, while the remaining 
patient still showed considerable staining for keratin 17 in the post-treatment biopsy. 
This patient also showed the smallest reduction in PASI-score. The presence of 
keratin 17 was most pronounced in areas that showed distinct hyperparakeratosis. No 
keratin 17 expression was seen in the basal layers of the epidermis. 
All patients showed a marked improvement of their psoriatic lesions during the 
treatment period. PASI-scores are also shown in Table I. The average reduction in 
PASI-score was 8.2, varying from 2.4 to 19. 
DISCUSSION 
Keratin expression in different epithelia has been investigated extensively during the 
last decade. Various types of epithelia show different patterns of keratin expression. 
In addition, many tumors and cultured cell lines partly retain the keratin composition 
and distribution of their tissue of origin14. 
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Figure 1: A: E3 staining reaction showing keratin 17 in an untreated lesion of patient 1 (x250), B: E3 
staining reaction after 8 weeks of treatment with anthralin in the same patient (x250). Bar = 40 /im. 
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In this study the presence and localization of keratin 17 in psoriatic skin was 
investigated, using the monoclonal antibody E3. In addition, changes in keratin 17 
content in response to antipsoriatic therapy were examined. 
In all biopsies of untreated psoriatic lesions, E3-staining was observed in the most 
superficial layers of the living epidermis, just underneath the stratum comeum. 
Keratin 17 is not present in normal interfollicular epidermis, but can be found in the 
outer root sheath of the hair follicle and in myoepithelial cells of the sebaceous 
gland. Also in other epithelia exclusive staining of the basal cell compartments was 
reported". Keratin 17 is also expressed in basal cell carcinomas which has led to the 
hypothesis that basal cell carcinomas have a follicular origin12. In earlier studies also 
a correlation of keratin 17 expression and hyperproliferation has been suggested12. 
The results of the present investigation suggest an association with abnormal 
terminal differentiation of keratinocytes in psoriasis, since keratin 17 is seen 
exclusively in the upper layers of the stratum spinosum. 
During treatment with anthralin and treatment with MC903, also the expression of 
keratin 16 is reduced1015, a well established marker for hyperproliferation of 
keratinocytes16. Based on immunohistochemical studies using the antibody Ks8.12, 
keratin 16 was found to be present not only in the most superficial layers of the 
psoriatic lesion, but in the entire suprabasal compartment. Following treatment 
Ks8.12 staining was largely diminished7·10,15. Treatment with anthralin or MC903 
proved to result in an even more marked decrease of keratin 17 expression, which 
correlated well with the clinical response. 
The present study suggests that keratin 17 is a useful and sensitive marker to 
monitor improvement of psoriatic lesions. 
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CHAPTER 4 
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(ILVEN) VERSUS LINEAR PSORIASIS; A CLINICAL, HIS-
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SUMMARY 
Inflammatory Linear Verrucous Epidermal Nevus (ILVEN) has been suggested to be 
a separate disease entity. However, the delineation from linear psoriasis has been 
discussed in the literature of the last decades. 
The aim of the present study was to investigate in addition to the clinical and 
histological criteria, the immunohistochemical aspects of inflammation, epidermal 
proliferation and keratinization. From a clinical and histological point of view 
ILVEN and psoriasis, according to the established criteria, proved to overlap. The 
immunohistochemical study suggest that the following procedures have an additional 
diagnostic impact: assessment of elastase positive cells, assessment of keratin 16 and 
of keratin 10. 
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INTRODUCTION 
Since the first description of inflammatory linear verrucous epidermal nevus 
(ILVEN) by Unna', various investigators endeavoured to formulate both clinical and 
histopathological criteria to delineate ILVEN from psoriasis2,3. 
The clinical appearance of ILVEN varies from lichenoid to psoriasiform, from 
scaling to markedly verrucous2,4·5. The nosology becomes even more complex by the 
observation that linear lesions might coexist with typical psoriatic lesions'. 
At the histological level the alternation of orthokeratosis and parakeratosis has been 
suggested to be typical for ILVEN, although such pattern can be seen in psoriasis as 
well. On the other hand, micropustules of Munro, a characteristic feature of the 
psoriatic lesion, can be seen in ILVEN. 
In order to delineate ILVEN from linear psoriasis we investigated a group of 6 
patients suffering from linear erythematous lesions with scaling and or a verrucous 
appearance. 
In addition to clinical and histological description the aim of the present study was to 
assess inflammation, proliferation and keratinization using immunohistochemical 
methods. 
MATERIALS AND METHODS 
CASE REPORTS 
Clinical features of the patients are summarized in table I. Table II specifies the 
histological observations. 
Case 1 
The first patient was a 77-year-old female who had had extensive symmetrical 
erythematosquamous papular lesions all over her body ever since she was 5 years 
old. On her right arm, right upper leg and right half of the thorax the lesions were 
linearly arranged. The patient suffered from severe pruritus. In some biopsies the 
histopathological findings were compatible with ILVEN and in other biopsies with 
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psoriasis. Treatment with PUVA and dithranol did reduce psoriasis, but failed to 
influence ILVEN. Multiple excisions of linear lesions were carried out. 
Case 2 
The second patient was a 28-year-old female with erythematous hyperkeratotic 
papular eruptions in the right groin and on the vulva. These lesions, which had been 
present since birth, caused severe itching and were both clinically and his-
topathologically classified as a linear verrucous nevus. Topical treatment with all-
trans-retinoid acid, solutio carbonis detergens, corticosteroids, or treatment with 
argon laser or cryotherapy, did not bring any positive effect. 
Case 3 
The third patient was a 28-year-old female with slightly scaling linear ery-
thematosquamous papules on the right half of the trunk extending into the medial 
right leg (Figure 1). Pruritus was absent. Clinically the lesions, which were present 
during one year, were compatible with lichen striatus. Histopathologically the lesions 
could not be designated with certainty as ILVEN or lichen striatus. Without any 
therapy, a partial regression of the lesions was seen. 
Case 4 
The fourth patient was a 37-year-old male with linear erythematosquamous lesions, 
which were diagnosed as ILVEN. The lesions appeared at the age of 24 and were 
localised on the left arm and axilla. Severe pruritus was experienced. Cryotherapy 
and several topical therapies did not improve his condition. No spontaneous regres-
sion was seen. Multiple excisions reduced the extent of the lesions. 
Ca<fe5 
The fifth patient was a 26-year-old female who had a one years history of ILVEN-
like lesions on the left arm and left half of the thorax following the lines of Blasch-
ko. These lesions caused minimal pruritus. Histologically the diagnosis lichen 
striatus was made. Treatment with all-trans-retinoic acid caused much irritation, but 
smoothened the surface of the lesions. A partial regression was seen. 
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Case 6 
The sixth patient was a 46-year-old male who had slightly itching linear ery-
thematosquamous lesions on his left leg and trunk since the age of 14 (Figure 2). He 
also had signs of classical psoriasis. Histologically both diagnoses could be con­
firmed. Dithranol reduced the psoriatic lesions. The linear verrucous lesions did not 
respond. 
IMMUNOHISTOCHEMICAL INVESTIGATIONS 
In each patient a punch biopsy (3mm) was taken from the linear lesions and snap 
frozen in liquid nitrogen. Staining was performed using the following antibodies in 
order to characterize inflammation and proliferation. A direct or indirect peroxidase 
technique, or a peroxidase-anti-peroxidase technique was used on acetone-fixed 
slides of 7 μτη. 
Inflammation 
Anti-elastase (Serotec, Oxford, England) to assess elastase, a marker enzyme for 
polymorphonuclear leukocytes (PMN) 
Ti l (Dakopatts, Copenhagen, Denmark) to assess T-lymphocytes (CD2) 
WT14 (Dept. Medicine, Div. Nephrol., University Hospital Nijmegen) to assess 
CD14-positive cells (monocytes and macrophages)7, 
OKT6 (Ortho Diagnostic Systems, Raritan, USA) to assess Langerhans cells (CDla) 
Stained cells in the epidermal compartment were assessed using a scale ranging from 
0 to 4 points: 0 = no expression, 1 = sporadic expression, 2 = minimal expres­
sion, 3 = moderate expression, 4 = pronounced expression. 
Stained cells in the dermis were expressed as a percentage of the total number of 
infiltrate cells: 0 = no cells stained, 1 = sporadically cells stained, 2 = 1-25% of 
the infiltrate cells stained, 3 = 26-50% of the infiltrate cells stained, 4 = 51-75% of 
the infiltrate cells stained, 5 = 76-99% of the infiltrate cells stained, 6 = 100% of 
the infiltrate cells stained. 
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Figure 1. Linear lesion on the Figure 2. Linear lesion on the 
right leg of patient 3. left leg of patient 6. 
Proliferation: 
Ki-67 (Dakopatts, Copenhagen, Denmark) was used to visualise nuclei of cycling 
cells 
The number of Ki-67 positive nuclei was counted per mm length of epidermis. 
Keratinization: 
Ks8.12 (Sigma, St. Louis, USA), an antibody directed against keratin 13 and 16. 
Keratin 16 is present in hyperproliferative epidermis8, whereas keratin 13 is absent 
in human adult skin9. 
RKSE60 (a generous gift of Dr. F.C.S. Ramaekers), directed against keratin 10, 
present in differentiated epidermal cells. 
Staining with Ks8.12 and RKSE60 were scored using the same scale as used for 
inflammation-parameters in the epidermal compartment. Staining of suprabasal 
(differentiated) and basal (undifferentiated) compartment were assessed separately. 
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Table I. Clinical Characteristics 
Pat. 
1 
2 
Э 
4 
5 
6 
Age of onset 
(years) 
Б 
0-1 
27 
24 
25 
14 
Duration 
Wears) 
72 
28 
1 
13 
1 
32 
Refractoriness 
to treatment 
yes (trunk) 
yes (upper leg) 
not treated 
yes 
? 
partly (trunk) 
Spontaneous 
regression 
no 
no 
partial 
no 
partial 
no 
F/M 
F 
F 
F 
M 
F 
M 
Localization 
right arm + 
leg 
vulva + 
right groin 
right ab­
domen 
left arm + 
axilla 
left arm + 
trunk 
left leg + 
trunk 
Pruritus 
yes 
yes 
no 
yes 
slight 
yes 
Psoriatic 
lesions 
yes 
no 
no 
no 
no 
yes 
ТаЫе M. Histological characteristics 
Patient 
1a 
1b 
2 
3 
4 
5 
6a (Verru­
cous lesion) 
6b (Psonati-
form lesion) 
Papil­
lomatosis 
+ 
+ 
+ /-
+ /-
+ +.-
+ 
+ 
Acan­
thosis 
+ 
+ 
+ 
+ 
+ +.-
+ .-
+ + 
+ 
Epidermal 
PMN 
+ 
+ 
-
-
-
-
-
+ 
Hyperkeratosis 
ort ho/para 
+ / + 
+ / + 
+ / + 
+ / + 
+ /+ 
+ /-
+ / + 
+ / + 
Inflammatory 
infiltrate 
pronounced 
moderate 
moderate 
band-like. 
pronounced 
mild, 
exocytoeis 
band-like, 
pronounced 
moderate 
mild 
Remarks 
saw tooth 
follicular plug­
ging 
saw tooth 
Histological 
diagnosis 
ILVEN 
psoriasis 
ILVEN 
ILVEN/lichen 
stnatus 
ILVEN 
lichen stnatus 
linear poroke­
ratosis 
ILVEN/-
psonasis 
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RESULTS 
The results of the immunohistochemical investigations are presented in table III. 
Staining with the monoclonal antibody KS8.12, assessing keratin 16, showed foci of 
suprabasal staining coinciding with areas of parakeratosis in 3 out of the 4 patients 
suffering from ILVEN (patients 1,4,6). In the lesions diagnosed as lichen striatus 
(patients 3 and 5), a diffuse suprabasal staining was found in patient 5, the focal 
pattern was seen in the other patient. 
The number of Ki-67 positive nuclei was increased slightly to markedly in all 
biopsies as well in ILVEN as in lichen striatus. Both conditions could not be 
differentiated using this marker. In contrast to the focal distribution pattern of the 
hyperproliferation related keratin 16 in the suprabasal compartment, the germinative 
zone showed an equal distribution of Ki-67 positive nuclei. 
Keratin 10 was equally distributed in the suprabasal compartment, only in one 
biopsy of a psoriatiform lesion (6b) distinct areas, overlying dermal papillae showing 
less intense staining were seen. 
Infiltrate analysis revealed a consistent composition in all biopsies. However, in 
patient 6 who had a superimposed psoriasis, the occurrence of PMN in the more 
psoriasiform lesion was increased. The identity of the mononuclear infíltrate cells 
proved to be predominantly T-lymphocytes. CD14-positive cells and Langerhans 
cells were found in the dermal infiltrate as well as in the epidermal compartment. 
DISCUSSION 
Clinical criteria for the diagnosis Inflammatory Linear Verrucous Epidermal Nevus 
(ILVEN) have been described by Altman and Mehregan in 19712. In a study of 25 
patients they defined as diagnostic criteria: (i) early age of onset, (ii) a predomi-
nance in females (f : m = 4 : 1) (iii) frequent involvement of the left lower 
extremity, (iv) substantial pruritus, (v) persistency of the lesions and (vi) refrac-
toriness to treatment. 
From these criteria, criteria (ii) and (iii) have reported to be associated with ILVEN 
in larger surveys. In the individual patient, however, both criteria have a limited 
diagnostic value. 
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Figure 3. Immunohistochemical staining with the antibody Ks8.12 (keratin 16) showing a focal distri­
bution pattern (x200). 
If we analyze the clinical findings of the present series (table I) using the 4 discrimi­
native criteria (i, iv, v, vi), 2 out of 6 patients (patients 1 and 2) appeared to be 
"classical cases" of ILVEN. Two out of 6 patients (patients 3 and 5) fulfilled to 
none of the 4 criteria, the clinical characteristics in these patients were compatible 
with the diagnosis lichen striatus10. The two remaining patients (patients 4 and 6) did 
show some of the criteria. Firstly a relatively late age of onset was mentioned by 
patients 4 and 6. However, relatively minor manifestations of ILVEN may have 
been overlooked by the patient. In patient 6 superimposed psoriasis is complicating 
the picture. Therefore, the partial regression mentioned, can be explained as a 
reduction of the psoriatic component. 
Histological criteria for the diagnosis ILVEN have been defined by several au­
thors2·3. Altman and Mehregan found in biopsies an inflammatory and psoriasiform 
appearance. Acanthosis, papillomatosis, spongiosis and exocytosis leading to spotty 
areas of parakeratosis were often seen. Sometimes small Munro-abscesses were 
found. Areas of parakeratosis with loss of the granular layer, and of orthokeratosis 
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Table Illa. Immunohistochemical observations 
Antibody 
Patients 
1 
2 
3 
4 
5 
6a 
6b 
Proliferation 
Ki-67 
number/mm, mean +/- SEM 
counting not possible 
102.8 +/- 8.8 
174.3 +/- 11.3 
48.7 +/- 5.4 
70.6 +/- 13.1 
224.5 +/- 26.7 
490.0 +/- 102.0 
Keratinization 
Ks8.12 RKSE60 
suprabasal basal suprabasal basal 
0-4 0-3 3.5 0 
0-2.5 1 3.25 0 
0-3 0-1 2 0 
3 0 3 0 
3 0 2 0 
2 2 2.5 0 
3.5 1 2 0 
Table Illb. Immunohistochemical observations. E = epidermal, D = dermal. 
Antibody 
Patients 
1 
2 
3 
4 
5 
6a 
6b 
Inflammation 
Anti-elastase 
E D 
1 1 
1 1 
0 1 
0 1 
0 1 
0 0 
2 1.5 
TU 
E D 
3 5 
2.5 4 
3 5 
3 5 
2.5 5 
3 3 
3 3 
WT14 
E D 
1 2 
1 2 
1 3 
0 2.5 
1 3 
0 2 
1 3 
OKT6 
E D 
3 2 
3 2 
3.5 2 
3 2 
3.5 2 
2.5 2 
3 2 
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with a prominent granular layer with a sharp demarcation were seen. A mild 
perivascular infiltrate consisting mainly of T-lymphocytes was present. Dupré and 
Christol further developed these criteria. They stated that specific and non-specific 
lesions of ILVEN exist. Essential features of specific lesions were: alternation of 
hypergranulotic, depressed areas with overlying othohyperkeratosis, and of areas of 
agranulosis with overlying parakeratosis. Papillomatosis, acanthosis and a lymfohis-
tocytic infiltrate were non-specific features. 
In psoriasis the criteria designated as "non-specific for ILVEN" by Dupré and 
Christol are usually expressed. The "specific criteria for ILVEN" can be observed 
occasionally in psoriasis. The micro-abscesses of Munro are supposed to be a 
"specific criterion for psoriasis"". However this feature occasionally has been 
reported in ILVEN. Therefore delineation between ILVEN and psoriasis is difficult 
on histological grounds. 
In the present series, the 2 patients with classical ILVEN on clinical grounds 
(patients 1 and 2) showed the "specific histological ILVEN hallmarks". In the 
patients with incomplete clinical presentation of ILVEN (patients 4 and 6) again this 
specific picture was observed. In the 2 patients with a clinical presentation of lichen 
striatus (patients 3 and 5), a saw tooth dermo-epidermal delineation was observed. In 
2 patients with ILVEN superimposed by psoriasis, intra-epidermal PMN ac-
cumulation was seen. 
The present immunohistochemical study demonstrates that abnormal keratinization 
and epidermal hyperproliferation are dissociated in ILVEN. No direct topographical 
relation was observed between the localization of the infiltrate and the epidermal 
changes. However, studies on incipient lesions might reveal such a relationship. The 
remarkable focal distribution pattern of Ks8.12 (keratin 16 expression, Figure 3) 
suggests that further studies on the keratinization process in ILVEN are worthwhile. 
From an immunohistochemical point of view ILVEN and psoriasis show certain 
differences. In ILVEN we observed a relatively low occurrence of elastase positive 
cells (PMN), a focal staining pattern of Ks8.12 (anti-keratin 16) and a homogeneous 
distribution of RKSE60 (anti-keratin 10). In psoriasis the occurrence of elastase 
positive cells is more substantial, Ks8.12 staining is homogeneous and RKSE60 
staining shows foci of decreased staining12. It is attractive to speculate that the 
relatively low occurrence of PMN in ILVEN is the cellbiological explanation for 
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refractoriness to anti-psoriatic treatment. In conclusion, this investigation suggests 
that visualizing PMN, keratin 16 and keratin 10 adds valuable information to 
distinguish ILVEN from psoriasis. 
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SUMMARY 
A patient is described who presented with a clinical picture compatible with 
psoriasis, later shifting to pityriasis rubra pilaris. He was treated with the vitamin D3 
analogue MC903, and biopsies were taken before, after 1, 2, 4 and 12 weeks of 
treatment. Monoclonal antibodies to assess epidermal proliferation, differentiation 
and inflammation were applicated. A substantial clinical improvement was seen. 
Immunohistochemically epidermal proliferation, keratin 16 content and T-lym-
phocytes decreased. This case report indicates that the vitamin D3 analogue MC903 
might have more applications than chronic plaque psoriasis alone. 
INTRODUCTION 
Topical treatment with the vitamin Ό3 analogue MC903 has been shown to be 
effective in psoriasis1·2. Several mechanisms of action may be of relevance: inter­
ference with the Τ cell response3, inhibition of epidermal proliferation4 and or 
interference with keratinization5. Pityriasis rubra pilaris could well be responsive to 
166 
MC903 as abnoraial keratinization, increased epidermal proliferation and infiltration 
of Τ lymphocytes characterize the histological picture in this disorder. 
The relationship between psoriasis and pityriasis rubra pilaris has been discussed by 
many authors. Firstly it can be rather difficult to differentiate both conditions on 
clinical grounds*·7,8, secondly the transition of the one in the other has been sug­
gested6·9. 
Recently we had the opportunity to investigate the effect of longterm topical 
treatment with MC903 in a patient who was initially diagnosed as psoriasis but 
developed a classical manifestation of pityriasis rubra pilaris during the course of the 
treatment. 
CASE REPORT: CLINICAL OBSERVATIONS 
A 81-year-old man presented with an erythematosquamous skin disorder of many 
years duration which had been diagnosed as psoriasis. Previous treatments with 
topical corticosteroids, photochemotherapy and MC903 ointment had resulted in 
substantial but temporary improvement. In april 1989 the disorder covered 10-29% 
of the skinsurface of the arms and legs. The lesions consisted of sharply demarcated 
erythematosquamous plaques. The nails had a normal appearance. As the clinical 
appearance at that time was compatible with psoriasis, the patient was included in a 
trial on the longterm efficiency of MC903 in this disease. The patient was treated 
for 10 months and at monthly intervals the Psoriasis Areas Severity Index (PASI) 
was recorded. Figure 1 shows PASI scores before and during the treatment. At these 
visits blood investigations (haematology and biochemistry including calcium and 
phosphate) were carried out and no abnormalities were observed. After one month a 
substantial improvement was seen, however the clinical picture adopted more and 
more a non-psoriatic appearance. Follicular hyperkeratotic papules with a perifolli­
cular erytheme, coalescing to erythematous plaques dominated the picture. 
As the clinical diagnosis was not compatible anymore with psoriasis, a biopsy was 
taken for histological assessment (H and E staining). The epidermis showed some 
hyperkeratosis with perifollicular parakeratosis. A perivascular mononuclear 
infiltrate was seen in particular around the hair follicles. No elongation of rete 
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Figure 1. PASI scores before and at monthly intervals during treatment with MC903. 
ridges, no papillomatosis and no accumulation of polymorphonuclear leukocytes 
were observed. 
IMMUNOHISTOCHEMICAL OBSERVATIONS 
Before and after 1, 2, 4 and 12 weeks of treatment, punch biopsies (3 mm diameter) 
were taken. Monoclonal antibodies were used against a nuclear antigen present in 
cycling cells (Ki-67, Dakopatts Copenhagen, Denmark)10·11, and against keratin 13 
and 16 (Ks8.12, Sigma, St Louis, USA), to assess epidermal proliferation. Keratin 
16 is present in hyperproliferative epidermis12, meanwhile keratin 13 has not been 
found in adult human skin13. To characterise the inflammatory infiltrate staining was 
performed with antibodies against leukocyte-elastase which visualizes PMN (Serotec, 
Oxford, England); against T-lymphocytes (CD2) (Til, Dakopatts, Copenhagen, 
Denmark); against B-lymphocytes (CD22) (Pan-B, Dakopatts, Copenhagen, Den­
mark); against CD14-positive cells which represent monocytes and macrophages 
(WT14, Dept. Medicine, Div. Nephrol. University Hospital Nijmegen)14; and 
against Langerhans cells (OKT6, Ortho Diagnostic Systems, Raritan, USA)15. 
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Stainings were carried out using an indirect peroxidase-, a direct immunoperoxidase-
or a peroxidase-anti-peroxidase technique. 
Epidermal proliferation was measured by counting the number of Ki-67 positive 
nuclei per mm length of section, and by assessing Ks8.12-staining in suprabasal and 
basal layers of the epidermis using a 5-point scale: 0= no staining, 1= sporadic 
staining, 2= minimal staining, 3= moderate staining, 4= pronounced staining. 
Dermal inflammation (PMN, T-lymphocytes, B-lymphocytes, Langerhans cells, 
CD14-positive cells) was semiquantitatively enumerated by expressing the number of 
positively stained cells as a percentage of the total number of infiltrate cells similar 
to Synkowski and Provost": 0= no positive cells, 1= sporadic, 2= 1-25%, 3= 26-
50%, 4= 51-75%, 5= 76-99%, 6= 100%. Inflammatory cells in the epidermis 
were assessed using the 5-point scale as used for Ks8.12-staining. 
RESULTS 
Table I summarizes the immunohistochemical observations. Before treatment and 
after 1 week treatment, nuclear binding of Ki-67 (indicator for proliferation) is 
Table I. Binding of monoclonal antibodies, charactenzmg inflammation, epidermal proliferation and 
keratmization, before and at regular time intervals during МС90Э treatment. E= Epidermal binding; 
D= Dermal binding. Ki-67 positive nuclei per mm length of epidermis. 
Weeks 
0 
1 
2 
4 
12 
0-12 
Ki-67 
53.3 
148.4 
159.4 
114 6 
90.3 
t 
Ks8.12 
2-4 
4 
1-2 
2 
2 
i 
Anti-elas-
tase 
E:0, D:0 
E:0, D:l 
E.O, D:l 
E:0, D:l 
E-0, D:0 
= 
Til 
E:1.5, D:3 
ΕΛ.5,Ό·.3 
ЕЛ, D:2.5 
E:1,D:1.5 
E:l, D:2.5 
t 
WT14 
E:0, D:2 
E:0, D:0 
E:0, D:0 
E:0, D:0 
E:0, D:0 
=/* 
OKT6 
E:3.5PD:2.5 
E:3.5,D:2.5 
E:3, D:2.5 
E:3.5tD:1.5 
E:3.5, D:2 
= /t 
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substantially lower than values as observed in untreated psoriatic plaques (305 ± 
32)17. After 2-4 weeks treatment nuclear binding to Ki-67 increased but remained 
below the psoriatic range. Remarkably, no anti-elastase binding (PMN) was ob-
served before nor during MC903 treatment. The complete absence of elastase in all 
biopsies is not compatible with the diagnosis psoriasis. Ks8.12 binding (keratin 16 
expression) is reduced after 2 weeks treatment and the binding of Ti l (T cells) and 
WT14 (monocytes and macrophages) showed a reduction within the first 2 weeks. 
DISCUSSION 
A patient presented with a clinical picture compatible with the diagnosis psoriasis, 
well responding to antipsoriatic therapies and therefore was included in a trial on the 
longterm efficacy of the vitamin Dj analogue MC903. During the trial some clinical 
characteristics of pityriasis rubra pilaris became more and more prominent. The 
ultimate diagnosis pityriasis rubra pilaris was confirmed histologically. 
In biopsies taken before the initiation of MC903 treatment, absence of elongated rete 
ridges and papillomatosis, the relatively low nuclear binding of Ki-67 (proliferation) 
and especially the absence of anti-elastase binding (PMN), are not compatible with 
psoriasis and indicative for pityriasis rubra pilaris. 
The differentiation of pityriasis rubra pilaris from psoriasis can be difficult^9. In 
addition to the difficulty to separate two disease entities from each other the 
possibility of an Overlap' between the entities has been suggested:"Some patients 
seem to start with pityriasis rubra pilaris and end up with psoriasis"6. The present 
case suggests the reversed transition. Niemi et al. reported a 27% incidence of 
HLA-B13 in a series of patients with pityriasis rubra pilaris'. The authors suggested 
that this association was of interest in the light of the interrelation between psoriasis 
and pityriasis rubra pilaris, however, the series of Niemi et al. was to small to reach 
statistical significancy'. Although an overlap between psoriasis and pityriasis rubra 
pilaris has been suggested, a distinct separation of the two entities is possible on 
clinical, histological and cell kinetic criteria20. The folliculair hyperkeratotic papules 
and the general histological appearance without any PMN, virtually excludes the 
diagnosis psoriasis. 
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In psoriasis intraepidermal accumulation of PMN is a characteristic feature21. In 
chronic plaque psoriasis however polymorphonuclear leukocytes may be sparse22. 
Using elastase as a marker enzyme for PMN, the sensitivity of PMN detection is 
markedly increased as PMN remnants will also be detected. In previous series of 
untreated psoriatic plaques binding to anti-elastase was a consistent finding17. The 
cell proliferation (labeling index) of lesionai skin in pityriasis rubra pilaris is raised, 
however the values were below the level of the psoriatic lesion9·20·23"26. In this study 
we used nuclear Ki-67 binding as a parameter for epidermal proliferation. So far, we 
are not aware of a report on keratin 16 expression in pityriasis rubra pilaris. This 
cytokeratin is expressed in hyperproliferative skin in general27. MC903 treatment has 
been shown to be effective in psoriasis1'2. In an immunohistochemical study of skin 
biopsies from psoriatic plaques taken at intervals during MC903 treatment we 
observed a decrease of PMN accumulation after 1 week, a reduction of nuclear Ki-
67 binding after 2 weeks, after 4 weeks a reduction of T-lymphocytes and between 
between 4 and 12 weeks some reduction of Ks8.12 binding. In pityriasis rubra 
pilaris (present case), the reduction of Ks8.12 proved to be an early event which was 
accompanied by a reduction of Τ lymphocytes. The nuclear binding of Ki-67 
remained above the normal range (24.7 ± 2.2)11. 
Baised on the present case report it is feasible that the vitamin Dj analogue MC903 
might have more applications than psoriasis. Further studies on the efficacy in 
disorders of keratinization seem worthwhile. 
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SUMMARY 
Discoid lupus erythematosus (DLE) lesions show hyperkeratosis and atrophy, which 
may reflect abnormal epidermal proliferation and/or differentiation. In this inves­
tigation, markers for epidermal proliferation and differentiation were studied in 
cutaneous lesions of DLE. Frozen sections of biopsies from 20 patients were 
examined immunohistochemically regarding Кі-67-staining and keratin 16 expression 
(parameters for proliferation), and the expression of keratin 10, involucrin and 
filaggrin (parameters for differentiation). Using these markers, epidermal prolifera­
tion was found to be increased in DLE. Keratin 10 expression, a marker for early 
differentiation, showed the pattern of normal skin. Involucrin and filaggrin, markers 
for terminal differentiation, were expressed already in the lower part of the stratum 
spinosum, whereas in normal skin these markers were restricted to the stratum 
granulosum and the upper layers of the stratum spinosum, and the stratum granu-
losum and comeum, respectively. We conclude that in cutaneous lesions of DLE, 
ЬурефгоІіГегаІіоп is combined with normal early differentiation and premature 
terminal differentiation of keratinocytes. 
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INTRODUCTION 
Cutaneous lesions of discoid lupus erythematosus (DLE) show a clinical picture of 
well-defined erythematous patches, with adherent scales and follicular plugging. If 
not treated, a marked atrophy results1. 
In two previous investigations, an increased incorporation of 3[H]-thymidine was 
shown in lesionai skin of DLE2,3. This seems in contrast to the marked atrophy that 
results from these lesions. 
Very little is known about the epidermal differentiation in DLE. Apparently, in this 
disease, hyperproliferation does not result in acanthosis or in a parakeratotic homy 
layer. In contrast, atrophy and orthokeratosis are established histological features of 
DLE. 
In this investigation therefore, the proliferation and differentiation-processes were 
examined using monoclonal antibodies on frozen sections. Ki-67, an antibody to a 
nuclear antigen, present in cycling cells has been used as a marker for proliferation4, 
in combination with an antibody directed against keratin 13 and 16. Keratin 16 is 
expressed by hyperproliferative keratinocytes as well in vitro as in vivo5. As markers 
for differentiation, antibodies were used against keratin 10, which is expressed in the 
suprabasal compartment of normal skin6; to involucrin, a cytoplasmatic protein 
precursor of the comified envelope7; and to filaggrin, a protein involved in the 
formation of keratohyalin granules8. In normal skin, involucrin is expressed in the 
upper stratum spinosum and granulosum'. Filaggrin is present in stratum comeum 
and the granular layer10. In addition, the distribution of Langerhans cells, T-lym-
phocytes and monocytes/macrophages was studied to correlate epidermal changes 
with the degree of inflammation. 
MATERIALS AND METHODS 
Patients and biopsies 
Twenty patients with a clinical picture of discoid lupus erythematosus (DLE) were 
studied. Two punch biopsies were taken from lesionai skin. One was fixed in 
formalin and processed for Haematoxylin and Eosin stained (H&E) sections, one 
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was embedded in Tissue Тек OCT Compound (Miles Scientific, NaperviUe, USA) 
and snap frozen in liquid nitrogen for immunofluorescence and for additional 
staining on cryostat sections of 7 μη with monoclonal antibodies. 
Immunohistochemical techniques 
Epidermal proliferation was studied with the antibodies: Ki-67 (Dakopatts, Copen­
hagen, Denmark), that stains a nuclear antigen expressed by cycling cells; and with 
Ks8.12 (Sigma, St Louis, USA) that binds to keratin 13 and 16. 
Epidermal differentiation was studied using the following antibodies: RKSE60 (a gift 
of Dr F Ramaekers, Maastricht, The Netherlands) binding to keratin 10; anti-
involucrin (Biomedical Technologies Inc., Stoughton, USA), directed against 
involucrin, a cytoplasmatic protein precursor of the comified envelope; and anti-
filaggrin (Biomedical Technologies Inc., Stoughton, USA), directed against filag-
grin, a protein involved in the formation of keratohyalin granules. 
Slides were fixed in acetone/ether (60/40%) for staining with Ki-67 or in acetone for 
staining with Ks8.12, RKSE60, anti-involucrin and anti-filaggrin. Slides were 
rehydrated in phosphate buffer (pH 7.0), and incubated with the antibodies at room 
temperature in the dark in a dilution of 1:40, 1:25, 1:10, 1:10 and 1:500 in phos­
phate buffer, respectively. After 3 washing steps in phosphate buffer, slides were 
incubated for 30 minutes with swine-anti-rabbit-immunoglobulin conjugated with 
peroxidase (for involucrin-staining, a polyclonal antibody) or with rabbit-anti-mouse-
immunoglobulin conjugated with peroxidase, diluted 1:50 in phosphate buffer 
containing 5% human AB-serum. Three more washing steps in phosphate buffer and 
preincubation in sodium acetate buffer (pH 4.9) were followed by final staining in a 
solution of 3-amino-ethyl-carbazole (AEC) in sodium acetate buffer containing 
0.01 % H2O2 for 10 minutes. The slides were counterstained with Mayer's haemato-
xylin (Sigma, St Louis, USA) and mounted in glycerin gelatin. 
Inflammation was investigated in epidermis and dermis using the following an­
tibodies: Ti l (Dakopatts, Copenhagen, Denmark) for T-lymphocytes (CD2); OKT6 
(Ortho Diagnostic Systems, Raritan, USA) for Langerhans cells (CDla); and WT14 
(Dr WJ Tax, Dept. Medicine, Div. Nephrol. University Hospital Nijmegen) for 
CD14-positive cells (monocytes and macrophages)11. 
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Slides were dried at room temperature for 30 minutes and fixed in acetone for 10 
minutes. After rehydration in phosphate buffer (pH 7.0) slides were incubated for 60 
minutes with the antibodies in a dilution of 1:100. A peroxidase-anti-peroxidase 
technique was used consisting of an incubation step with rabbit-anti-mouse-im-
munoglobulin (RAM-Ig, Dakopatts, Copenhagen, Denmark) 1:25 in phosphate 
buffer for 20 minutes, washing in phosphate buffer and incubation for 20 minutes 
with peroxidase-anti-peroxidase complexes (PAP, Dakopatts, Copenhagen, Denmark) 
1:100. These last two incubation steps were repeated to amplify the signal. Finally 
slides were stained in AEC-solution, counterstained with Mayer's haematoxylin and 
mounted in glycerin gelatin. 
Scores 
On H&E sections, scoring for different histological features was done using a four-
point scale: 0= not present, 1= slight, 2= moderate, 3= heavy. The features 
reviewed were the degree of atrophy, acanthosis, hyperkeratosis, follicular plugging, 
hydropic degeneration, patchy infiltrate, perifollicular infiltrate and epidermotropy. 
Immunohistochemical stainings were assessed using a 7-point scale. For the dermal 
compartment: 0= no staining, 1= sporadically cells present, 2= 1-25% of the 
infiltrate cells stained, 3= 26-50%, 4= 51-75%, 5= 76-99%, 6= 100%. In the 
epidermal compartment: 0= no staining, 1= sporadically stained, 2= minimal 
staining, 3= moderate staining, 4= moderate-pronounced staining, 5= pronounced 
staining, 6= whole epidermis stained. 
Кі-67-positive nuclei were counted and expressed per mm length of section. 
RESULTS 
Patients 
The group consisted of 14 women and 6 men. Their age varied between 24 and 70 
years with an average of 41 years. The time that the patients had been affected 
varied between two weeks and 30 years, with an average duration of 6 years. 
Sixteen patients used no therapy at the time of the investigation, one patient applied 
hydrocortisone-17-butyrate (Locoid") topically, one patient used prednisone 7.5 mg 
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daily, one patient used etretinate (TigasonR) 35 mg daily, and one patient used 
hydrochloroquinesulfate (Plaquenil") 600 mg daily. Biopsies were taken from 
lesionai skin from various locations (9 χ face, 5 χ arm, 3 χ back, 1 χ leg, 1 χ scalp, 
1 χ neck). 
H&E sections and immunofluorescence 
Immunofluorescence studies showed a pattern compatible with DLE in all patients. 
H&E sections of the 20 patients showing positive immunofluorescence revealed a 
classic picture of DLE in 18, in two specimens the features of subacute cutaneous 
lupus erythematosus were seen. 
Immunohistochemistry (Table I) 
Epidermal proliferation Кі-67-positive nuclei were uniformly distributed in the basal 
layer of the epidermis. The mean number of stained nuclei was 56.1 +/- 8.2 per 
mm length of epidermis (mean +/- sem). This is illustrated in Figure 1. A substan­
tial variation between different biopsies existed, however. The highest number 
counted came to 151 nuclei/mm, the lowest to 9 nuclei/mm. Substantial Ks8.12-
binding (keratin 13 and 16), was demonstrated in the suprabasal compartment, mean 
score +/- sem was 3.25 +/- 0.4. In the basal layers only sporadically Ks8.12-
binding was seen (Fig 2). 
Epidermal differentiation RKSE60 (keratin 10) was expressed in the suprabasal 
compartment and showed a homogeneous pronounced binding (Fig 3) in all biopsies. 
The mean score for RKSE60-binding was 4.5 +/- 0.2 (mean +/- sem). Binding of 
anti-involucrin was seen not only in the stratum granulosum and upper stratum 
spinosum, but also in lower cell layers (Fig 4). In some biopsies, binding was seen 
immediately above the cells of the basal layer. In 7 out of the 20 patients, the 
increase in stained cell layers coincided with a decrease in staining of the higher 
cells of the stratum granulosum. The average score for anti-involucrin-binding was 
4.3 +/- 0.3 (mean +/- sem). Anti-filaggrin was also expressed in cell layers below 
the granular layer (Fig 5). However, staining was never seen in the cell-layers just 
above the basal keratinocytes. The extension of its binding pattern was less pro­
nounced than the extension of binding of anti-involucrin. Scores for expression of 
anti-filaggrin were 2.9 +/- 0.1 (mean +/- sem). 
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Inflammation In all biopsies the infiltrate consisted mainly of T-lymphocytes (about 
75%) as shown by Til-staining (score 4.3 +/- 0.12, mean +/- sem). T-lym­
phocytes were present in the epidermis as well in 19 out of 20 biopsies (score 1.6 
+/- 0.2, mean +/- sem). WT14-expression, showing CD14-positive cells (mono­
cytes and macrophages) accounted for less than 25% of the infiltrate (score 2.1 +/-
0.04, mean +/- sem). These cells could sporadically be found in the epidermal 
compartment as well (score 0.7 +/- 0.1, mean +/- sem). ОКТб-staining Langerhans 
cells showed sporadically expression in the dermal compartment (score 0.8 +/-0.1, 
mean +/- sem), and were consistently present in the epidermis (2.0 +/- 0.2, mean 
+/- sem). 
Correlations 
The number of Кі-67-positive nuclei indeed was increased compared with normal 
skin, but tended to diminish when the degree of atrophy was greater, as seen in 
Table I: Immunohislochemical scores for proliferation, differenlmlion and inflammation in DLE 
(means +/- SEM). Ki-67 staining is expressed as Dumber of stained nuclei per mm length of epider­
mis, remaining antibodies are expressed using a semi-quantitative 7-point scale. 
Antibody 
Ki-67 
Ks8.12 
RKSE60 
Anti-involucrin 
Anti-filaggrin 
Til 
WT14 
OKT6 
Specificity 
cycling cells 
keratin 16 
keratin 10 
involucrin 
filaggrin 
T-lymphocytes 
monocytes/macrophages 
Langerhans cells 
Score 
56.1 +/-8.2 
3.3 +/- 0.4 
4.5 +/- 0.2 
4.3 +/- 0.3 
2.9 +/-0.1 
epidermis 1.6 +/- 0.2 
dermis 4.3 +/-0.1 
epidermis 0.7 +/- 0.1 
dermis 2.1 +/- 0.04 
epidermis 2.0 +/- 0.2 
dermis 0.8 +/-0.1 
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Figure 1. Staining with the antibody Ki-67 in lesionai skin of DLE (x500). 
Figure 2. Ks8.12-staming in the suprabasal compartment (keratin 16) of a DLE-lesion (x625). 
Figure 3. Homogeneous expression of keratin 10 in DLE (x500). 
H&E-sections. In addition, the number of Кі-67-stained nuclei correlated well with 
suprabasal Ks8.12-binding (keratin 13 and 16), and with involucrin- and filaggrin-
expression. Filaggrin expression correlated well with the degree of hyperkeratosis. 
The remaining histological hallmarks of DLE did not correlate with markers for 
proliferation and differentiation. Differentiation markers did not correlate with either 
the degree of atrophy or the amount of inflammation. The four patients who were 
receiving treatment showed values representative of the total group. Clinical data, 
such as the age of the patient or the years a patient had been affected, were not 
correlated with histologic aberrations. 
DISCUSSION 
For this study 20 patients with DLE were selected. The immunohistochemical results 
were compared with results in normal skin as reported in literature. Preliminary 
experiments by our group in normal skin revealed the same staining pattern as 
described in the literature. 
Markers for inflammation conformed in all patients to the established features of the 
infiltrate in DLE11. The infiltrate consisted mainly of T-lymphocytes and of mono­
cytes and macrophages, whereas only a few Langerhans cells were present. In this 
study, the observation of a hyperproliferative state of the epidermis in discoid lupus 
erythematosus lesions measured by '[HJ-thymidine1·2, has been confirmed and 
extended using the antibodies Ki-67 and Ks8.12 as markers. The number of Ki-67-
stained nuclei was increased compared to normal skin of healthy individuals (14.7 
+/- 2.2), but lower compared to the psoriatic lesion (196.9 +/- 22.4)13. A homo­
geneous distribution of the Кі-67-positive nuclei through the basal layer of the skin 
was seen. However, the number of Кі-67-stained nuclei tended to diminish as the 
degree of atrophy was higher. The occurence of some Ki-67 positive nuclei just 
above the basal layer suggests an extension of the germinative pool. A similar 
situation has been observed in psoriatic lesions14. The expression of Ks8.12 in the 
suprabasal compartment of the epidermis of DLE provides further support to the 
observation that DLE is hyperproliferative. Ks8.12-binding (keratin 13 and 16) is 
seen in psoriatic lesions and in normal skin after tape-stripping and decreases during 
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Figure 4. Staining with anti-involucrin in the lower layers of the stratum spinosum of DLE (x625). 
Figure 5. Anti-filaggrin staining in the upper stratum spinosum of DLE (x500). 
anti-psoriatic therapy1516. Keratin 16 is expressed by hyperproliferative keratinocytes 
in vitro as well as in vivo5. The hyperproliferative state of the epidermis in DLE 
might be a repair mechanism in an attempt to restore the damage of the basal cell 
layer. Possibly this reaction ultimately extinguishes and results in atrophy. 
In a previous investigation a normal differentiation pattern and a shortened transit 
time of keratinocytes has been postulated in DLE2. In the present study it is shown 
that epidermal differentiation is disturbed compared to normal skin. RKSE60-binding 
(keratin 10) is pronounced, but involucnn and filaggrin are expressed in lower cell 
layers of the epidermis compared to normal skin9·10. Keratin 10 is a marker for early 
differentiating keratinocytes, whereas involucrin and filaggrin are markers for the 
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later phase of differentiation. Keratin 10 is diminished in psoriasis and after 
sellotape-stripping of normal skin17·18. Differentiation in these two situations is 
altered, which is also reflected by a parakeratotic homy layer. In DLE, or-
thokeratosis occurs and we observed a binding pattern of RKSE60 as seen in normal 
skin6. The early differentiation phase therefore, seems to proceed normally. Howe-
ver, although orthokeratotic comification takes place, markers for the late phase of 
differentiation -involucrin and filaggnn- are expressed in lower cell layers compared 
to normal skin. This staining pattern of involucrin is also found in hyperproliferative 
skin disorders such as benign neoplasms, malignant tumours and psoriasis'. The 
increase in involucrin-expression is thus in agreement with the high number of Ki-
67-stained nuclei and with the increased Ks8.12-expression in DLE. In a previous 
study on various skm disorders, increased filaggnn expression correlated with 
hyperkeratosis and hypergranulosis10. In DLE, the distribution of filaggnn is 
extended. High magnification examination revealed that filaggnn is present in the 
stratum granulosum and in cell layers beneath it. In the present study, filaggnn 
expression correlated well with hyperkeratosis, but no thickening of the stratum 
granulosum was seen. 
Markers for terminal differentiation are expressed early in DLE. From in vitro 
studies, some regulatory mechanisms have been postulated which influence differen-
tiation of keratinocytes. Loss of contact with the basal membrane and extracelluar 
matrix (ECM) constituents such as laminin, collagens and proteoglycans is needed to 
differentiate19. When human keratinocytes are cultured in suspension, withdrawal 
from the cell-cycle and the synthesis of involucrin is induced19·20. Possibly a decrease 
in contact of the basal cells with the basal membrane and ECM, caused by in-
filtrating cells or by upward pressure from dividing basal keratinocytes, induces the 
early expression of late differentiation markers by suprabasal keratinocytes. 
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CHAPTERS 
DISCUSSION 

5.1 ON THE IMMUNOHISTOCHEMICAL APPROACH 
In psoriasis, the histological abberations are considerable compared to normal skin. 
In this thesis immunohistochemical methods have been used to investigate epidermal 
growth and inflammation during evolution and regression of psoriatic lesions. A 
panel of monoclonal and polyclonal antibodies directed against cellular constituents 
involved in epidermal proliferation and differentiation, and against inflammatory 
cells and dermal extracellular matrix proteins has been used on frozen sections. This 
approach has advantages and disadvantages. 
ADVANTAGES: 
One of the most important advantages is that topographical information is preserved. 
This permits to investigate interrelations between different cell types, such as 
between Langerhans cells and PMN (Chapter 2.1). In addition, when untreated 
psoriatic skin is compared to treated, or to normal skin, the divergence is sufficient 
for reliable assessment using a semi-quantitative method. This approach permits to 
carry out multiparameter analysis in time and/or place. 
LIMITATIONS: 
A histological picture is not easily quantitated. Especially when multiple parameters 
are assessed, or when cells are abundantly present, counting of cells raises serious 
difficulties and is fairly impossible. Quantitative approaches such as flowcytometry 
or enzyme measurement of marker enzymes are more sensitive. This is illustrated in 
Chapter 3.1, where during treatment with MC903, no significant reduction in 
Ks8.12-bmding was seen, whereas a clear decline was demonstrated by flowcytome-
trical assessment using the same antibody'. However limitations of flowcytometry 
and measurements of marker enzymes such as elastase2 are loss of topography. 
Using the immunohistochemical markers chosen in this thesis, less information is 
obtained about functional aspects or about the timing of regulation/dysregulation of 
the phenomena assessed, which may take place at the molecular level. In addition, 
possible masking of epitopes and cross reactivity limit the interpretations. 
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SYNTHESIS: 
In understanding and investigating diseases, histology remains the point of departure. 
In this respect, quantitative and qualitative methods are complementary. Measure-
ments at the RNA level might be useful techniques in future investigations. Mul-
tiparameter immunohistochemical analysis, as used in this thesis, might provide an 
indication of the dynamics of events important in induction and regression of 
psoriatic lesions. 
5.2 ON THE PASI-SCORE 
The Psoriasis Area and Severity Index is introduced by Fredriksson in 19783, and is 
a score to describe the clinical condition of a patient, by integrating the degree of 
erythema, desquamation, infiltration and body surface involved. A standardized 
clinical description, internationally accepted, is useful in comparing results of 
various anti-psoriatic therapies, and in comparing different investigations. Never-
theless the disadvantage of such a score is that it is subjective and thus varies with 
the investigator. A considerable variation can exist in the clinical picture of two 
patients with the same PASI-score. For example, a PASI-score of 8.4 can be either a 
patient with extensive (50-69%) psoriasis, with only slight erythema, desquamation 
and infiltration, or a patient with only a few lesions (< 10%) that show the severest 
possible erythema, desquamation and infiltration. It might therefore be useful to 
compare not exclusively the PASI-scores, but in addition the constituing com-
ponents. 
5.3 SEQUENTIAL STUDIES ON IN VIVO MODELS FOR PSORIASIS 
INTRODUCTION 
In this thesis two investigations were carried out to study the phases of the psoriatic 
process during evolution of a lesion (Chapter 2). The approaches used were firstly 
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studying the transition zone between involved and uninvolved skin of spreading 
psoriatic plaques, and secondly simulation of a psoriatic lesion by application of 
leukotriene B4 on normal skin. In the following paragraphs firstly the abberations 
known to be present in distant uninvolved skin from psoriatic patients are reviewed, 
followed by changes seen in the fully developed psoriatic lesion. A part of this is 
described in Chapter 3. Subsequently, the two in vivo models used in this thesis are 
discussed. 
DISTANT UNINVOLVED SKIN 
From a clinical point of view, uninvolved skin from psoriatic patients, seems 
essentially normal. However, the Koebner phenomenon indicates that uninvolved 
psoriatic skin is intrinsically abnormal. Morphologic examination of uninvolved skin 
using H&E staining, reveals no abnormalities in epidermal or dermal compartment. 
However, cellkinetic studies on epidermal growth demonstrated a slight but sig­
nificant increase in percentage of keratinocytes in SGjM-phase in biopsies taken 
from uninvolved skin4. In addition the number of mitoses5 and the incorporation of 
tritiated thymidine6 is reported to be increased compared to normal skin. Bioche­
mically several abnormalities compared to normal skin have been postulated. 
Increased amounts of phospholipase Aj7·', increased release of arachidonic acid 
metabolites9, increased ornithine decarboxylase activity10 and polyamine synthesis10 
were demonstrated, whereas the activity of protein kinase С proved to be reduced". 
Recently, fibroblasts from uninvolved psoriatic skin proved to be abnormal in 
culture11. Barton et al. suggested that the endothelium in clinically uninvolved skin 
of psoriatic patients was abnormal with respect to vascular mass and vessel dilata­
tion13. 
THE PSORIATIC LESION 
In the fully developed psoriatic lesion, morphological changes in epidermis as well 
as in dermis are prominent. Acanthosis, papillomatosis, hyperparakeratosis, and an 
inflammatory infiltrate are the most striking features (Chapter 1). From cellkinetic 
studies it is clear that a large increase in the number of epidermal cells and in the 
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rate of production of these cells exists in psoriatic lesions. This is probably due to an 
increase in the absolute size of the germinative compartment and to recruitment of 
Go cells. Nowadays the cell cycle time in psoriatic epidermis is believed to be 
relatively normal'4. Biochemical abnormalities in the lesionai skin include increased 
amounts of arachidonic acid metabolites9, increased activity of phospholipase A27·8, 
phospholipase C15, and ornithine decarboxylase with an increased production of 
polyamines10. In addition, decreased activity of protein kinase C" and adenylate 
cyclase16 have been reported. The level of calmodulin, the calcium binding protein, 
is increased17. Calmodulin-calcium enhances the activities of phospholipase Aj and 
adenylate cyclase. In the psoriatic lesion many inflammatory changes are found1819. 
Recently, it has been shown that TNF-a, IFN-T and IL-8 induce the expression of 
TGF-a20. It has been hypothesized by prof. P. Mier that inflammation and epidermal 
proliferation can be triggered by activation of the TGF-a loop21. 
In the present thesis we could confirm that inflammation and proliferation is 
profoundly disturbed in lesionai psoriatic skin (Chapter 2 and 3). The expression of 
keratin 16 and 17 is increased in the epidermis. At the same time the expression of 
keratin 10 is decreased. Epidermal proliferation, indicated by the number of nuclei 
staining with the antibody Ki-67 is increased. Numbers of T-lymphocytes and PMN 
are raised in as well epidermis as dermis. Langerhans cells and monocytes/macro-
phages are present in the dermal infiltrate and in the epidermis of psoriatic lesions. 
In the epidermal compartment Langerhans cells show focal aggregation. 
THE TRANSITION ZONE BETWEEN UNINVOLVED AND LESIONAL SKIN 
In the transition zone of spreading psoriatic plaques, simultaneous assessment of 
epidermal growth, inflammation and the extracellular matrix components was carried 
out in consecutive sections using immunohistochemistry (Chapter 2.1). In this study, 
dermal changes preceeded epidermal changes. An inflammatory infiltrate composed 
mainly of T-cells was found in the more peripheral sections of the transition zone in 
combination with increased expression of the extracellular matrix protein tenascin. 
This was observed more distantly too, that means before any epidermal alteration 
was seen. The first epidermal change was a slight acanthosis, followed by keratin 16 
expression and increased binding of the antibody Ki-67. A striking observation is 
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that nor the dermal infiltrate nor the epidermal compartment contained PMN in the 
distant uninvolved skin adjacent to psoriatic lesions. This is in contrast to studies on 
pre-pinpoint lesions, pointing out the early involvement of PMN in the initiation of a 
lesion22·23. 
In a previous study on markers for epidermal proliferation and keratinization in the 
margin of the psoriatic lesion, the first epidermal change was also initial acanthosis, 
followed by increased staining with the antibody KS8.121. Other investigators 
studying dermal changes in spreading psoriatic lesions, showed that increased 
alkaline phosphatase (marker enzyme for vascular endothelium) can be found distant 
from the psoriatic lesion24. An increased blood flow measured by laser-doppler 
flowmetry is detectable at sites where no change in the number of T-lymphocytes or 
Langerhans cells can be seen25. 
Alltogether, the dermal compartment is likely to be the tissue, showing the earliest 
changes in the evolution of a psoriatic lesion. 
SIMULATION OF THE PSORIATIC LESION 
One of the most striking features of a psoriatic lesion is the accumulation of PMN in 
the epidermis, as microabscesses of Munro or Kogoj26. A potent chemoattractant for 
PMN is leukotriene B4 (LTB,,)27, a product derived from arachidonic acid via the 
enzyme 5-lipoxygenase2e, and found in high amounts in lesionai psoriatic skin 
compared to uninvolved or normal skin'. Epicutaneous application of leukotriene B4 
on normal skin produces an acute inflammation dominated by PMN29, followed by 
hyperproliferation of the epidermis30, features as seen in the psoriatic lesion. Anti-
psoriatic therapies proved to inhibit LTB4-induced accumulation of PMN31. In 
Chapter 2.2 the interrelations between cells involved in epidermal growth and 
inflammation are investigated. A migration of Langerhans cells to intra-epidermal 
microabscesses containing PMN was shown. The composition of the inflammatory 
infiltrate changed from predominantly PMN and monocytes after 8 and 24 hours, to 
T-lymphocytes and Langerhans cells after 48 and 72 hours. Changes as seen in 
initial psoriatic lesions were approached using this model. As a model for chronic 
plaque psoriasis it is less suitable. 
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SYNTHESIS 
The uninvolved skin from psoriatic patients shows no morphological but some 
cellkinetic and biochemical deviations. Uninvolved skin seems to be in an adaptive 
state as epicutaneous application of leukotriene B4 induces less accumulation of PMN 
in uninvolved psoriatic skin compared to normal skin12. Uninvolved skin can be 
triggered by a still unknown stimulus (microtrauma) to evolve to subclinically 
involved skin. This is characterized by dermal alterations such as increased presence 
of T-lymphocytes, increased expression of the extracellular matrix protein tenascin, 
and increased blood now. Subclinical epidermal changes are augmented acanthosis 
and Ks8.12-binding. In the initial lesion, early events are again Ks8.12-binding in 
the suprabasal compartment of the epidermis, and increased binding of Ki-67 in-
dicating hyperproliferation in the epidermis. The maximal inflammatory infiltrate is 
located at the edge ot the psoriatic lesion, consisting of T-lymphocytes, Langerhans 
cells and PMN. In the chronic lesion, the classical psoriatic features are present: 
considerable hyperparakeratosis, acanthosis and papillomatosis, PMN trapped in the 
stratum comeum, and a heavy inflammatory infiltrate consisting of T-lymphocytes 
and monocytes. 
HYPOTHESIS 
The concerted finding of T-lymphocytes and epidermal acanthosis, accompanied by 
an abnormal composition of the extracellular matrix, early in the transition from 
uninvolved to involved skin suggests that interactions between lymphocytes and 
keratinocytes, and between lymphocytes, keratinocytes and extracellular matrix are 
of pathogenetic significance in the transition from uninvolved to involved skin. 
Further studies on signal transduction and modulation of interactions (cytokines, 
mediators of inflammation, intercellular adhesion, biochemical parameters) might 
unravel this process. So far it remains unclear whether the epidermal compartment 
or the dermal compartment is master in inducing psoriatic features. 
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5.4 CLINICAL AND HISTOLOGICAL CHANGES DURING ANTI-PSORIA-
TIC TREATMENT 
5.4a CLINICAL CHANGES 
In the therapeutical battle against psoriasis many alternative treatment modalities are 
available. Unfortunately no absolute cure exists. As psoriasis is a chronic, life-long 
disease, treatment should meet high standards for safety and tolerability. Therefore, 
the search for better new or modified classical therapies goes on. In this thesis, 
various topical and systemic experimental treatments have been investigated. 
Clinically effective treatments 
MC903 
The observation of Morimoto et al in 1985" of a psoriastic patient ameliorating after 
treatment with oral la,25(OH)2vitamin Dj, in combination with the knowledge about 
the proliferation-inhibiting and differentiation-inducing effect of vitamin Dj on 
cultured keratinocytes34, led to a wave of trials with oral and topical vitamin D3. 
Systemic side effects limited its use, however. Therefore the vitamin D3 analogue 
MC903 has been developed in 1987. MC903 binds to the same cytoplasmatic recep-
tor, is as effective on proliferation and differentiation of cultured keratinocytes, but 
is lOOx less active on calcium and phosphate metabolism in vivo as la,25(0-
H)2vitamin D335. Topical treatment with MC903 proved to be a succesful treatment 
for chronic plaque psoriasis36·37. In a study on 345 patients MC903 was at least as 
efficacious as betamethasone valerate38 assessed by the severity of symptoms and 
percentage body surface involved (PASI-score). In Chapter 3.1 the results of topical 
treatment of nine patients with MC903 ointment 0.05% during 12 weeks is reported. 
PASI-scores diminished from 7.7 +/- 1.2 (mean +/- SEM) before treatment, to 2.3 
+/- 0.5 after 12 weeks of treatment, an average reduction of 5.4. The improvement 
was most pronounced in the first 8 weeks of treatment. No total clearing was 
achieved in any of them. This trial was part of a multicenter trial, from which 
clinical results are not yet available. Systemic side effects have not been found. One 
patient had to be withdrawn from treatment with MC903 because of a repeated 
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burning sensation after applying MC903 on to the skin. The patient compliance was 
very good, as they were satisfied with the clinical results and as the ointment was 
easy applicable. MC903 appears to be an effective, well-tolerable, and safe addition 
to the therapeutic arsenal in the treatment of chronic plaque psoriasis. It is registered 
as a new anti-psoriatic treatment modality in the Netherlands in september 1992. 
Dithranol 
Ever since the first use of dithranol for psoriasis, people have endeavoured to find 
formulations which would be easier to apply. Short-contact therapy has made 
dithranol treatment available for the out patient department39. Nevertheless staining 
of textile is a serious practical problem. Therefore, developing dithranol-for-
mulations that exert a good clinical effect on the psoriatic lesions, but that are easy 
to wash off, remains important. In this thesis (Chapter 3.3) the clinical effect of a 
new formulation (dithranol in a new emulsifying ointment in the concentrations 
0.5%-5%) has been investigated, which permits efficient removal of dithranol from 
the skin. This therapy proved to have a satisfactory response in 12 out of 20 
patients. Only two patients dropped out because of non-compliance. In the remaining 
patients this dithranol treatment was well tolerated. An average reduction of the 
PASI-score of 10.1 was obtained. The remission period averaged 6.3 weeks. These 
results are comparable with previous studies on the efficacy of dithranol40,41. 
Budesonide 
Topical application of corticosteroids in the treatment of psoriasis has proven to be 
an effective treatment42. As psoriasis is a chronic dermatose, one has to bear in mind 
the accumulative impact of local and systemic side effects. Budesonide is a new 
corticosteroid with little effect on plasma Cortisol levels and urinary Cortisol 
excretion43. The clinical efficacy of Budesonide ointment 0.025% in a three weeks 
treatment period has been described in Chapter 3.6. An average reduction in PASI-
scores of 3.24 was recorded (from 5.3 +/- 1 to 3.6 +/- 0.7, means +/- SEM). No 
side effects were seen. Patient compliance was very good, as corticosteroids are easy 
to apply, do not smell or stain. Prolonged use however, is still to be avoided in view 
of the local side effects. 
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Clinically ineffective treatments 
13-cis-retinoic acid 
Systemic treatment of psoriasis with retinoids has nowadays a well-established 
position*1. Because of the serious side effects that can occur, their use has been 
limited to patients with extensive psoriasis. Topical administration of retinoids might 
exert fewer side effects. In Chapter 3.2 an investigation on the efficacy of topical 
13-cis-retinoic acid 0.1% in a cream base has been described. During a four weeks 
period of treatment, no improvement could be demonstrated. Nevertheless, 13-cis-
retinoic acid showed to improve Darier's disease45. Also a beneficial effect of 
topically applied all-trans-retinoic acid in the treatment of chronic plaque psoriasis 
has been shown46·47. Possibly, increasing the concentration of 13-cis-retinoic acid, or 
changing the cream base into an ointment base might improve its clinical effect. So 
far, the value of topical 13-cis-retinoic acid 0.1% in a cream base in the treatment of 
chronic plaque psoriasis remains unsubstantial. 
MK886 
In psoriatic skin, increased amounts of products from the arachidonic acid cascade 
have been found, inclusing leukotriene B4W. Inhibitors of the key enzyme in the 
production of leukotriene B4, 5-lipoxygenase, have proven to ameliorate psoriasis49. 
Side effects forced a withdrawal of this inhibitor. In Chapter 3.5 the effect of a new 
oral leukotriene biosynthesis inhibitor (MK886)50 on chronic plaque psoriasis has 
been investigated. Despite a significant reduction in systemic leukotriene levels of 
more than 70%, no changes in the clinical parameters were detectable. In addition, 
levels of leukotriene B4 in lesionai skin did not change. Possibly, MK886 reached 
concentrations in skin that were not sufficient to inhibit leukotriene biosynthesis, due 
to either a suboptimal concentration of MK886, or to a too short treatment period. 
Synthesis 
In this thesis, five experimental therapies for treating chronic plaque psoriasis have 
been examined. The objective was to acquire new, or improved classical effective 
therapeutics with few side effects. 
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Treatment with the vitamin Dj analogue MC903 is as effective as a class 3 cor-
ticosteroid, and has until now exerted no systemic side effects. Local side effects 
(burning sensation) are seen in about 3% of the patients. MC903 is therefore an 
important novel addendum in the treatment of psoriasis. 
Short-contact treatment using dithranol in a new cream base proved to be as 
effective as treatment with the spécialité Psoralon (Hermal, Hamburg, FRG) and to 
induce a remission period comparable with that after classical Ingram therapy. An 
important advantage is that this new formulation is easy to apply in the out-patient 
department, can well be removed and can be manufactured by the local phar-
macologist. Therefore this formulation opens new perspectives for the out-patient 
treatment with dithranol. 
Tretment with the new corticosteroid Budesonide proved to be very effective. It is 
positioned as a class 3-4 steroid. In view of local side effects Budesonide is com-
parable to other steroids from that class. 
Topical treatment with 13-cis-retinoic acid (0.1% in cream) and systemic treatment 
using a leukotriene biosynthesis inhibitor (MK886) were not clinically effective, and 
the value of these formulations so far is limited in the treatment of chronic plaque 
psoriasis. 
5.4b HISTOLOGICAL CHANGES 
In order to obtain information on working mechanisms of anti-psoriatic treatments, 
the order of events taking place during therapeutical regression of psoriatic lesions 
was studied (Chapter 3). During the treatment course, biopsies were taken and 
processed for immunohistochemistry. Changes in time in topography and quantity of 
cells involved in epidermal growth and inflammation were analyzed. 
The application of dithranol on to psoriatic lesions induces regression of those 
lesions. It seems contradictory that this effect is reached using concentrations which 
induce some inflammation. To further analyze the inflammatory action of dithranol, 
we have investigated the effect of this application on normal skin in Chapter 3.4. 
In addition, the impact of a new histological marker in psoriasis, keratin 17, has 
been described in Chapter 3.7. 
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Order of events 
The various changes in numbers of cells involved in epidermal growth and inflam­
mation during treatment with the investigated anti-psoriatic therapies are summarized 
in Table I. 
MC903 
la,25(OH)2vitamin D3 and its analogue MC903 both bind to the same cytoplasmatic 
receptor, are transported to the nucleus resulting in transcription and translation of 
proteins involved in calcium homeostasis and growth control35,51,52. In addition a 
direct and rapid effect on intracellular calcium and cGMP has been reported53,54. 
Many cells possess receptors for vitamin D3, including keratinocytes55. 1οί,25(ΟΗ)2. 
vitamin Dj as well as MC903 affect proliferation and differentiation of cultured 
cells34, and both show an immunomodulating effect56,57. Whether the anti-psoriatic 
effect of MC903 is exerted primary via regulation of proliferation and differentiation 
of keratinocytes, or via regulation of the number of inflammatory cells, is inves­
tigated in Chapter 3.1. As the number of epidermal PMN, and the number of nuclei 
stained with the antibody Ki-67, diminished early in the treatment period, while the 
number of T-lymphocytes, Langerhans cells and CD14-positive cells remained 
unchanged, it is feasible that MC903 interferes firstly with PMN and epidermal 
growth. In a later stage of treatment, the number of T-lymphocytes decreased. 
However, the immunoregulatory function of these cells might be altered before a 
decline in number is detected. 
Dithranol 
The working principle of dithranol in the treatment of psoriasis, is despite many 
investigations still not exactly known. Inhibition of epidermal proliferation and 
inflammation is the ultimate result58,59. But in contrast, dithranol also induces 
erythema and inflammation60. Which cell or cellular component forms the main 
target for dithranol is not known. When epidermal growth and inflammation are 
investigated simultaneously (Chapter 3.3), it becomes apparent that the first changes, 
seen after two weeks of treatment, are visible in the epidermal compartment. 
Epidermal proliferation (Ki-67 staining, Ks8.12-staining) and the number of epider-
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mal PMN show then an already statistically significant decrease. Inflammation 
persisted relatively long during treatment with dithranol, especially T-lymphocytes, 
CD14-positive cells, Langerhans cells, and dermal PMN. 
When dithranol is applied to normal skin (Chapter 3.4) some analogies and some 
contrasting findings are seen compared to psoriasis. As in psoriasis, an inflammatory 
infiltrate is induced. The infiltrate, however consists mainly of T-lymphocytes and of 
relatively few PMN. In contrast to psoriasis, the expression of keratin 13/16 
(Ks8.12-binding) and hyperprol i feration (Кі-67-binding) is increased. Strikingly, in 
accordance with the treatment of psoriatic plaques with dithranol, in normal skin 
epidermal changes are induced before dermal changes occur. 
Budesonide 
Corticosteroids are anti-proliferative, anti-inflammatory, and immunosuppressive42,61. 
They possess a cytoplasmatic receptor and are transported to the nucleus after 
binding, but also non-nuclear working mechanisms are described62. In Chapter 3.6 it 
is shown that topical application of Budesonide 0.025% ointment induces a sig­
nificant decrease in epidermal proliferation (Кі-67-binding, Ks8.12-binding) and in 
dermal accumulation of PMN already after one week. The remaining inflammatory 
cells remained relatively high. Epidermal proliferation therefore, seems an important 
target in the anti-psoriatic working principle of Budesonide. 
13-cis-retinoic acid 
Vitamin A and derivatives bind to a cytoplasmatic receptor and act at the level of 
gene transcription63. Orally administered etretinate and acitretin have previously 
shown a clear antipsoriatic effect in about 60% of the patients44·*4. Topical treatment 
with 13-cis-retinoic acid 0.1% in a cream base showed no clinical and histological 
improvement of lesions and resulted in a status quo of epidermal growth and inflam­
mation (Chapter 3.2). The untreated and treated psoriatic lesions showed a charac­
teristic psoriatic appearance without any difference between pre- and posttreatment 
biopsies. 
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MK886 
MK886 is an indirect leukotriene biosynthesis inhibitor which acts through binding 
of a membrane-bound 5-lipoxygenase-activating protein (FLAP), and thereby inhibits 
the translocation and activation of S-lipoxygenase5065. Before and after treatment 
with MK886, no significant changes in epidermal proliferation, differentiation or in 
inflammation parameters could be seen in biopsy specimens from psoriatic lesions 
(Chapter 3.5). Solely a decrease in the number of PMN in the epidermis, reaching 
borderline significancy (p=0.05) was detectable. 
Synthesis 
A quite uniform pattern of immunohistochemically detected changes was seen during 
treatment with the various anti-psoriatic therapies. 
In the early phases of treatment (from 0 to 2 weeks), mainly changes in epidermal 
cells occured. The features involved in this early change were the number of Ki-67 
stained nuclei, of polymorphonuclear leukocytes (PMN), and the expression of 
keratin 16. The most consistent finding was the strikingly rapid decrease of the 
number of Кі-67-positive nuclei in the epidermis in all effective treatments. The 
amount of keratin 16 in the suprabasal epidermal compartment showed a decrease 
during treatment with dithranol and budesonide, but not during treatment with 
MC903. PMN in the epidermis decreased after MC903- and dithranol-treatment, but 
not after topical application of budesonide. This caused in contrast a decline in 
dermal PMN. Markedly, the number of PMN in the epidermis during the clinically 
ineffective systemic treatment with MK886 decreased, reaching borderline statistical 
significance. 
In the later phases of treatment, the number of T-lymphocytes in dermis as well as 
epidermis decreased, in combination with a decline in dermal PMN. 
Epidermal CDU-positive cells (monocytes/macrophages) showed a statistically 
significant decrease after two weeks of treatment with budesonide, and after eight 
weeks of treatment with dithranol. Dermal CD14-positive cells showed no major 
changes. ОКТб-positive Langerhans cells tended to increase in the epidermis, and to 
decrease in the dermal compartment during all effective treatments, but never 
reached statistical significance. 
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Hypothesis 
It is apparent that epidermal immunohistochemical changes dominate the picture in 
the early phases of anti-psoriatic treatment. In the early phase of treatment, epider-
mal growth and PMN are important targets. T-lymphocytes persist relatively long 
during therapy, and are still prominent even when a clear clinical effect is reached. 
These observations raise the question whether T-lymphocytes are important in 
relapses of psoriasis after therapy. Possibly a major reduction in the number of T-
lymphocytes is needed for a prolonged remission period. 
Keratin 17 
In Chapter 3.7 we have described the presence, localization, and changes of keratin 
17 in psoriatic lesions before and after therapy. Discovering new aberrations in 
psoriasis, and studying these aberrations during regression of lesions, might provide 
more knowledge about, and insight in, psoriasis. 
Keratin 17 is not present in normal human epidermis. It can only be found in the 
outer root sheath of the hair follicle and in myoepithelial cells of the sebaceous 
gland66·67. In untreated psoriatic lesions, keratin 17 was present in the upper layers of 
the epidermis. After MC903 or dithranol therapy, a clear reduction was found. 
Decline in keratin 16 content and Ks8.12 binding is used as a marker for monitoring 
therapies37·68. Expression of keratin 16 is known to be associated with hyperprolifera-
tion of keratinocytes69·70. From some investigations however, evidence arises that 
Ks8.12 binding might be sign of a more general disturbance of the epidermal 
condition40. The functional meaning of keratin 17 is not known. Because of its 
location, the expression of this keratin might be associated with abnormal differen-
tiation, more than with abnormal proliferation. Further studies on the functional sig-
nificance of keratin 17 expression are indicated. Assessing keratin 17 content in 
psoriatic lesions before and after therapy might be a useful approach in monitoring 
anti-psoriatic therapies at the level of epidermal differentiation. 
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Table I. Timing of the first statistically significant changes of histological markers during various anti-psoriatic treatments, χ = investigated time points, ep = 
epidermal, de = dermal. 
Treatment 
MC903 
Dithranol 
Budesonide 
13-cis-RA 
MK886 
Time 
weeks 
0 
X 
X 
X 
X 
X 
1 
X 
PMN (ep) 
X 
Ki-67 
Ks8.12 
PMN (de) 
X 
PMN (ep) 
2 
X 
Ki-67 
X 
Ki-67 
Ks8.12 
PMN(ep) 
3 
X 
WT14 
(ep) 
4 
X 
Til (ep/de) 
PMN (ep/de) 
X 
5 6 7 8 
X 
RKSE60 
TU (eld) 
PMN (de) 
WT14 (ep) 
9 10 
И 
12 
X 
U ) 
5.5 EPIDERMAL GROWTH AND INFLAMMATION IN PSORIASIS-RELA-
TED SKIN DISEASES 
The clinical picture of psoriasis is well-defined and often easy to recognize71. 
Nevertheless, sometimes the picture may be difficult to delineate from other 
erythematosquamous skin disorders. Histologically, using H&E staining, the exact 
diagnosis can mostly be achieved. In skin disorders showing clinically overlap with 
psoriasis, our question was whether parameters for epidermal growth and inflam-
mation were similar or distinctive. In Chapter 4 we have investigated three of these 
skin disorders. 
Inflammatory Linear Verrucous Epidermal Nevus (ILVEN) versus linear 
psoriasis 
The delineation of ILVEN from psoriasis has been discussed by many authors72,73,74. 
In Chapter 4.1 we have investigated six patients with linear erythematosquamous 
lesions. From a clinical point of view, ILVEN and linear psoriasis proved to 
overlap. Immunohistochemically, a distinction between ILVEN and psoriasis could 
be made. In ILVEN, we observed focal suprabasal staining with Ks8.12 (keratin 
16), homogenous staining using the antibody RKSE60 (keratin 10), and a relatively 
low occurrence of PMN. In psoriasis, keratin 16 is distributed homogeneously in the 
suprabasal compartment, keratin 10 is absent in distinct areas, and PMN are a more 
consistent finding. All other immunohistochemical parameters revealed no differen-
ces between ILVEN and psoriasis. In previous investigations, it has been shown that 
various antipsoriatic therapies inhibit the intraepidermal accumulation of PMN31. It is 
attractive to hypothesise that the absence of PMN in ILVEN might form an explana-
tion for its refractoriness to treatment. 
Pityriasis Rubra Pilaris 
Extensive psoriasis and pityriasis rubra pilaris (PRP) can be difficult to differentiate 
clinically, especially since transition from the one in to the other has been descri-
bed75. In chapter 4.2 of this thesis we describe a patient who was first diagnosed as 
204 
having psoriasis, but the clinical picture developed into pityriasis rubra pilaris. 
Immunohistochemically, a low number of Ki-67 stained nuclei and absence of PMN 
were discriminative. 
Dicoid Lupus Erythematosus 
Clinically, discoid lupus erythematosus (DLE) is characterized by sharply demar-
cated erythematosquamous lesions. In contrast to psoriasis, scales are adherent and 
follicular plugging is present. Ultimately DLE results in atrophy76, whereas psoriasis 
does not. In Chapter 4.3, biopsies from twenty patients with a clinical picture of 
DLE have been investigated immunohistochemically. Epidermal proliferation 
measured by Ki-67 staining turned out to be increased compared to normal skin, but 
decreased compared to psoriasis77. In addition, the amount of keratin 16 in the 
suprabasal compartment was high. Lesions of DLE are in a hyperproliferative state, 
but this tends to diminish with the degree of atrophy. Early epidermal differen-
tiation, measured as expression of keratin 10 is unchanged compared to normal skin. 
A homogenous distribution in the suprabasal compartment is present, whereas in 
psoriasis keratin 10 is absent in foci1. In DLE, parameters for terminal differen-
tiation (filaggrin and involucrin) are expressed early compared to normal skin78,79. In 
psoriasis, filaggin expression is decreased79, whereas involucrin expression is 
increased78. In conclusion, in DLE hyperproliferation (however not as extreme as in 
psoriasis) is associated with normal early differentiation and premature terminal 
differentiation of keratinocytes. In psoriasis, pronounced hyperproliferation is 
associated with abnormal early differentiation80 in combination with abnormal 
terminal differentiation78·79. 
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5.6 GENERAL CONCLUSIONS 
1. During the induction of a psoriatic lesion, immunohistochemically detectable 
dermal changes precede epidermal changes. Increased expression of tenascin 
and increased numbers of T-lymphocytes are the earliest detectable aberrations 
in the margin zone of spreading psoriatic plaques. Secondly, a slight epidermal 
acanthosis is present. Therefore, mechanisms involved in T-lymphocyte-
keratinocyte interaction, and the interrelations between T-lymphocytes, 
keratinocytes and extracellular matrix should form an important part of future 
studies. 
Epicutaneous application of LTB4 is rather a model for acute inflammation 
than a selctive model for psoriasis, especially since in the margin zone of 
spreading psoriatic plaques, PMN were virtually absent using elastase as a 
marker enzyme. 
2. During treatment of psoriatic lesions, epidermal changes precede dermal 
changes. Epidermal growth is early affected during treatment, in combination 
with the number of epidermal PMN. The early reduction of PMN ac-
cumulation during treatment is intniiging. T-lymphocytes persist relatively 
long. This indicates that a more substantial reduction of the number of T-lym-
phocytes could well induce prolonged remission periods. 
3. The immunohistochemical investigation of markers described in this thesis 
provide a "fingerprint" of epidermal growth and inflammation in various skin 
disorders. The contribution of these markers to the diagnosis of psoriasis and 
psoriasis-related skin diseases is relatively limited, as a reasonable overlap 
exists. Extra information is given by assessment of PMN, Ks8.12 binding and 
RKSE60 binding in IL VEN (Chapter 4.1), and of PMN in pityriasis rubra 
pilaris (Chapter 4.2). In DLE, a close look at the epidermal differentiation 
process shows aberrations compared to normal skin and variations compared to 
psoriasis. It is intniiging that in both acanthotic psoriatic lesions, and in 
atrophic DLE-lesions, increased Ki-67 binding and altered differentiation is 
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seen. Studying the regulation of these processes uncovers more of the cellbio-
logical and molecular causes involved. 
4. The observation that corticosteroids, vitamin A and -derivatives, and vitamin 
D and -derivatives are effective in the treatment of psoriasis, suggest that the 
steroid receptor supergene family induces an important collective working 
mechanism, which can implicate that this family is relevant for the understan­
ding of the pathogenesis of psoriasis. 
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SUMMARY 
In this thesis, parameters for epidermal growth and inflammation have been inves-
tigated in the induction and regression of psoriasis. In addition, clinical efficacy of 
some new and modified classical treatments were studied. The described parameters 
were also examined in three psoriasis-related skin diseases. 
In Chapter 1, psoriasis is introduced by describing its epidemiological, aetiological 
and genetica! features. Clinical and histological aspects of this skin disease are 
pictured as well. In the pathogenesis of psoriasis, still many controversies exists as 
to which cells or events are crucial. The role of various cell types is described. The 
established and some new treatments are presented. The applied methods used for 
clinical and immunohistochemical assessment in this thesis are introduced. 
In Chapter 2, the induction of psoriatic lesions has been investigated using two 
different in vivo models: the margin zone of spreading plaques, and epicutaneous 
application of leukotriene B4 (LTB4) on normal skin. In the margin zone, increased 
expression of the extracellular matrix protein tenascin and increased numbers of T-
lymphocytes in the dermis preceded initial acanthosis of the epidermis. Epicutaneous 
application of LTB4 on normal skin induces an acute inflammatory reaction, which 
partly corresponds with changes as seen in initial psoriatic lesions. The low numbers 
of polymorphonuclear leukocytes (PMN) in the margin zone using elastase as a 
marker enzyme raises doubts as to the specificity of the LTB4 model. 
In Chapter 3, the effects of new anti-psoriatic therapies on clinical parameters and 
on markers for epidermal growth and inflammation are described. Treatment with 
the vitamin Dj analogue MC903 proved to be an effective and safe acquisition. 
Short-contact treatment with dithranol in a new cream base, proved to be as effective 
as other dithranol treatment schemes. Advantages of this formulation are that it can 
be manufactured by the local pharmacologist, and that it is easy to remove from 
skin. Budesonide, a class 3-4 corticosteroid proved to be very effective in the 
treatment of psoriasis. Topical application of 13-cis-retinoic acid 0.1% in a cream 
base and oral administration of a leukotriene biosynthesis inhibitor (MK886) showed 
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no clinical effect. Corticosteroids, vitamin A and -derivatives, and vitamin D and -
derivatives are effective therapies. Therefore the steroid receptor supergene family 
can provide important information for understanding more of the mechanisms 
involved in regression of psoriatic lesions and maybe in it's pathogenesis. 
Immunohistochemical investigations concerning epidermal growth and inflammation 
during anti-psoriatic treatment revealed that the epidermal compartment shows 
changes before the dermal compartment is altered. Especially epidermal growth and 
the number of PMN are early affected. T-lymphocytes persist relatively long. 
Langerhans cells and monocytes/macrophages show slight but not statistically 
significant changes in number. These observations might indicate that more substan-
tial reduction in the number of T-lymphocytes induces prolonged remission periods. 
In Chapter 4 three skin disorders are investigated that show clinically overlap with 
psoriasis: inflammatory linear verrucous epidermal nevus (ILVEN) versus linear 
psoriasis, pityriasis rubra pilaris (PRP), and discoid lupus erythematosus (DLE). The 
immunohistochemical stainings concerning epidermal growth and inflammation, 
compared to those in psoriasis, revealed corresponding and deviating features. Extra 
information is given by assessment of PMN, Ks8.12- and RKSE60-binding in 
ILVEN, by measuring PMN in PRP, and by studying proliferation and differen-
tiation markers in DLE. 
In Chapter 5 the immunohistochemical approach and the PASI-score used for 
assessment of clinical parameters are discussed. A synthesis of the interrelation 
between parameters for epidermal growth and inflammation during induction and 
regression of the psoriatic lesion is made. During induction, dermal changes prepon-
derate, whereas during regression epidermal changes do. Epidermal growth and 
PMN play an important role in the initial therapeutic effect. As after treatment still 
dermal aberrations exist, especially concerning T-lymphocytes, a more substantial 
decline of these cells is suggested to be important for prolonged remission. Studying 
regulation of epidermal growth and inflammation in psoriasis-related skin disorders 
provides additional information on the mechanisms involved. 
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SAMENVATTING 
in dit proefschrift zijn parameters voor epidermale groei en ontsteking bestudeerd 
tijdens ontstaan en tijdens regressie van psonasis. Eveneens is het klinisch effect van 
enkele nieuwe en gemodificeerde klassieke therapieën onderzocht. Bovengenoemde 
parameters zijn tevens bij drie aan psonasis gerelateerde ziektebeelden bekeken. 
In Hoofdstuk 1 wordt het ziektebeeld psoriasis geïntroduceerd en worden de 
epidemiologische, aetiologische en genetische kenmerken beschreven. Klinische en 
histologische aspecten van deze huidziekte worden behandeld. Over de Pathogenese 
van psoriasis bestaan nog steeds verschillen van inzicht wat betreft de vraag welke 
cellen of gebeurtenissen cruciaal zijn. De rol van verschillende celtypes worden 
besproken. De klassieke, gevestigde en enkele nieuwe behandelingsmethoden worden 
gepresenteerd. Bovendien worden de klinische en immunohistochemische methodes, 
toegepast in dit proefschrift, geïntroduceerd. 
In Hoofdstuk 2 is het ontstaan van psoriasislaesies onderzocht met behulp van twee 
in vivo modellen: de randzone van groeiende plaques en epicutane applicatie van 
leukotriene B4 (LTB4) op normale huid. In de randzone werd toegenomen expressie 
van het extracellulaire matrix eiwit tenascin, en een toegenomen aantal T-lymfocyten 
in de dermis gezien. Deze gebeurtenissen gingen vooraf aan beginnende acanthose 
van de epidermis. Epicutane applicatie van LTB4 op normale huid induceert een 
acute ontstekingsreactie, die gedeeltelijk overeenkomt met de veranderingen die te 
zien zijn bij vroege psoriasislaesies. De lage aantallen polymorfkemige leukocyten 
(PMN) die in de randzone gevonden worden wanneer elastase als marker enzym 
wordt gebruikt, doen twijfelen aan de specificiteit van het LTB^model voor 
psoriasis. 
In Hoofdstuk 3 wordt het effect van nieuwe anti-psoriatische behandelingen op 
klinische parameters en op parameters voor epidermale groei en ontsteking beschre-
ven. Behandeling met het vitamine D, analoog MC903 heeft bewezen een effectieve 
en veilige aanwinst te zijn. Korte duur-behandeling met dithranol in een nieuwe 
crème basis bleek even effectief als andere dithranol-behandelinsschema's. Voordeel 
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van dit nieuwe preparaat is dat het kan worden gemaakt door de lokale apotheek, en 
dat het gemakkelijk van de huid kan worden verwijderd. Budesonide, een klasse 3 à 
4 corticosteroid bleek zeer effectief bij de behandeling van psoriasis. Lokale 
applicatie van 13-cis-retinoinezuur 0.1% in een crèmebasis en orale toediening van 
een leukotriene-biosynthese-remmer (MK886) lieten geen klinisch effect zien. 
Corticosteroiden, vitamine A en -afgeleiden en vitamine D en -afgeleiden zijn 
effectieve behandelingen voor psoriasis. De steroid receptor supergene family lijkt 
belangrijke extra informatie te kunnen brengen wat betreft therapeutische regressie 
en mogelijk ook de Pathogenese van psoriasis. 
Immunohistochemisch onderzoek van epidermale groei en ontsteking tijdens behan-
deling van psoriasis bracht aan het licht dat het epidermale compartiment veranderin-
gen liet zien voordat veranderingen te zien waren in de dermis. Met name epider-
male groei en het aantal PMN veranderden vroeg in de tijd. T-lymfocyten bleven 
relatief lange tijd aanwezig. Langerhans cellen en monocyten/macrofagen verander-
den in aantal, echter dit was niet statistisch significant. Uit deze observaties zou 
kunnen blijken dat een meer substantiële reductie van het aantal T-lymfocyten 
mogelijk een langere remissie-periode geeft. 
In Hoofdstuk 4 zijn drie huidziektes onderzocht die klinisch overeenkomsten laten 
zien met psoriasis: inflammatoire lineaire verruceuze epidermale naevus (ILVEN) 
versus lineaire psoriasis, pityriasis rubra pilaris (PRP), en discoide lupus erythe-
matodes (DLE). De immunohistochemische kleuringen wat betreft epidermale groei 
en inflammatie werden vergeleken met de resultaten hiervan bij psoriasis, en lieten 
zowel overeenkomsten als verschillen zien. Extra informatie geeft bepaling van 
PMN en kleuring met behulp van de antilichamen Ks8.12 en RKSE60 bij ILVEN, 
het aantal PMN bij PRP, en het bestuderen van proliferatie- en differentiatie-
parameters bij DLE. 
In hoofdstuk 5 worden de immunohistochemische kleuringen en de PASI-score 
(Psoriasis Area and Severity Index) bediscussieerd. Een synthese van de interrelatie 
tussen parameters voor epidermale groei en ontsteking tijdens ontstaan en ver-
betering van de psoriasis laesie wordt gepresenteerd. Tijdens inductie staan dermale 
veranderingen op de voorgrond, terwijl dit bij regressie de epidermale veranderingen 
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zijn. Epidermale groei en het aantal PMN spelen een belangrijke rol bij het vroege 
therapeutische effect van een behandeling. Aangezien na behandeling nogal eens 
dermale afwijkingen blijven bestaan, met name wat betreft T-lymfocyten, lijkt 
verdere vermindering van deze cellen belangrijk voor langere remissie-periodes. Het 
onderzoeken van regulering van epidermale groei en ontsteking bij aan psoriasis 
gerelateerde huidziektes, zorgt voor uitbreiding van onze kennis over de mechanis-
mes die hierbij betrokken zijn. 
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